Controlled release corticosteroid compositions and methods for the treatment of otic disorders

ABSTRACT

Disclosed herein are compositions and methods for the treatment of otic disorders with steroid, NSAID, and/or adenosine triphosphatase (“ATPase”) modulator agents. In these methods, the steroidal, NSAID, and/or ATPase compositions and formulations are administered locally to an individual afflicted with an otic disorder, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).

CROSS-REFERENCE

This application is a Continuation of U.S. Ser. No. 14/300,030, filedJun. 9, 2014, which is a Continuation of U.S. Pat. No. 8,828,980, whichis a Divisional application of U.S. Ser. No. 12/466,310, filed 14 May2009, now patented as U.S. Pat. No. 8,030,297, which claims the benefitof U.S. Provisional Application No. 61/127,713 filed May 14, 2008, U.S.Provisional Application No. 61/060,425 filed Jun. 10, 2008, U.S.Provisional Application No. 61/074,583 filed Jun. 20, 2008, U.S.Provisional Application No. 61/094,384 filed Sep. 4, 2008, U.S.Provisional Application No. 61/101,112 filed Sep. 29, 2008, U.S.Provisional Application No. 61/140,033 filed Dec. 22, 2008, U.S.Provisional Application No. 61/095,248 filed Sep. 8, 2008, U.S.Provisional Application No. 61/087,940 filed Aug. 11, 2008, U.S.Provisional Application No. 61/082,450 filed Jul. 21, 2008, GBApplication No., 0823378.5 filed Dec. 22, 2008, each of which is herebyincorporated by reference in its entirety.

JOINT RESEARCH AGREEMENT

The claimed invention was made as a result of activities undertakenwithin the scope of a joint research agreement between Jay BenjaminLichter, Benedikt K. Vollrath, Otonomy, Inc., and Avalon Ventures VIIIGP, LLC that was in effect on or before the date the invention was made.

BACKGROUND OF THE INVENTION

Vertebrates have a pair of ears, placed symmetrically on opposite sidesof the head. The ear serves as both the sense organ that detects soundand the organ that maintains balance and body position. The ear isgenerally divided into three portions: the outer ear, auris media (ormiddle ear) and the auris interna (or inner ear).

SUMMARY OF THE INVENTION

Described herein are compositions, formulations, manufacturing methods,therapeutic methods, uses, kits, and delivery devices for the controlledrelease of at least one corticosteroid to at least one structure orregion of the ear. Disclosed herein are controlled release formulationsfor delivering a corticosteroid to the ear. In some embodiments, thetarget portion of the ear is the middle ear or auris media. In someembodiments, the target portion of the ear is the inner ear, or aurisinterna. In other embodiments, the target portion of the ear is both theauris media and the auris interna. In some embodiments, the controlledrelease formulations further comprise a rapid or immediate releasecomponent for delivering a corticosteroid to the targeted aurisstructure. All formulations comprise excipients that areauris-acceptable.

Also disclosed herein are methods, compositions and devices for thetreatment of otic disorders by administration of controlled releaseformulations comprising a corticosteroid. In some embodiments the oticdisorder is Meniere's disease, Meniere's syndrome, or sensorineuralhearing loss. In additional embodiments, the otic disorder is anautoimmune inner ear disorder (AIED). Also disclosed herein is the localdelivery of controlled release steroid compositions and formulations tosuppress or ameliorate auditory and vestibular impairment as a result ofAIED, which may be provoked by other autoimmune conditions, includingAnkylosing Spondylitis, Systemic Lupus Erythematosis (SLE), Sjögren'sSyndrome, Cogan's disease, ulcerative colitis, Wegener's granulomatosis,rheumatoid arthritis, scleroderma and Behçet's disease (also known asBechet's disease and adamantiades). In other embodiments, the oticdisorder is otitis media. In additional embodiments the otic disorder isvestibular neuronitis, postural vertigo, Ramsay Hunt's Syndrome (herpeszoster infection), syphilis infection, drug-induced inner ear damage,auditory nerve tumors, presbycusis, otosclerosis, or temporomandibularjoint disease.

Described herein are controlled release compositions and devices fortreating otic disorders comprising a therapeutically-effective amount ofa corticosterioid, a controlled release auris-acceptable excipient andan auris-acceptable vehicle. In one aspect, the controlled releaseauris-acceptable excipient is chosen from an auris-acceptable polymer,an auris-acceptable viscosity enhancing agent, an auris-acceptable gel,an auris-acceptable hydrogel, an auris-acceptable thermoreversible gelor combinations thereof.

In some embodiments, the compositions are formulated for pH, and apractical osmolality and/or osmolarity to ensure that homeostasis of thetarget auris structure is maintained. A perilymph-suitableosmolarity/osmolality is a practical/deliverable osmolarity/osmolalitythat maintains the homeostasis of the target auris structure duringadministration of the pharmaceutical formulations described herein.

For example, the osmolarity of the perilymph is between about 270-300mOsm/L, and the compositions described herein are optionally formulatedto provide a practical osmolarity of about 150 to about 1000 mOsm/L. Incertain embodiments, the formulations described herein provide apractical and/or deliverable osmolarity within about 150 to about 500mOsm/L at the target site of action (e.g., the inner ear and/or theperilymph and/or the endolymph). In certain embodiments, theformulations described herein provide a practical osmolarity withinabout 200 to about 400 mOsm/L at the target site of action (e.g., theinner ear and/or the perilymph and/or the endolymph). In certainembodiments, the formulations described herein provide a practicalosmolarity within about 250 to about 320 mOsm/L at the target site ofaction (e.g., the inner ear and/or the perilymph and/or the endolymph).In certain embodiments, the formulations described herein provide aperilymph-suitable osmolarity within about 150 to about 500 mOsm/L,about 200 to about 400 mOsm/L or about 250 to about 320 mOsm/L at thetarget site of action (e.g., the inner ear and/or the perilymph and/orthe endolymph). In certain embodiments, the formulations describedherein provide a perilymph-suitable osmolality within about 150 to about500 mOsm/kg, about 200 to about 400 mOsm/kg or about 250 to about 320mOsm/kg at the target site of action (e.g., the inner ear and/or theperilymph and/or the endolymph). Similarly, the pH of the perilymph isabout 7.2-7.4, and the pH of the present formulations is formulated(e.g., with the use of buffers) to provide a perilymph-suitable pH ofabout 5.5 to about 9.0, about 6.0 to about 8.0 or about 7.0 to about7.6. In certain embodiments, the pH of the formulations is within about6.0 to about 7.6. In certain instances, the pH of the endolymph is about7.2-7.9, and the pH of the present formulations is formulated (e.g.,with the use of buffers) to be within about 5.5 to about 9.0, withinabout 6.5 to about 8.0 or within about 7.0 to about 7.6.

In some aspects, the controlled-release auris-acceptable excipient isbiodegradable and/or bioeliminated (e.g., degraded and/or eliminatedthrough urine, feces or other routes of elimination). In another aspect,the controlled release composition further comprises an auris-acceptablemucoadhesive, an auris-acceptable penetration enhancer or anauris-acceptable bioadhesive.

In one aspect, the controlled release composition is delivered using adrug delivery device, which is a needle and syringe, a pump, amicroinjection device, and in situ forming spongy material orcombinations thereof. In some embodiments, the corticosteroid of thecontrolled release composition has limited or no systemic release, istoxic when administered systemically, has poor pK characteristics orcombinations thereof. In further aspects, the corticosteroid isdexamethasone, betamethasone, prednisolone, methylprednisolone,deoxycorticosterone, 11-deoxycorticosterone,18-hydroxy-11-deoxycorticosterone, beclomethasone, triamcinolone orcombinations thereof. In another aspect, the corticosteroid is aphosphate or ester prodrug of the steroid. In another aspect, thecorticosteroid is a salt of the steroid.

Also disclosed herein is a method for treating an otic disordercomprising administering at least once every 3, 4, 5, 6, 7, 8, 9, 10,11, 12, 13, 14, or 15 days, at least once a week, once every two weeks,once every three weeks, once every four weeks, once every five weeks, oronce every six weeks; or once a month, once every two months, once everythree months, once every four months, once every five months, once everysix months, once every seven months, once every eight months, once everynine months, once every ten months, once every eleven months, or onceevery twelve months with the compositions and formulations disclosedherein. In particular embodiments, the controlled release formulationsdescribed herein provide a sustained dose of corticosteroid to the innerear between subsequent doses of the controlled release formulation. Thatis, taking one example only, if new doses of the corticosteroidcontrolled release formulation are adminstered via intratympanicinjection to the round window membrane every 10 days, then thecontrolled release formulation provides an effective dose ofcorticosteroid to the inner ear (e.g., across the round window membrane)during that 10-day period.

In another aspect, the composition is administered so that thecomposition is in contact with the round window membrane. In one aspectthe composition is administered by intratympanic injection.

Provided herein are pharmaceutical compositions or devices for use inthe treatment of an otic disease or condition formulated to provide atherapeutically effective amount of dexamethasone, methylprednisolone,or prednisolone, the pharmaceutical compositions or devices comprisingsubstantially low degradation products of dexamethasone,methylprednisolone, or prednisolone, the pharmaceutical compositions ordevices further comprising two or more characteristics selected from:

-   -   (i) between about 0.1% to about 10% by weight of dexamethasone,        methylprednisolone, or prednisolone, or pharmaceutically        acceptable prodrug or salt thereof;    -   (ii) between about 16% to about 21% by weight of a        polyoxyethylene-polyoxypropylene triblock copolymer of general        formula E106 P70 E106;    -   (iii) sterile water, q.s., buffered to provide a pH between        about 5.5 and about 8.0;    -   (iv) multiparticulate dexamethasone, methylprednisolone, or        prednisolone;    -   (v) a gelation temperature between about 19° C. to about 42° C.;    -   (vi) less than about 50 colony forming units (cfu) of        microbiological agents per gram of formulation, and    -   (vii) less than about 5 endotoxin units (EU) per kg of body        weight of a subject.

In some embodiments, a pharmaceutical composition or device describedherein comprises:

-   -   (i) between about 0.1% to about 10% by weight of dexamethasone,        methylprednisolone, or prednisolone, or pharmaceutically        acceptable prodrug or salt thereof;    -   (ii) between about 16% to about 21% by weight of a        polyoxyethylene-polyoxypropylene triblock copolymer of general        formula E106 P70 E106; and    -   (iii) multiparticulate dexamethasone, methylprednisolone, or        prednisolone.

In some embodiments, a pharmaceutical composition or device describedherein comprises:

-   -   (i) between about 0.1% to about 10% by weight of dexamethasone,        methylprednisolone, or prednisolone, or pharmaceutically        acceptable prodrug or salt thereof;    -   (ii) between about 16% to about 21% by weight of a        polyoxyethylene-polyoxypropylene triblock copolymer of general        formula E106 P70 E106;    -   (iii) multiparticulate dexamethasone, methylprednisolone, or        prednisolone; and    -   (iv) a gelation temperature between about 19° C. to about 42° C.

In some embodiments a pharmaceutical composition or device describedabove provides a practical osmolarity between about 150 and 500 mOsm/L.In some embodiments a pharmaceutical composition or device describedabove provides a practical osmolarity between about 200 and 400 mOsm/L.In some embodiments a pharmaceutical composition or device describedabove provides a practical osmolarity between about 250 and 320 mOsm/L.

In some embodiments, the dexamethasone, methylprednisolone, orprednisolone is released from the pharmaceutical formulation or devicedescribed above for a period of at least 3 days. In some embodiments,the dexamethasone, methylprednisolone, or prednisolone is released fromthe pharmaceutical formulation or device described above for a period ofat least 5 days. In some embodiments, the dexamethasone,methylprednisolone, or prednisolone is released from the pharmaceuticalformulation or device described above for a period of at least 10 days.In some embodiments, the dexamethasone, methylprednisolone, orprednisolone is released from the pharmaceutical formulation or devicedescribed above for a period of at least 14 days. In some embodiments,the dexamethasone, methylprednisolone, or prednisolone is released fromthe pharmaceutical formulation or device described above for a period ofat least one month.

In some embodiments, a pharmaceutical composition or device describedabove comprises dexamethasone, methylprednisolone, or prednisolone as afree acid, a free alcohol, a salt or a prodrug. In some embodiments, apharmaceutical composition or device described above comprisesdexamethasone, methylprednisolone, or prednisolone as a free acid, afree alcohol, a salt or a prodrug, or a combination thereof.

In some embodiments, a pharmaceutical composition or device describedabove comprises dexamethasone, methylprednisolone, or prednisolone asmultiparticulates. In some embodiments, a pharmaceutical composition ordevice described above comprises dexamethasone, methylprednisolone, orprednisolone in the form of micronized particles. In some embodiments, apharmaceutical composition or device described above comprisesdexamethasone, methylprednisolone, or prednisolone as micronizedpowders.

In some embodiments, a pharmaceutical composition or device describedabove has a pH between about 5.5 to about 8.0. In some embodiments, apharmaceutical composition or device described above has a pH betweenabout 6.0 to about 8.0. In some embodiments, a pharmaceuticalcomposition or device described above has a pH between about 6.0 toabout 7.6.

In some embodiments, a pharmaceutical composition or device describedabove contains less than 100 colony forming units (cfu) ofmicrobiological agents per gram of formulation. In some embodiments, apharmaceutical composition or device described above contains less than50 colony forming units (cfu) of microbiological agents per gram offormulation. In some embodiments, a pharmaceutical composition or devicedescribed above contains less than 10 colony forming units (cfu) ofmicrobiological agents per gram of formulation.

In some embodiments, a pharmaceutical composition or device describedabove contains less than 5 endotoxin units (EU) per kg of body weight ofa subject. In some embodiments, a pharmaceutical composition or devicedescribed above contains less than 4 endotoxin units (EU) per kg of bodyweight of a subject.

In some embodiments a pharmaceutical composition or device describedabove provides a gelation temperature between about between about 19° C.to about 42° C. In some embodiments a pharmaceutical composition ordevice described above provides a gelation temperature between aboutbetween about 19° C. to about 37° C. In some embodiments apharmaceutical composition or device described above provides a gelationtemperature between about between about 19° C. to about 30° C.

In some embodiments, the pharmaceutical composition or device is anauris-acceptable thermoreversible gel. In some embodiments, thepolyoxyethylene-polyoxypropylene triblock copolymer is biodegradableand/or bioeliminated (e.g., the copolymer is eliminated from the body bya biodegradation process, e.g., elimination in the urine, the feces orthe like). In some embodiments, a pharmaceutical composition or devicedescribed herein further comprises a mucoadhesive. In some embodiments,a pharmaceutical composition or device described herein furthercomprises a penetration enhancer. In some embodiments, a pharmaceuticalcomposition or device described herein further comprises a thickeningagent. In some embodiments, a pharmaceutical composition or devicedescribed herein further comprises a dye.

In some embodiments, a pharmaceutical composition or device describedherein further comprises a drug delivery device selected from a needleand syringe, a pump, a microinjection device, a wick, an in situ formingspongy material or combinations thereof.

In some embodiments, a pharmaceutical composition or device describedherein is a pharmaceutical composition or device wherein thedexamethasone, methylprednisolone, or prednisolone, or pharmaceuticallyacceptable salt thereof, has limited or no systemic release, systemictoxicity, poor PK characteristics, or combinations thereof. In someembodiments of the pharmaceutical compositions or devices describedherein, the dexamethasone, methylprednisolone, or prednisolone is in theform of a free base, a free acid, a salt, a prodrug, or a combinationthereof. In some embodiments of the pharmaceutical compositions ordevices described herein, the dexamethasone, methylprednisolone, orprednisolone is administered in the form of a phosphate or esterprodrug. In some embodiments of the pharmaceutical compositions ordevices described herein, the steroid is dexamethasone phosphate ordexamethasone acetate. In some embodiments pharmaceutical compositionsor devices described herein comprise dexamethasone, methylprednisolone,prednisolone, or pharmaceutically acceptable salt thereof, prodrug orcombination thereof as an immediate release agent.

In some embodiments, pharmaceutical compositions or devices describedherein are pharmaceutical compositions or devices wherein thedexamethasone, methylprednisolone, or prednisolone comprisesmultiparticulates. In some embodiments, pharmaceutical compositions ordevices described herein are pharmaceutical compositions or deviceswherein the dexamethasone, methylprednisolone, or prednisolone isessentially in the form of micronized particles. In some embodiments ofthe pharmaceutical compositions or devices described herein, thedexamethasone is in the form of micro-dexamethasone powder.

In some embodiments, pharmaceutical compositions or devices describedherein further comprise an additional therapeutic agent. In someembodiments, the additional therapeutic agent is a Na/K ATPasemodulator, a chemotherapeutic agent, a collagen, a gamma-globulin, aninterferon, an anti-microbial agent, an antibiotic, a local actinganesthetic agent, a platelet activator factor antagonist, anotoprotectant, a nitric oxide synthase inhibitor, an anti-vertigo agent,a vasopressin antagonist, an anti-viral agent, an anti-emetic agent, ananti-TNF agent, a vasopressin receptor modulator, methotrexate,cyclophosphamide, immunosuppressants, macrolides, latanoprost, a TNFconverting enzyme inhibitor, an IKK inhibitor, a glutamate receptormodulator, an anti-apoptotic agent, a neuroprotectant, thalidomide,c-jun inhibitor compound, hyaluronidase, antioxidants, M-1 betamodulators, ERR-beta antagonist, IGF-1 modulators, Toll-like receptors,KCNQ channel modulators, neurotropin modulators, ATOH modulators orcombinations thereof.

In some embodiments, pharmaceutical compositions or devices describedherein are pharmaceutical compositions or devices wherein the pH of thepharmaceutical composition or device is between about 6.0 to about 7.6.

In some embodiments of the pharmaceutical compositions or devicesdescribed herein, the ratio of a polyoxyethylene-polyoxypropylenetriblock copolymer of general formula E106 P70 E106 to a thickeningagent is from about 40:1 to about 5:1. In some embodiments, thethickening agent is carboxymethyl cellulose, hydroxypropyl cellulose orhydroxypropyl methylcellulose.

In some embodiments, the otic disease or condition is Meniere's disease,sudden sensorineural hearing loss, noise induced hearing loss, agerelated hearing loss, auto immune ear disease or tinnitus.

Also provided herein is a method of treating an otic disease orcondition comprising administering to an individual in need thereof anintratympanic composition or device comprising a therapeuticallyeffective amount of dexamethasone, methylprednisolone, or prednisolone,the composition or device comprising substantially low degradationproducts of dexamethasone, methylprednisolone, or prednisolone, thecomposition or device further comprising two or more characteristicsselected from:

-   -   (i) between about 0.1% to about 10% by weight of dexamethasone,        methylprednisolone, or prednisolone, or pharmaceutically        acceptable prodrug or salt thereof;    -   (ii) between about 16% to about 21% by weight of a        polyoxyethylene-polyoxypropylene triblock copolymer of general        formula E106 P70 E106;    -   (iii) sterile water, q.s., buffered to provide a pH between        about 5.5 and about 8.0;    -   (iv) multiparticulate dexamethasone, methylprednisolone, or        prednisolone;    -   (v) a gelation temperature between about 19° C. to about 42° C.;    -   (vi) less than about 50 colony forming units (cfu) of        microbiological agents per gram of formulation, and    -   (vii) less than about 5 endotoxin units (EU) per kg of body        weight of a subject.

In some embodiments of the methods described herein, the dexamethasone,methylprednisolone, or prednisolone is released from the composition ordevices for a period of at least 3 days. In some embodiments of themethods described herein, the dexamethasone, methylprednisolone, orprednisolone is released from the composition or device for a period ofat least 5 days. In some embodiments of the methods described herein,the dexamethasone, methylprednisolone, or prednisolone is released fromthe composition or device for a period of at least 10 days. In someembodiments of the method described above, the dexamethasone,methylprednisolone, or prednisolone is essentially in the form ofmicronized particles.

In some embodiments of the methods described herein, the composition isadministered across the round window. In some embodiments of the methodsdescribed herein, the otic disease or condition is Meniere's disease,sudden sensorineural hearing loss, noise induced hearing loss, agerelated hearing loss, auto immune ear disease or tinnitus.

BRIEF DESCRIPTION OF FIGURES

FIG. 1. illustrates in vitro release profile of Dexamethasone vs.varying concentrations of Poloxamer 407.

FIG. 2 illustrates the relationship between the mean dissolution time(MDT) of a formulation and the P407 concentration.

FIG. 3. illustrates release profiles of various steroidal formulationscontaining 17% P407.

FIG. 4. illustrates the correlation between mean dissolution time (MDT)and apparent viscosity of formulation

FIG. 5 illustrates the effect of concentration on the viscosity ofaqueous solutions of Blanose refined CMC

FIG. 6 illustrates the effect of concentration on the viscosity ofaqueous solutions of Methocel

FIG. 7 illustrates the gel fate in the guinea pig ear up to 5 days afterintratympanic injection.

FIG. 8A-8B illustrates the gel elimination time course for formulationsdescribed herein

FIG. 9 illustrates the release profile for formulations described herein

FIG. 10 illustrates the anatomy of the ear

DETAILED DESCRIPTION OF THE INVENTION

Provided herein are controlled release corticosteroid compositions andformulations to treat diseases of the ear, including Meniere's diseaseand sensineural hearing loss.

A few therapeutic products are available for the treatment of oticdisorders such as AIED, however, systemic routes via oral, intravenousor intramuscular routes are currently used to deliver these therapeuticagents. Systemic drug administration may create a potential inequalityin drug concentration with higher circulating levels in the serum, andlower levels in the target auris media and auris interna organstructures. As a result, fairly large amounts of drug are required toovercome this inequality in order to deliver sufficient, therapeuticallyeffective quantities to the inner ear. In addition, systemic drugadministration may increase the likelihood of systemic toxicities andadverse side effects as a result of the high serum amounts required toeffectuate sufficient local delivery to the target site. Systemictoxicities may also occur as a result of liver breakdown and processingof the therapeutic agents, forming toxic metabolites that effectivelyerase any benefit attained from the administered therapeutic.

To overcome the toxic and attendant side effects of systemic delivery,disclosed herein are methods and compositions and devices for localdelivery of therapeutic agents to targeted auris structures. Access to,for example, the vestibular and cochlear apparatus will occur throughthe auris media including round window membrane, the oval window/stapesfootplate, the annular ligament and through the otic capsule/temporalbone.

Accordingly, provided herein are controlled release corticosteroidformulations and compositions to locally treat targeted aurisstructures, thereby avoiding side effects as a result of systemicadministration of the corticosteroid formulations and compositions. Thelocally applied corticosteroid formulations and compositions and devicesare compatible with the targeted auris structures, and administeredeither directly to the desired targeted auris structure, e.g. thecochlear region, the tympanic cavity or the external ear, oradministered to a structure in direct communication with areas of theauris interna, including but not limited to the round window membrane,the crista fenestrae cochleae or the oval window membrane. Byspecifically targeting an auris structure, adverse side effects as aresult of systemic treatment are avoided. Moreover, clinical studieshave shown the benefit of having long term exposure of drug to theperilymph of the cochlea, for example with improved clinical efficacy ofsudden hearing loss when the therapeutic agent is given on multipleoccasions. Thus, by providing a controlled release corticosteroidformulation or composition to treat otic disorders, a constant, variableand/or extended source of corticosteroid is provided to the individualor patient suffering from an otic disorder, reducing or eliminating thevariability of treatment. Accordingly, one embodiment disclosed hereinis to provide a formulation that enables at least one corticosteroid tobe released in therapeutically effective doses either at variable orconstant rates such as to ensure a continuous release of the at leastone agent. In some embodiments, the corticosteroids disclosed herein areadministered as an immediate release formulation or composition. Inother embodiments, the steroid and/or ATPase modulator agents areadministered as a sustained release formulation, released eithercontinuously, variably or in a pulsatile manner, or variants thereof. Instill other embodiments, corticosteroid formulation is administered asboth an immediate release and sustained release formulation, releasedeither continuously, variably or in a pulsatile manner, or variantsthereof. The release is optionally dependent on environmental orphysiological conditions, for example, the external ionic environment(see, e.g. Oros® release system, Johnson & Johnson).

In addition, localized treatment of the targeted auris structure alsoaffords the use of previously undesired therapeutic agents, includingagents with poor pK profiles, poor uptake, low systemic release and/ortoxicity issues. Because of the localized targeting of thecorticosteroid formulations and compositions and devices, as well as thebiological blood barrier present in the auris interna, the risk ofadverse effects will be reduced as a result of treatment with previouslycharacterized toxic or ineffective corticosteroids. Accordingly, alsocontemplated within the scope of the embodiments herein is the use ofcorticosteroids in the treatment of otic disorders that have beenpreviously rejected by practitioners because of adverse effects orineffectiveness of the corticosteroid.

Also included within the embodiments disclosed herein is the use ofadditional auris-compatible agents in combination with thecorticosteroid formulations and compositions and devices disclosedherein. When used, such agents assist in the treatment of hearing orequilibrium loss or dysfunction as a result of an autoimmune disorder,including vertigo, tinnitus, hearing loss, balance disorders,infections, or combinations thereof. Accordingly, agents that ameliorateor reduce the effects of vertigo, tinnitus, hearing loss, balancedisorders, infections, inflammatory response or combinations thereof arealso contemplated to be used in combination with the corticosteroid(s),including anti-TNF agents, anti-emetic agents, chemotherapeutic agents,including cytoxan, azathiaprine or methotrexate; treatment withcollagen, gamma globulin, interferons, copaxone, central nervous systemagents, local acting anesthetic agents, antibiotics, platelet-activatingfactor antagonists, nitric oxide synthase inhibitors and combinationsthereof.

In addition, the auris-acceptable controlled-release corticosteroidformulations and treatments described herein are provided to the targetear region of the individual in need, including the inner ear, and theindividual in need is additionally administered an oral dose ofcorticosteroid. In some embodiments, the oral dose of corticosteroid isadministered prior to administration of the auris-acceptablecontrolled-release corticosteroid formulation, and then the oral dose istapered off over the period of time that the auris-acceptablecontrolled-release corticosteroid formulation is provided.Alternatively, the oral dose of corticosteroid is administered duringadministration of the auris-acceptable controlled-release corticosteroidformulation, and then the oral dose is tapered off over the period oftime that the auris-acceptable controlled-release corticosteroidformulation is provided. Alternatively, the oral dose of corticosteroidis administered after administration of the auris-acceptablecontrolled-release corticosteroid formulation has been initiated, andthen the oral dose is tapered off over the period of time that theauris-acceptable controlled-release corticosteroid formulation isprovided.

In addition, the corticosteroid pharmaceutical compositions orformulations or devices included herein also include carriers,adjuvants, such as preserving, stabilizing, wetting or emulsifyingagents, solution promoters, salts for regulating the osmotic pressure,and/or buffers. Such carriers, adjuvants, and other excipients will becompatible with the environment in the targeted auris structure(s).Accordingly, specifically contemplated are carriers, adjuvants andexcipients that lack ototoxicity or are minimally ototoxic in order toallow effective treatment of the otic disorders contemplated herein withminimal side effects in the targeted regions or areas. To preventototoxicity, corticosteroid pharmaceutical compositions or formulationsor devices disclosed herein are optionally targeted to distinct regionsof the targeted auris structures, including but not limited to thetympanic cavity, vestibular bony and membranous labyrinths, cochlearbony and membranous labyrinths and other anatomical or physiologicalstructures located within the auris interna.

CERTAIN DEFINITIONS

The term “auris-acceptable” with respect to a formulation, compositionor ingredient, as used herein, includes having no persistent detrimentaleffect on the auris media (or middle ear) and the auris interna (orinner ear) of the subject being treated. By “auris-pharmaceuticallyacceptable,” as used herein, refers to a material, such as a carrier ordiluent, which does not abrogate the biological activity or propertiesof the compound in reference to the auris media (or middle ear) and theauris interna (or inner ear), and is relatively or is reduced intoxicity to the auris media (or middle ear) and the auris interna (orinner ear), i.e., the material is administered to an individual withoutcausing undesirable biological effects or interacting in a deleteriousmanner with any of the components of the composition in which it iscontained.

As used herein, amelioration or lessening of the symptoms of aparticular otic disease, disorder or condition by administration of aparticular compound or pharmaceutical composition refers to any decreaseof severity, delay in onset, slowing of progression, or shortening ofduration, whether permanent or temporary, lasting or transient that isattributed to or associated with administration of the compound orcomposition.

“Antioxidants” are auris-pharmaceutically acceptable antioxidants, andinclude, for example, butylated hydroxytoluene (BHT), sodium ascorbate,ascorbic acid, sodium metabisulfite and tocopherol. In certainembodiments, antioxidants enhance chemical stability where required.Antioxidants are also used to counteract the ototoxic effects of certaintherapeutic agents, including agents that are used in combination withthe corticosteroids disclosed herein.

“Auris interna” refers to the inner ear, including the cochlea and thevestibular labyrinth, and the round window that connects the cochleawith the middle ear.

“Auris-bioavailability” or “Auris-interna bioavailability” or“Auris-media bioavailability” or “Auris-externa bioavailability” refersto the percentage of the administered dose of compounds disclosed hereinthat becomes available in the targeted auris structure of the animal orhuman being studied.

“Auris media” refers to the middle ear, including the tympanic cavity,auditory ossicles and oval window, which connects the middle ear withthe inner ear.

“Auris externa” refers to the outer ear, including the pinna, theauditory canal, and the tympanic membrane, which connects the outer earwith the middle ear.

“Blood plasma concentration” refers to the concentration of compoundsprovided herein in the plasma component of blood of a subject.

“Carrier materials” are excipients that are compatible withcorticosteroid(s), the targeted auris structure(s) and the releaseprofile properties of the auris-acceptable pharmaceutical formulations.Such carrier materials include, e.g., binders, suspending agents,disintegration agents, filling agents, surfactants, solubilizers,stabilizers, lubricants, wetting agents, diluents, and the like.“Auris-pharmaceutically compatible carrier materials” include, but arenot limited to, acacia, gelatin, colloidal silicon dioxide, calciumglycerophosphate, calcium lactate, maltodextrin, glycerine, magnesiumsilicate, polyvinylpyrrolidone (PVP), cholesterol, cholesterol esters,sodium caseinate, soy lecithin, taurocholic acid, phosphatidylcholine,sodium chloride, tricalcium phosphate, dipotassium phosphate, celluloseand cellulose conjugates, sugars sodium stearoyl lactylate, carrageenan,monoglyceride, diglyceride, pregelatinized starch, and the like.

The term “diluent” refers to chemical compounds that are used to dilutethe corticosteroid prior to delivery and which are compatible with thetargeted auris structure(s).

“Dispersing agents,” and/or “viscosity modulating agents” are materialsthat control the diffusion and homogeneity of the corticosteroid throughliquid media. Examples of diffusion facilitators/dispersing agentsinclude but are not limited to hydrophilic polymers, electrolytes,Tween® 60 or 80, PEG, polyvinylpyrrolidone (PVP; commercially known asPlasdone®), and the carbohydrate-based dispersing agents such as, forexample, hydroxypropyl celluloses (e.g., HPC, HPC-SL, and HPC-L),hydroxypropyl methylcelluloses (e.g., HPMC K100, HPMC K4M, HPMC K15M,and HPMC K100M), carboxymethylcellulose sodium, methylcellulose,hydroxyethylcellulose, hydroxypropylcellulose,hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcelluloseacetate stearate (HPMCAS), noncrystalline cellulose, magnesium aluminumsilicate, triethanolamine, polyvinyl alcohol (PVA), vinylpyrrolidone/vinyl acetate copolymer (S630),4-(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide andformaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronic F127,Pluronics F68®, F88®, and F108®, which are block copolymers of ethyleneoxide and propylene oxide); and poloxamines (e.g., Tetronic 908®, alsoknown as Poloxamine 908®, which is a tetrafunctional block copolymerderived from sequential addition of propylene oxide and ethylene oxideto ethylenediamine (BASF Corporation, Parsippany, N.J.)),polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidoneK25, or polyvinylpyrrolidone K30, polyvinylpyrrolidone/vinyl acetatecopolymer (S-630), polyethylene glycol, e.g., the polyethylene glycolhas a molecular weight of about 300 to about 6000, or about 3350 toabout 4000, or about 7000 to about 5400, sodium carboxymethylcellulose,methylcellulose, polysorbate-80, sodium alginate, gums, such as, e.g.,gum tragacanth and gum acacia, guar gum, xanthans, including xanthangum, sugars, cellulosics, such as, e.g., sodium carboxymethylcellulose,methylcellulose, sodium carboxymethylcellulose, polysorbate-80, sodiumalginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitanmonolaurate, povidone, carbomers, polyvinyl alcohol (PVA), alginates,chitosans and combinations thereof. Plasticizers such as cellulose ortriethyl cellulose are also be used as dispersing agents. Optionaldispersing agents useful in liposomal dispersions and self-emulsifyingdispersions of the corticosteroids disclosed herein are dimyristoylphosphatidyl choline, phosphatidyl cholines (c8-c18),phosphatidylethanolamines (c8-c18), phosphatidyl glycerols (c8-c18),natural phosphatidyl choline from eggs or soy, natural phosphatidylglycerol from eggs or soy, cholesterol and isopropyl myristate.

“Drug absorption” or “absorption” refers to the process of movement ofthe corticosteroid(s) from the localized site of administration, by wayof example only, the round window membrane of the inner ear, and acrossa barrier (the round window membranes, as described below) into theauris interna or inner ear structures. The terms “co-administration” orthe like, as used herein, are meant to encompass administration of thecorticosteroids to a single patient, and are intended to includetreatment regimens in which the corticosteroids are administered by thesame or different route of administration or at the same or differenttime.

The terms “effective amount” or “therapeutically effective amount,” asused herein, refer to a sufficient amount of the corticosteroids beingadministered that would be expected to relieve to some extent one ormore of the symptoms of the disease or condition being treated. Forexample, the result of administration of the corticosteroid agentsdisclosed herein is reduction and/or alleviation of the signs, symptoms,or causes of MED. For example, an “effective amount” for therapeuticuses is the amount of the corticosteroid, including a formulation asdisclosed herein required to provide a decrease or amelioration indisease symptoms without undue adverse side effects. The term“therapeutically effective amount” includes, for example, aprophylactically effective amount. An “effective amount” of acorticosteroid composition disclosed herein is an amount effective toachieve a desired pharmacologic effect or therapeutic improvementwithout undue adverse side effects. It is understood that “an effectiveamount” or “a therapeutically effective amount” varies, in someembodiments, from subject to subject, due to variation in metabolism ofthe compound administered, age, weight, general condition of thesubject, the condition being treated, the severity of the conditionbeing treated, and the judgment of the prescribing physician. It is alsounderstood that “an effective amount” in an extended-release dosingformat may differ from “an effective amount” in an immediate-releasedosing format based upon pharmacokinetic and pharmacodynamicconsiderations.

The terms “enhance” or “enhancing” refers to an increase or prolongationof either the potency or duration of a desired effect of thecorticosteroid, or a diminution of any adverse symptomatology such aslocalized pain that is consequent upon administration of the therapeuticagent. Thus, in regard to enhancing the effect of the corticosteroidsdisclosed herein, the term “enhancing” refers to the ability to increaseor prolong, either in potency or duration, the effect of othertherapeutic agents that are used in combination with the corticosteroidsdisclosed herein. An “enhancing-effective amount,” as used herein,refers to an amount of corticosteroids, or other therapeutic agent, thatis adequate to enhance the effect of another therapeutic agent orcorticosteroids in a desired system. When used in a patient, amountseffective for this use will depend on the severity and course of thedisease, disorder or condition, previous therapy, the patient's healthstatus and response to the drugs, and the judgment of the treatingphysician.

The term “inhibiting” includes preventing, slowing, or reversing thedevelopment of a condition, for example, AIED, or advancement of acondition in a patient necessitating treatment.

The terms “kit” and “article of manufacture” are used as synonyms.

“Pharmacodynamics” refers to the factors which determine the biologicresponse observed relative to the concentration of drug at the desiredsite within the targeted auris structure.

“Pharmacokinetics” refers to the factors which determine the attainmentand maintenance of the appropriate concentration of drug at the desiredsite within the targeted auris structure.

In prophylactic applications, compositions containing thecorticosteroids described herein are administered to a patientsusceptible to or otherwise at risk of a particular disease, disorder orcondition, for example, Meniere's disease, or patients that aresuffering from diseases associated with AIED, including by way ofexample only, Ankylosing spondylitis, Systemic Lupus Erythematosus(SLE), Sjögren's Syndrome, Cogan's disease, ulcerative colitis,Wegener's granulomatosis, inflammatory bowel disease, rheumatoidarthritis, scleroderma and Behçet's disease. Such an amount is definedto be a “prophylactically effective amount or dose.” In this use, theprecise amounts also depend on the patient's state of health, weight,and the like.

As used herein, a “pharmaceutical device” includes any compositiondescribed herein that, upon administration to an ear, provides areservoir for extended release of an active agent described herein.

A “prodrug” refers to the corticosteroid that is converted into theparent drug in vivo. In certain embodiments, a prodrug is enzymaticallymetabolized by one or more steps or processes to the biologically,pharmaceutically or therapeutically active form of the compound. Toproduce a prodrug, a pharmaceutically active compound is modified suchthat the active compound will be regenerated upon in vivoadministration. In one embodiment, the prodrug is designed to alter themetabolic stability or the transport characteristics of a drug, to maskside effects or toxicity, or to alter other characteristics orproperties of a drug. Compounds provided herein, in some embodiments,are derivatized into suitable prodrugs.

“Round window membrane” is the membrane in humans that covers thefenestrae cochlea (also known as the circular window, fenestrae rotunda,or round window). In humans, the thickness of round window membrane isabout 70 micron.

“Solubilizers” refers to auris-acceptable compounds such as triacetin,triethylcitrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate,sodium caprate, sucrose esters, alkylglucosides, sodium doccusate,vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone,N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropyl cyclodextrins, ethanol, n-butanol, isopropylalcohol, cholesterol, bile salts, polyethylene glycol 200-600,glycofurol, transcutol, propylene glycol, and dimethyl isosorbide andthe like.

“Stabilizers” refers to compounds such as any antioxidation agents,buffers, acids, preservatives and the like that are compatible with theenvironment of the targeted auris structure. Stabilizers include but arenot limited to agents that will do any of (1) improve the compatibilityof excipients with a container, or a delivery system, including asyringe or a glass bottle, (2) improve the stability of a component ofthe composition, or (3) improve formulation stability.

“Steady state,” as used herein, is when the amount of drug administeredto the targeted auris structure is equal to the amount of drugeliminated within one dosing interval resulting in a plateau or constantlevels of drug exposure within the targeted structure.

As used herein, the term “subject” is used to mean an animal, preferablya mammal, including a human or non-human. The terms patient and subjectmay be used interchangeably.

“Surfactants” refers to compounds that are auris-acceptable, such assodium lauryl sulfate, sodium docusate, Tween® 60 or 80, triacetin,vitamin E TPGS, sorbitan monooleate, polyoxyethylene sorbitanmonooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate,copolymers of ethylene oxide and propylene oxide, e.g., Pluronic®(BASF), and the like. Some other surfactants include polyoxyethylenefatty acid glycerides and vegetable oils, e.g., polyoxyethylene (60)hydrogenated castor oil; and polyoxyethylene alkylethers and alkylphenylethers, e.g., octoxynol 10, octoxynol 40. In some embodiments,surfactants are included to enhance physical stability or for otherpurposes.

The terms “treat,” “treating” or “treatment,” as used herein, includealleviating, abating or ameliorating a disease or condition symptoms,preventing additional symptoms, ameliorating or preventing theunderlying metabolic causes of symptoms, inhibiting the disease orcondition, e.g., arresting the development of the disease or condition,relieving the disease or condition, causing regression of the disease orcondition, relieving a condition caused by the disease or condition, orstopping the symptoms of the disease or condition eitherprophylactically and/or therapeutically.

Anatomy of the Ear

As shown in the illustration below, the outer ear is the externalportion of the organ and is composed of the pinna (auricle), theauditory canal (external auditory meatus) and the outward facing portionof the tympanic membrane, also known as the ear drum. The pinna, whichis the fleshy part of the external ear that is visible on the side ofthe head, collects sound waves and directs them toward the auditorycanal. Thus, the function of the outer ear, in part, is to collect anddirect sound waves towards the tympanic membrane and the middle ear.

The middle ear is an air-filled cavity, called the tympanic cavity,behind the tympanic membrane. The tympanic membrane, also known as theear drum, is a thin membrane that separates the external ear from themiddle ear. The middle ear lies within the temporal bone, and includeswithin this space the three ear bones (auditory ossicles): the malleus,the incus and the stapes. The auditory ossicles are linked together viatiny ligaments, which form a bridge across the space of the tympaniccavity. The malleus, which is attached to the tympanic membrane at oneend, is linked to the incus at its anterior end, which in turn is linkedto the stapes. The stapes is attached to the oval window, one of twowindows located within the tympanic cavity. A fibrous tissue layer,known as the annular ligament connects the stapes to the oval window.Sound waves from the outer ear first cause the tympanic membrane tovibrate. The vibration is transmitted across to the cochlea through theauditory ossicles and oval window, which transfers the motion to thefluids in the auris interna. Thus, the auditory ossicles are arranged toprovide a mechanical linkage between the tympanic membrane and the ovalwindow of the fluid-filled auris interna, where sound is transformed andtransduced to the auris interna for further processing. Stiffness,rigidity or loss of movement of the auditory ossicles, tympanic membraneor oval window leads to hearing loss, e.g. otosclerosis, or rigidity ofthe stapes bone.

The tympanic cavity also connects to the throat via the eustachian tube.The eustachian tube provides the ability to equalize the pressurebetween the outside air and the middle ear cavity. The round window, acomponent of the auris interna but which is also accessible within thetympanic cavity, opens into the cochlea of the auris interna. The roundwindow is covered by round window membrane, which consists of threelayers: an external or mucous layer, an intermediate or fibrous layer,and an internal membrane, which communicates directly with the cochlearfluid. The round window, therefore, has direct communication with theauris interna via the internal membrane.

Movements in the oval and round window are interconnected, i.e. as thestapes bone transmits movement from the tympanic membrane to the ovalwindow to move inward against the auris interna fluid, the round window(more correctly, round window membrane) is correspondingly pushed outand away from the cochlear fluid. This movement of the round windowallows movement of fluid within the cochlea, which leads in turn tomovement of the cochlear inner hair cells, allowing hearing signals tobe transduced. Stiffness and rigidity in round window membrane leads tohearing loss because of the lack of ability of movement in the cochlearfluid. Recent studies have focused on implanting mechanical transducersonto the round window, which bypasses the normal conductive pathwaythrough the oval window and provides amplified input into the cochlearchamber.

Auditory signal transduction takes place in the auris interna. Thefluid-filled auris interna, or inner ear, consists of two majorcomponents: the cochlear and the vestibular apparatus. The auris internais located in part within the osseous or bony labyrinth, an intricateseries of passages in the temporal bone of the skull. The vestibularapparatus is the organ of balance and consists of the threesemi-circular canals and the vestibule. The three semi-circular canalsare arranged relative to each other such that movement of the head alongthe three orthogonal planes in space can be detected by the movement ofthe fluid and subsequent signal processing by the sensory organs of thesemi-circular canals, called the crista ampullaris. The cristaampullaris contains hair cells and supporting cells, and is covered by adome-shaped gelatinous mass called the cupula. The hairs of the haircells are embedded in the cupula. The semi-circular canals detectdynamic equilibrium, the equilibrium of rotational or angular movements.

When the head turns rapidly, the semicircular canals move with the head,but endolymph fluid located in the membranous semi-circular canals tendsto remain stationary. The endolymph fluid pushes against the cupula,which tilts to one side. As the cupula tilts, it bends some of the hairson the hair cells of the crista ampullaris, which triggers a sensoryimpulse. Because each semicircular canal is located in a differentplane, the corresponding crista ampullaris of each semi-circular canalresponds differently to the same movement of the head. This creates amosaic of impulses that are transmitted to the central nervous system onthe vestibular branch of the vestibulocochlear nerve. The centralnervous system interprets this information and initiates the appropriateresponses to maintain balance. Of importance in the central nervoussystem is the cerebellum, which mediates the sense of balance andequilibrium.

The vestibule is the central portion of the auris interna and containsmechanoreceptors bearing hair cells that ascertain static equilibrium,or the position of the head relative to gravity. Static equilibriumplays a role when the head is motionless or moving in a straight line.The membranous labyrinth in the vestibule is divided into two sac-likestructures, the utricle and the saccule. Each structure in turn containsa small structure called a macula, which is responsible for maintenanceof static equilibrium. The macula consists of sensory hair cells, whichare embedded in a gelatinous mass (similar to the cupula) that coversthe macula. Grains of calcium carbonate, called otoliths, are embeddedon the surface of the gelatinous layer.

When the head is in an upright position, the hairs are straight alongthe macula. When the head tilts, the gelatinous mass and otoliths tiltscorrespondingly, bending some of the hairs on the hair cells of themacula. This bending action initiates a signal impulse to the centralnervous system, which travels via the vestibular branch of thevestibulocochlear nerve, which in turn relays motor impulses to theappropriate muscles to maintain balance.

The cochlea is the portion of the auris interna related to hearing. Thecochlea is a tapered tube-like structure which is coiled into a shaperesembling a snail. The inside of the cochlea is divided into threeregions, which is further defined by the position of the vestibularmembrane and the basilar membrane. The portion above the vestibularmembrane is the scala vestibuli, which extends from the oval window tothe apex of the cochlea and contains perilymph fluid, an aqueous liquidlow in potassium and high in sodium content. The basilar membranedefines the scala tympani region, which extends from the apex of thecochlea to the round window and also contains perilymph. The basilarmembrane contains thousands of stiff fibers, which gradually increase inlength from the round window to the apex of the cochlea. The fibers ofthe basement membrane vibrate when activated by sound. In between thescala vestibuli and the scala tympani is the cochlear duct, which endsas a closed sac at the apex of the cochlea. The cochlear duct containsendolymph fluid, which is similar to cerebrospinal fluid and is high inpotassium.

The organ of Corti, the sensory organ for hearing, is located on thebasilar membrane and extends upward into the cochlear duct. The organ ofCorti contains hair cells, which have hairlike projections that extendfrom their free surface, and contacts a gelatinous surface called thetectorial membrane. Although hair cells have no axons, they aresurrounded by sensory nerve fibers that form the cochlear branch of thevestibulocochlear nerve (cranial nerve VIII).

As discussed, the oval window, also known as the elliptical windowcommunicates with the stapes to relay sound waves that vibrate from thetympanic membrane. Vibrations transferred to the oval window increasespressure inside the fluid-filled cochlea via the perilymph and scalavestibuli/scala tympani, which in turn causes the round window membraneto expand in response. The concerted inward pressing of the ovalwindow/outward expansion of the round window allows for the movement offluid within the cochlea without a change of intra-cochlear pressure.However, as vibrations travel through the perilymph in the scalavestibuli, they create corresponding oscillations in the vestibularmembrane. These corresponding oscillations travel through the endolymphof the cochlear duct, and transfer to the basilar membrane. When thebasilar membrane oscillates, or moves up and down, the organ of Cortimoves along with it. The hair cell receptors in the Organ of Corti thenmove against the tectorial membrane, causing a mechanical deformation inthe tectorial membrane. This mechanical deformation initiates the nerveimpulse which travels via the vestibulocochlear nerve to the centralnervous system, mechanically transmitting the sound wave received intosignals that are subsequently processed by the central nervous system.

Diseases

Otic disorders, including auris interna, auris media and auris externadisorders, produce symptoms which include but are not limited to hearingloss, nystagmus, vertigo, tinnitus, inflammation, swelling, infectionand congestion. These disorders may have many causes, such as infection,injury, inflammation, tumors and adverse response to drugs or otherchemical agents. Several causes of hearing and/or equilibrium impairmentor inflammation may be attributed to an autoimmune disorder and/or acytokine-mediated inflammatory response. In one embodiment, the oticdisorder is Meniere's disease. In one embodiment, the otic disorder issensineural hearing loss. In one embodiment the otic disorder isautoimmune inner ear disease (MED). In one embodiment, the otic disorderis Meniere's disease. In further embodiments the otic disorder isMeniere's syndrome, vestibular neuronitis, postural vertigo, RamsayHunt's Syndrome (herpes zoster infection), syphilis infection,drug-induced inner ear damage, auditory nerve tumors, hearing loss fromexcessive noise, presbycusis, otosclerosis, or temporomandibular jointdisease.

The disease presented herein, included those presented below are treatedusing the steroid pharmaceutical compositions described herein.

Meniere's Disease

Meniere's Disease is an idiopathic condition characterized by suddenattacks of vertigo, nausea and vomiting that may last for 3 to 24 hours,and may subside gradually. Progressive hearing loss, tinnitus and asensation of pressure in the ears accompanies the disease through time.The cause of Meniere's disease is unknown but is probably related to animbalance of inner ear fluid homeostasis, including an increase inproduction or a decrease in reabsorption of inner ear fluid.

Surgical procedures that have been used to relieve symptoms include thedestruction of vestibular and/or cochlear function to relieve vertigosymptoms. These procedures aim to either reduce fluid pressure in theinner ear and/or to destroy inner ear balance function. An endolymphaticshunt procedure, which relieves fluid pressure, may be placed in theinner ear to relieve symptoms of vestibular dysfunction. Othertreatments include gentamicin application, which when injected into theeardrum destroys sensory hair cell function, thereby eradicating innerear balance function. Severing of the vestibular nerve may also beemployed, which while preserving hearing, may control vertigo.

A standard of care for Meniere's Disease requires an individual tofollow a low salt diet. In certain instances, the low salt diet issupplemented with administration of an antibiotic. In certain instances,the low salt diet is supplemented with administration of gentamycin. Incertain instances, the low salt diet is supplemented with administrationof an oral steroid. In certain instances, the low salt diet issupplemented with administration of oral prednisone (25-50 mg PO/IM/PRq4-6h).

In one set of embodiments, a patient who is being treated for Meniere'sDisease using a standard of care presented above, is instead treatedusing the controlled-release corticosteroid auris-acceptableformulations and methods described herein. In another set ofembodiments, a patient who is being treated for Meniere's Disease usinga standard of care presented above, but who is refractory orunresponsive to such treatment, is instead treated using thecontrolled-release corticosteroid auris-acceptable formulations andmethods described herein.

In some embodiments, mechanical or imaging devices are used to monitoror survey the hearing, balance or other auris disorder. For example,magnetic resonance imaging (MRI) devices are specifically contemplatedwithin the scope of the embodiments, wherein the MRI devices (forexample, 3 Tesla MRI devices) are capable of evaluating Meniere Diseaseprogression, and subsequent treatment with the pharmaceuticalformulations disclosed herein. Gadolinium-based dyes, iodine-base dyes,barium-based dyes or the like are also contemplated for use with anyauris-compatible composition or device described herein and/or with anymechanical or imaging devices described herein. In certain embodiments,gadolinium hydrate is used in combination with MRI and/or anypharmaceutical composition or device described herein to evaluatedisease severity (e.g., size of endolymphatic hydrops), formulationpenetration into the inner ear, and/or therapeutic effectiveness of thepharmaceutical formulations/devices in the otic diseases describedherein (e.g., Meniere's disease).

Meniere's Syndrome

Meniere's Syndrome, which displays similar symptoms as Meniere'sdisease, is attributed as a secondary affliction to another diseaseprocess, e.g. thyroid disease or inner ear inflammation due to syphillisinfection. Meniere's syndrome, thus, are secondary effects to variousprocess that interfere with normal production or resporption ofendolymph, including endocrine abnormalities, electrolyte imbalance,autoimmune dysfuntion, medications, infections (e.g. parasiticinfections) or hyperlipidemia. Treatment of patients afflicted withMeniere's Syndrome is similar to Meniere's Disease.

Sensorineural Hearing Loss

Sensorineural hearing loss occurs when the components of the inner earor accompanying neural components are affected, and may contain aneural, i.e. when the auditory nerve or auditory nerve pathways in thebrain are affected, or sensory component. Sensory hearing loss may behereditary, or it may be caused by acoustic trauma (e.g., very loudnoises), a viral infection, drug-induced or Meniere's disease. Neuralhearing loss may occur as a result of brain tumors, infections, orvarious brain and nerve disorders, such as stroke. Some hereditarydiseases, such as Refsum's disease (defective accumulation of branchedfatty acids), may also cause neural disorders affecting hearing loss.Auditory nerve pathways may be damaged by demyelinating diseases, e.g.idiopathic inflammatory demyelinating disease (including multiplesclerosis), transverse myelitis, Devic's disease, progressive multifocalleukoencephalopathy, Guillain-Barre syndrome, chronic inflammatorydemyelinating polyneuropathy and anti-MAG peripheral neuropathy.

The incidence of sudden deafness, or sensorineural hearing loss, occursin about 1 in 5000 individuals, and may be caused by viral or bacterialinfections, e.g. mumps, measles, influenza, chickenpox, cytomegalovirus,syphilis or infectious mononucleosis, or physical injury to the innerear organ. In some cases, no cause can be identified. Tinnitus andvertigo may accompany sudden deafness, which subsides gradually. Oralcorticosteroids are prescribed to treat sensorineural hearing loss. Insome cases, surgical intervention may be necessary.

The formulations and methods described herein include the treatment ofsensineural hearing loss, including, treatment for sudden sensineuralhearing loss, including idiopathic sudden sensineural hearing loss. ForSSHL, current treatment options include a high dose oral steroid 2 weektreatment (4-7 day course+7-10 days taper) with either dexamethasone(4-10 mg/ml), or methyl-prednisolone (40-62.5 mg/ml). As noted herein,high doses of oral steroids are associated with undesired side effectsand adverse events. Accordingly, the methods and formulations describedherein, which are directed to sustained release, localized delivery ofthe steroids to the inner ear are expected to result in significantlyless side effects than oral/systemic steroid use. In one embodiment, theISSHL is characterized by unilateral sensorineural hearing loss with anonset over a period of less than 72 hours, where the HL is defined asbeing >30 dB in at least 3 contiguous test frequencies.

A standard of care for Idiopathic Sudden Sensorineural Hearing Loss(ISSHL) is treatment with high dose oral steroid. In certain instances,an individual is treated with high dose oral steroid for about twoweeks. In certain instances, an individual is treated with high doseoral steroid for about two weeks followed by a tapering off of the oralsteroid for about seven to about ten days. In certain instances, theoral steroid is dexamethasone (4-10 mg/ml). In certain instances, theoral steroid is methyl-prednisolone (40-62.5 mg/ml).

In one set of embodiments, a patient who is being treated for ISSHLusing a standard of care presented above, is instead treated using thecontrolled-release corticosteroid auris-acceptable formulations andmethods described herein. In another set of embodiments, a patient whois being treated for ISSHL using a standard of care presented above, butwho is refractory or unresponsive to such treatment, is instead treatedusing the controlled-release corticosteroid auris-acceptableformulations and methods described herein.

Hearing Loss from Excessive Noise

Hearing loss may also occur from prolonged exposure to loud noises, suchas loud music, heavy equipment or machinery, airplanes, gunfire or otherhuman-based noises. The hearing loss occurs as result of destruction ofhair cell receptors in the inner ear. This hearing loss is oftenaccompanied by tinnitus. Permanent damage to hearing loss is oftendiagnosed.

Although there is currently no treatment for noise-induced hearing loss,several treatment regimens have been experimentally developed, includingtreatment with insulin-like growth factor 1 (IGF-1). Lee et al. Otol.Neurotol. (2007) 28:976-981).

Presbycusis

Presbycusis, or age-related hearing loss, occurs as a part of normalaging, and occurs as a result of degeneration of the receptor cells inthe spiral organ of Corti in the inner ear. Other causes may also beattributed to a decrease in a number of nerve fibers in thevestibulocochlear nerve, as well as a loss of flexibility of the basilarmembrane in the cochlea. There is currently no known cure for permanenthearing damage as a result of presbycusis or excessive noise.

Drug-Induced Inner Ear Damage

Damage from the administration of drugs, including certain antibiotics,diuretics (e.g. ethacrynic acid and furosemide), aspirin, aspirin-likesubstances (e.g. salicylates) and quinine includes, deterioration of theauris interna organ may be hastened by impaired kidney function, whichresults in decreased clearance of the affecting drugs and theirmetabolites. The drugs may affect both hearing and equilibrium, butlikely affects hearing to a greater extent.

For example, neomycin, kanamycin and amikacin have a greater effect onhearing than on balance. The antibiotics viomycin, gentamicin andtobramycin affect both hearing and equilibrium. Streptomycin, anothercommonly administered antibiotic, induces vertigo more than loss ofhearing, and can lead to Dandy's syndrome, where walking in the darkbecomes difficult and induces a sensation of the environment moving witheach step. Aspirin, when taken in very high doses, may also lead totemporary hearing loss and tinnitus, a condition where sound isperceived in the absence of external sound. Similarly, quinine,ethacrynic acid and furosemide can result in temporary or permanenthearing loss.

Autoimmune Inner Ear Disease

Autoimmune inner ear disease (AIED) is one of the few reversible causesof sensorineural hearing loss. It is a rare disorder appearing in bothadults and children that often involves a bilateral disturbance of theaudio and vestibular functions of the auris interna. In many cases, AIEDoccurs without systemic autoimmune symptoms, but up to one-third ofpatients also suffer from a systemic autoimmune illness, such asinflammatory bowel disease, rheumatoid arthritis (Murdin, L. et al(2007), Hearing difficulties are common in patients with rheumatoidarthritis, in Clin Rheumatol, 27(5):637-640), Ankylosing spondylitis,Systemic Lupus Erythematosus (SLE), Sjögren's Syndrome, Cogan's disease,ulcerative colitis, Wegener's granulomatosis and scleroderma. Behçet'sdisease, a multisystem disease, also commonly has audiovestibularproblems. There is some evidence for food-related allergies as a causefor cochlear and vestibular autoimmunity, but there is presently noagreement as to its importance in the aetiology of the disease. Aclassification scheme for AIED has been developed (Harris and Keithley,(2002) Autoimmune inner ear disease, in Otorhinolaryngology Head andNeck Surgery. 91, 18-32).

Treatment with corticosteroid relieves AIED symptoms. Oraladministration of the corticosteroid prednisone (60 mg/day for four (4)weeks) showed marked improvement in pure-tone and speech audiometricresults. Mediation of the corticosteroid affect occurs through eithercorticosteroid receptors or mineralocorticoid receptors.

Inflammatory Disorders

Inflammatory disorders of the ear include and are not limited to Otitismedia, otitis externa, mastoiditis, Bullous myringitis, Eustachian tubalcatarrh, or Eustachian salpingitis, Labyrinthitis or the like. Otitismedia (OM), which includes acute otitis media (AOM), otitis media witheffusion (OME) and chronic otitis media as examples, is a conditionaffecting both adults and children. OM susceptibility is multifactorialand complex, including environmental, microbial and host factors. Insome instances, increases in cytokine production, including inflammatorycytokines, e.g., interleukins and TNF, have been observed in theeffluent media of individuals afflicted with OM. Treatment withantiinflammatory steroids relieves the symptoms of inflammatorydisorders of the ear (e.g., otitis media, eustachian tube catarrh or thelike). In some instances, bacterial infection accounts for inflammatorydisorders (e.g, OM). In some instances, administration of an antibioticin combination with an antiinflammatory corticosteroid relieves thesymptoms of OM.

Pharmaceutical Agents

Provided herein are pharmaceutical compositions or formulations ordevices comprising steroids that ameliorate or lessen otic disorders,including Meniere's disease, sensineural hearing loss, and/orinflammatory disorders and their attendant symptoms, which include butare not limited to hearing loss, nystagmus, vertigo, tinnitus,inflammation, swelling, infection and congestion. Otic disorders,including AIED or Meniere's disease and/or inflammatory disorders, havecauses and symptoms that are responsive to the pharmaceutical agentsdisclosed herein, or other pharmaceutical agents. In specificembodiments, the steroids are corticosteroids, includingglucocorticosteroids and mineral corticosteroids. Any corticosteroiddescribed herein (including free acid, free base, free alcohol, salt,prodrug, or any combination thereof) is compatible with thepharmaceutical compositions or devices described herein. Corticosteroidswhich are not specifically disclosed herein but which are useful for theamelioration or eradication of otic disorders are expressly included andintended within the scope of the embodiments presented.

Moreover, pharmaceutical agents which have been previously shown to betoxic, harmful or non-effective during systemic or localized applicationin other organ systems, for example through toxic metabolites formedafter hepatic processing, toxicity of the drug in particular organs,tissues or systems, through high levels needed to achieve efficacy,through the inability to be released through systemic pathways orthrough poor pK characteristics, are useful in some embodiments herein.For example, side effects of dexamethasone include: sodium retention,excessive water retention, congestive heart failure in susceptiblepatients, hypertension, muscle weakness, muscle atrophy, osteoporosis,tendon rupture, peptic ulcer, ulcerative esophagitis, thinning of theskin, cutaneous reaction, impaired wound healing, convulsions, vertigo,headache, psychological disorders, Cushing's syndrome, delayed growth inchildren, diabetes, hirsutism, cataracts, glaucoma, weight gain,increased appetite, and nausea. Pharmaceutical agents (e.g.,corticosteroids) which have limited or no systemic release, systemictoxicity, poor pK characteristics or combinations thereof are explicitlycontemplated within the scope of the embodiments disclosed herein.

The corticosteroid formulations disclosed herein are optionally targeteddirectly to otic structures where treatment is needed; for example, oneembodiment contemplated is the direct application of the corticosteroidformulations disclosed herein onto the round window membrane or thecrista fenestrae cochlea of the auris interna, allowing direct accessand treatment of the auris interna, or inner ear components. In otherembodiments, the corticosteroid formulation disclosed herein is applieddirectly to the oval window. In yet other embodiments, direct access isobtained through microinjection directly into the auris interna, forexample, through cochlear microperfusion. Such embodiments alsooptionally comprise a drug delivery device, wherein the drug deliverydevice delivers the corticosteroid formulations through use of a needleand syringe, a pump, a microinjection device, an in situ forming spongymaterial or any combination thereof. In still other embodiments,application of the corticosteroid formulation is targeted to the aurismedia through piercing of the intratympanic membrane and application ofcorticosteroid formulation directly to the auris media structuresaffected, including the walls of the tympanic cavity or auditoryossicles. By doing so, the corticosteroid formulations disclosed hereinare confined to the targeted auris media structure, and will not belost, for example, through diffusion or leakage through the eustachiantube or pierced tympanic membrane.

Corticosteroids/Anti-Inflammatory Steroids

The corticosteroids are characterized by mineralocorticoid andglucocorticoid effects, depending on the pharmacology of the agent.Mineralocorticoids are characterized by their similarity to aldosteroneand their influence on electrolyte levels and water balance. Theglucocorticoids, such as the endogenous glucocorticoid cortisol, controlmetabolism and are anti-inflammatory by preventing cytokine release.Many agents possess a degree of both mineralocorticoid andglucocorticoid activity. The relative potency and activity of severalsynthetic glucocorticoids are shown in the table below.

Glucocorticoid Mineralocorticoid Steroid potency potency cortisol 10.054 prednisone 4 0.002 prednisolone 1.7 0.013 dexamethasone 21 0.0094betamethasone 45 0.0038 triamcinolone 0.35 0.0002 prednylidene 1820.0011 aldosterone 0.07 1.0

Systemic glucocorticoid treatment is the current therapy in use forautoimmune hearing loss. Typical treatment duration lasts for months andthe side effects from systemic therapy can be substantial. Fordexamethasone the side effects include: sodium retention, excessivewater retention, congestive heart failure in susceptible patients,hypertension, muscle weakness, muscle atrophy, osteoporosis, tendonrupture, peptic ulcer, ulcerative esophagitis, thinning of the skin,cutaneous reaction, impaired wound healing, convulsions, vertigo,headache, psychological disorders, Cushing's syndrome, delayed growth inchildren, diabetes, hirsutism, cataracts, glaucoma, weight gain,increased appetite, and nausea. One advantage of the use of aformulation described herein is the greatly reduced systemic exposure toanti-inflammatory glucocorticoid steroids.

Prednisolone is a corticosteroid drug with predominantly glucocorticoidand low mineralocorticoid activity. It has about 4-5 times the potencyof endogenous cortisol. It is an active metabolite of orallyadministered prednisone. Dexamethasone is a corticosteroid drug withglucocorticoid activity. It has about 25-30 times the potency ofendogenous cortisol. Dexamethasone sodium phosphate is a water solublephosphate ester prodrug of dexamethasone. A method for the analyticaldetermination of dexamethasone phosphate in cochlear perilymph fluid hasbeen published (Liu et al, J. of Chromatography B (2004),805(2):255-60). Triamcinolone is a synthetic glucocorticoid drug whichhas been administered orally, by injection, inhalation, or as a topicalcream or ointment. Triamcinolone acetonide is a more potent analog.Triamcinolone hexacetonide is the pivolyl ester of triamcinoloneacetonide. Beclomethasone dipropionate, also referred to asbeclometasone, is a very potent glucocorticoid drug. Clobetasol is avery potent corticosteroid used in topical formulations. It hasanti-inflammatory, antipruritic, vasoconstrictive, and immune-modulatingproperties.

In one embodiment, the active pharmaceutical ingredient of theformulation described herein is prednisolone. In another embodiment theactive pharmaceutical ingredient of the formulation described herein isdexamethasone. In another embodiment the active pharmaceuticalingredient of the formulation described herein is dexamethasonephosphate. In an additional embodiment, the active pharmaceuticalingredient of the formulation described herein is beclomethasone. In anadditional embodiment, the active pharmaceutical ingredient of theformulation described herein is betamethasone. In an additionalembodiment, the active pharmaceutical ingredient of the formulationdescribed herein is triamcinolone. In an additional embodiment, theactive pharmaceutical ingredient of the formulation described herein istriamcinolone acetonide. In an additional embodiment, the activepharmaceutical ingredient of the formulation described herein isclobetasol.

In an additional embodiment, the active pharmaceutical ingredient of theformulation described herein is a phosphate prodrug of a glucocorticoidsteroid. In an additional embodiment, the active pharmaceuticalingredient of the formulation described herein is an ester prodrug of aglucocorticoid steroid. In some embodiments, the active pharmaceuticalingredient of the formulations described herein is selected from21-acetoxypregnenolone, alclometasone, algestone, amcinonide,beclomethasone, betamethasone, budesonide, chloroprednisone, clobetasol,clobetasone, clocortolone, cloprednol, corticosterone, cortisone,cortivazol, deflazacort, desonide, desoximetasone, dexamethasone,diflorasone, diflucortolone, difluprednate, enoxolone, fluazacort,flucloronide, flumethasone, flunisolide, fluocinolone acetonide,fluocinonide, fluocortin butyl, fluocortolone, fluorometholone,fluperolone acetate, fluprednidene acetate, fluprednisolone,flurandrenolide, fluticasone propionate, formocortal, halcinonide,halobetasol propionate, halometasone, halopredone acetate,hydrocortamate, hydrocortisone, loteprednol etabonate, mazipredone,medrysone, meprednisone, methylprednisolone, mometasone furoate,paramethasone, prednicarbate, prednisolone, prednisolone25-diethylamino-acetate, prednisolone sodium phosphate, prednisone,prednival, prednylidene, rimexolone, tixocortol, triamcinolone,triamcinolone acetonide, triamcinolone benetonide, or triamcinolonehexacetonide, or phosphate prodrug or ester prodrug thereof.

In some embodiments, the formulations described herein have aconcentration of active pharmaceutical ingredient between about 0.01% toabout 20%, between about 0.01% to about 10%, between about 0.01% toabout 8%, between about 0.05 to 6%, between about 0.1 to 5%, betweenabout 0.2 to about 3%, or between about 0.1 to about 2% of the activeingredient, or pharmaceutically acceptable prodrug or salt thereof, byweight of the formulation. In some embodiments, the formulationsdescribed herein have a concentration of active pharmaceuticalingredient, between about 0.1 to about 70 mg/mL, between about 0.5 mg/mLto about 70 mg/mL, between about 0.5 mg/mL to about 50 mg/mL, betweenabout 0.5 mg/mL to about 20 mg/mL, between about 1 mg to about 70 mg/mL,between about 1 mg to about 50 mg/mL, between about 1 mg/mL and about 20mg/mL, between about 1 mg/mL to about 10 mg/mL, or between about 1 mg/mLto about 5 mg/mL, of the active agent, or pharmaceutically acceptableprodrug or salt thereof, by volume of the formulation.

In some embodiments, the formulations described herein further comprisean antibiotic and are useful in the treatment of an otic disease orcondition described herein. Antibiotics include and are not limited toamikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin,tobramycin, paromomycin, geldanmycin, herbimycin, loracarbef, ertapenem,doripenem, imipenem, cilastatin, meropenem, cefadroxil, cefazolin,cefalotin, cefalexin, cefaclor, cefamandole, cefoxitin, defprozil,cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime,cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone,cefepime, ceftobiprole, teicoplanin, vancomycin, azithromycin,clarithromycin, dirithromycin, erythromycin, roxithromycin,troleandomycin, telithromycin, spectinomycin, aztreonam, amoxicillin,ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin,flucloxacillin, mezlocillin, meticillin, nafcillin, oxacillin,penicillin, piperacillin, ticarcillan, bacitracin, colistin, polymyxinB, ciprofloxacin, enoxacin, gatifloxacin, levofloxacin, lomefloxacin,moxifloxacin, norfloxacin, ofloxacin, trovfloxacin, mafenide, prontosil,sulfacetamide, sulfamethizole, sulfanimilimde, sulfsalazine,sulfsioxazole, trimethoprim, demeclocycline, doxycycline, minocycline,oxtetracycline, tetracycline, arsphenamine, chloramphenicol,clindamycin, lincomycin, ethambutol, fosfomycin, fusidic acid,furazolidone, isoniazid, linezolid, metronidazole, mupirocin,nitrofurantoin, platensimycin, pyrazinamide, quinuspristin/dalfopristin,rifampin, tinidazole, AL-15469A (Alcon Research), AL-38905 (AlconResearch) or the like and combinations thereof.

General Methods of Sterilization

Provided herein are otic compositions that ameliorate or lessen oticdisorders described herein. Further provided herein are methodscomprising the administration of said otic compositions. In someembodiments, the compositions or devices are sterilized. Included withinthe embodiments disclosed herein are means and processes forsterilization of a pharmaceutical composition or device disclosed hereinfor use in humans. The goal is to provide a safe pharmaceutical product,relatively free of infection causing micro-organisms. The U. S. Food andDrug Administration has provided regulatory guidance in the publication“Guidance for Industry: Sterile Drug Products Produced by AsepticProcessing” available at: http://www.fda.gov/cder/guidance/5882fnl.htm,which is incorporated herein by reference in its entirety.

As used herein, sterilization means a process used to destroy or removemicroorganisms that are present in a product or packaging. Any suitablemethod available for sterilization of objects and compositions is used.Available methods for the inactivation of microorganisms include, butare not limited to, the application of extreme heat, lethal chemicals,or gamma radiation. In some embodiments is a process for the preparationof an otic therapeutic formulation comprising subjecting the formulationto a sterilization method selected from heat sterilization, chemicalsterilization, radiation sterilization or filtration sterilization. Themethod used depends largely upon the nature of the device or compositionto be sterilized. Detailed descriptions of many methods of sterilizationare given in Chapter 40 of Remington: The Science and Practice ofPharmacy published by Lippincott, Williams & Wilkins, and isincorporated by reference with respect to this subject matter.

Sterilization by Heat

Many methods are available for sterilization by the application ofextreme heat. One method is through the use of a saturated steamautoclave. In this method, saturated steam at a temperature of at least121° C. is allowed to contact the object to be sterilized. The transferof heat is either directly to the microorganism, in the case of anobject to be sterilized, or indirectly to the microorganism by heatingthe bulk of an aqueous solution to be sterilized. This method is widelypracticed as it allows flexibility, safety and economy in thesterilization process.

Dry heat sterilization is a method which is used to kill microorganismsand perform depyrogenation at elevated temperatures. This process takesplace in an apparatus suitable for heating HEPA-filteredmicroorganism-free air to temperatures of at least 130-180° C. for thesterilization process and to temperatures of at least 230-250° C. forthe depyrogenation process. Water to reconstitute concentrated orpowdered formulations is also sterilized by autoclave. In someembodiments, the formulations described herein comprise micronizedpharmaceutical agents (e.g., corticosteroids, (e.g.,micro-dexamethasone)) that are sterilized by dry heating, e.g., heatingfor about 7-11 hours at internal powder temperatures of 130-140° C., orfor 1-2 hours at interrnal temperatures of 150-180° C.

Chemical Sterilization

Chemical sterilization methods are an alternative for products that donot withstand the extremes of heat sterilization. In this method, avariety of gases and vapors with germicidal properties, such as ethyleneoxide, chlorine dioxide, formaldehyde or ozone are used as theanti-apoptotic agents. The germicidal activity of ethylene oxide, forexample, arises from its ability to serve as a reactive alkylatingagent. Thus, the sterilization process requires the ethylene oxidevapors to make direct contact with the product to be sterilized.

Radiation Sterilization

One advantage of radiation sterilization is the ability to sterilizemany types of products without heat degradation or other damage. Theradiation commonly employed is beta radiation or alternatively, gammaradiation from a ⁶⁰Co source. The penetrating ability of gamma radiationallows its use in the sterilization of many product types, includingsolutions, compositions and heterogeneous mixtures. The germicidaleffects of irradiation arise from the interaction of gamma radiationwith biological macromolecules. This interaction generates chargedspecies and free radicals. Subsequent chemical reactions, such asrearrangements and cross-linking processes, result in the loss of normalfunction for these biological macromolecules. The formulations describedherein are also optionally sterilized using beta irradiation.

Filtration

Filtration sterilization is a method used to remove but not destroymicroorganisms from solutions. Membrane filters are used to filterheat-sensitive solutions. Such filters are thin, strong, homogenouspolymers of mixed cellulosic esters (MCE), polyvinylidene fluoride (PVF;also known as PVDF), or polytetrafluoroethylene (PTFE) and have poresizes ranging from 0.1 to 0.22 μm. Solutions of various characteristicsare optionally filtered using different filter membranes. For example,PVF and PTFE membranes are well suited to filtering organic solventswhile aqueous solutions are filtered through PVF or MCE membranes.Filter apparatus are available for use on many scales ranging from thesingle point-of-use disposable filter attached to a syringe up tocommercial scale filters for use in manufacturing plants. The membranefilters are sterilized by autoclave or chemical sterilization.Validation of membrane filtration systems is performed followingstandardized protocols (Microbiological Evaluation of Filters forSterilizing Liquids, Vol 4, No. 3. Washington, D.C.: Health IndustryManufacturers Association, 1981) and involve challenging the membranefilter with a known quantity (ca. 10⁷¹ cm²) of unusually smallmicroorganisms, such as Brevundimonas diminuta (ATCC 19146).

Pharmaceutical compositions are optionally sterilized by passing throughmembrane filters. Formulations comprising nanoparticles (U.S. Pat. No.6,139,870) or multilamellar vesicles (Richard et al., InternationalJournal of Pharmaceutics (2006), 312(1-2):144-50) are amenable tosterilization by filtration through 0.22 μm filters without destroyingtheir organized structure.

In some embodiments, the methods disclosed herein comprise sterilizingthe formulation (or components thereof) by means of filtrationsterilization. In another embodiment the auris-acceptable otictherapeutic agent formulation comprises a particle wherein the particleformulation is suitable for filtration sterilization. In a furtherembodiment said particle formulation comprises particles of less than300 nm in size, of less than 200 nm in size, of less than 100 nm insize. In another embodiment the auris-acceptable formulation comprises aparticle formulation wherein the sterility of the particle is ensured bysterile filtration of the precursor component solutions. In anotherembodiment the auris-acceptable formulation comprises a particleformulation wherein the sterility of the particle formulation is ensuredby low temperature sterile filtration. In a further embodiment, lowtemperature sterile filtration is carried out at a temperature between 0and 30° C., between 0 and 20° C., between 0 and 10° C., between 10 and20° C., or between 20 and 30° C.

In another embodiment is a process for the preparation of anauris-acceptable particle formulation comprising: filtering the aqueoussolution containing the particle formulation at low temperature througha sterilization filter; lyophilizing the sterile solution; andreconstituting the particle formulation with sterile water prior toadministration. In some embodiments, a formulation described herein ismanufactured as a suspension in a single vial formulation containing themicronized active pharmaceutical ingredient. A single vial formulationis prepared by aseptically mixing a sterile poloxamer solution withsterile micronized active ingredient (e.g., dexamethasone) andtransferring the formulation to sterile pharmaceutical containers. Insome embodiments, a single vial containing a formulation describedherein as a suspension is resuspended before dispensing and/oradministration.

In specific embodiments, filtration and/or filling procedures arecarried out at about 5° C. below the gel temperature (Tgel) of aformulation described herein and with viscosity below a theoreticalvalue of 100 cP to allow for filtration in a reasonable time using aperistaltic pump.

In another embodiment the auris-acceptable otic therapeutic agentformulation comprises a nanoparticle formulation wherein thenanoparticle formulation is suitable for filtration sterilization. In afurther embodiment the nanoparticle formulation comprises nanoparticlesof less than 300 nm in size, of less than 200 nm in size, or of lessthan 100 nm in size. In another embodiment the auris-acceptableformulation comprises a microsphere formulation wherein the sterility ofthe microsphere is ensured by sterile filtration of the precursororganic solution and aqueous solutions. In another embodiment theauris-acceptable formulation comprises a thermoreversible gelformulation wherein the sterility of the gel formulation is ensured bylow temperature sterile filtration. In a further embodiment, the lowtemperature sterile filtration occurs at a temperature between 0 and 30°C., or between 0 and 20° C., or between 0 and 10° C., or between 10 and20° C., or between 20 and 30° C. In another embodiment is a process forthe preparation of an auris-acceptable thermoreversible gel formulationcomprising: filtering the aqueous solution containing thethermoreversible gel components at low temperature through asterilization filter; lyophilizing the sterile solution; andreconstituting the thermoreversible gel formulation with sterile waterprior to administration.

In certain embodiments, the active ingredients are dissolved in asuitable vehicle (e.g. a buffer) and sterilized separately (e.g. by heattreatment, filtration, gamma radiation). In some instances, the activeingredients are sterilized separately in a dry state. In some instances,the active ingredients are sterilized as a suspension or as a colloidalsuspension. The remaining excipients (e.g., fluid gel components presentin auris formulations) are sterilized in a separate step by a suitablemethod (e.g. filtration and/or irradiation of a cooled mixture ofexcipients); the two solutions that are separately sterilized are thenmixed aseptically to provide a final auris formulation. In someinstances, the final aseptic mixing is performed just prior toadministration of a formulation described herein.

In some instances, conventionally used methods of sterilization (e.g.,heat treatment (e.g., in an autoclave), gamma irradiation, filtration)lead to irreversible degradation of polymeric components (e.g.,thermosetting, gelling or mucoadhesive polymer components) and/or theactive agent in the formulation. In some instances, sterilization of anauris formulation by filtration through membranes (e.g., 0.2 μMmembranes) is not possible if the formulation comprises thixotropicpolymers that gel during the process of filtration.

Accordingly, provided herein are methods for sterilization of aurisformulations that prevent degradation of polymeric components (e.g.,thermosetting and/or gelling and/or mucoadhesive polymer components)and/or the active agent during the process of sterilization. In someembodiments, degradation of the active agent (e.g., any therapeutic oticagent described herein) is reduced or eliminated through the use ofspecific pH ranges for buffer components and specific proportions ofgelling agents in the formulations. In some embodiments, the choice ofan appropriate gelling agent and/or thermosetting polymer allows forsterilization of formulations described herein by filtration. In someembodiments, the use of an appropriate thermosetting polymer and anappropriate copolymer (e.g., a gelling agent) in combination with aspecific pH range for the formulation allows for high temperaturesterilization of formulations described with substantially nodegradation of the therapeutic agent or the polymeric excipients. Anadvantage of the methods of sterilization provided herein is that, incertain instances, the formulations are subjected to terminalsterilization via autoclaving without any loss of the active agentand/or excipients and/or polymeric components during the sterilizationstep and are rendered substantially free of microbes and/or pyrogens.

Microorganisms

Provided herein are auris-acceptable compositions or devices thatameliorate or lessen otic disorders described herein. Further providedherein are methods comprising the administration of said oticcompositions. In some embodiments, the compositions or devices aresubstantially free of microorganisms. Acceptable sterility levels arebased on applicable standards that define therapeutically acceptableotic compositions, including but not limited to United StatesPharmacopeia Chapters <1111> et seq. For example, acceptable sterilitylevels include about 10 colony forming units (cfu) per gram offormulation, about 50 cfu per gram of formulation, about 100 cfu pergram of formulation, about 500 cfu per gram of formulation or about 1000cfu per gram of formulation. In some embodiments, acceptable sterilitylevels for formulations include less than 10 cfu/mL, less that 50cfu/mL, less than 500 cfu/mL or less than 1000 cfu/mL microbial agents.In addition, acceptable sterility levels include the exclusion ofspecified objectionable microbiological agents. By way of example,specified objectionable microbiological agents include but are notlimited to Escherichia coli (E. coli), Salmonella sp., Pseudomonasaeruginosa (P. aeruginosa) and/or other specific microbial agents.

Sterility of the auris-acceptable otic therapeutic agent formulation isconfirmed through a sterility assurance program in accordance withUnited States Pharmacopeia Chapters <61>, <62> and <71>. A key componentof the sterility assurance quality control, quality assurance andvalidation process is the method of sterility testing. Sterilitytesting, by way of example only, is performed by two methods. The firstis direct inoculation wherein a sample of the composition to be testedis added to growth medium and incubated for a period of time up to 21days. Turbidity of the growth medium indicates contamination. Drawbacksto this method include the small sampling size of bulk materials whichreduces sensitivity, and detection of microorganism growth based on avisual observation. An alternative method is membrane filtrationsterility testing. In this method, a volume of product is passed througha small membrane filter paper. The filter paper is then placed intomedia to promote the growth of microorganisms. This method has theadvantage of greater sensitivity as the entire bulk product is sampled.The commercially available Millipore Steritest sterility testing systemis optionally used for determinations by membrane filtration sterilitytesting. For the filtration testing of creams or ointments Steritestfilter system No. TLHVSL210 are used. For the filtration testing ofemulsions or viscous products Steritest filter system No. TLAREM210 orTDAREM210 are used. For the filtration testing of pre-filled syringesSteritest filter system No. TTHASY210 are used. For the filtrationtesting of material dispensed as an aerosol or foam Steritest filtersystem No. TTHVA210 are used. For the filtration testing of solublepowders in ampoules or vials Steritest filter system No. TTHADA210 orTTHADV210 are used.

Testing for E. coli and Salmonella includes the use of lactose brothsincubated at 30-35° C. for 24-72 hours, incubation in MacConkey and/orEMB agars for 18-24 hours, and/or the use of Rappaport medium. Testingfor the detection of P. aeruginosa includes the use of NAC agar. UnitedStates Pharmacopeia Chapter <62> further enumerates testing proceduresfor specified objectionable microorganisms.

In certain embodiments, any controlled release formulation describedherein has less than about 60 colony forming units (CFU), less thanabout 50 colony forming units, less than about 40 colony forming units,or less than about 30 colony forming units of microbial agents per gramof formulation. In certain embodiments, the otic formulations describedherein are formulated to be isotonic with the endolymph and/or theperilymph.

Endotoxins

Provided herein are otic compositions that ameliorate or lessen oticdisorders described herein. Further provided herein are methodscomprising the administration of said otic compositions. In someembodiments, the compositions or devices are substantially free ofendotoxins. An additional aspect of the sterilization process is theremoval of by-products from the killing of microorganisms (hereinafter,“Product”). The process of depyrogenation removes pyrogens from thesample. Pyrogens are endotoxins or exotoxins which induce an immuneresponse. An example of an endotoxin is the lipopolysaccharide (LPS)molecule found in the cell wall of gram-negative bacteria. Whilesterilization procedures such as autoclaving or treatment with ethyleneoxide kill the bacteria, the LPS residue induces a proinflammatoryimmune response, such as septic shock. Because the molecular size ofendotoxins can vary widely, the presence of endotoxins is expressed in“endotoxin units” (EU). One EU is equivalent to 100 picograms of E. coliLPS. Humans can develop a response to as little as 5 EU/kg of bodyweight. The sterility is expressed in any units as recognized in theart. In certain embodiments, otic compositions described herein containlower endotoxin levels (e.g. <4 EU/kg of body weight of a subject) whencompared to conventionally acceptable endotoxin levels (e.g., 5 EU/kg ofbody weight of a subject). In some embodiments, the auris-acceptableotic therapeutic agent formulation has less than about 5 EU/kg of bodyweight of a subject. In other embodiments, the auris-acceptable otictherapeutic agent formulation has less than about 4 EU/kg of body weightof a subject. In additional embodiments, the auris-acceptable otictherapeutic agent formulation has less than about 3 EU/kg of body weightof a subject. In additional embodiments, the auris-acceptable otictherapeutic agent formulation has less than about 2 EU/kg of body weightof a subject.

In some embodiments, the auris-acceptable otic therapeutic agentformulation or device has less than about 5 EU/kg of formulation. Inother embodiments, the auris-acceptable otic therapeutic agentformulation has less than about 4 EU/kg of formulation. In additionalembodiments, the auris-acceptable otic therapeutic agent formulation hasless than about 3 EU/kg of formulation. In some embodiments, theauris-acceptable otic therapeutic agent formulation has less than about5 EU/kg Product. In other embodiments, the auris-acceptable otictherapeutic agent formulation has less than about 1 EU/kg Product. Inadditional embodiments, the auris-acceptable otic therapeutic agentformulation has less than about 0.2 EU/kg Product. In some embodiments,the auris-acceptable otic therapeutic agent formulation has less thanabout 5 EU/g of unit or Product. In other embodiments, theauris-acceptable otic therapeutic agent formulation has less than about4 EU/g of unit or Product. In additional embodiments, theauris-acceptable otic therapeutic agent formulation has less than about3 EU/g of unit or Product. In some embodiments, the auris-acceptableotic therapeutic agent formulation has less than about 5 EU/mg of unitor Product. In other embodiments, the auris-acceptable otic therapeuticagent formulation has less than about 4 EU/mg of unit or Product. Inadditional embodiments, the auris-acceptable otic therapeutic agentformulation has less than about 3 EU/mg of unit or Product. In certainembodiments, otic compositions described herein contain from about 1 toabout 5 EU/mL of formulation. In certain embodiments, otic compositionsdescribed herein contain from about 2 to about 5 EU/mL of formulation,from about 3 to about 5 EU/mL of formulation, or from about 4 to about 5EU/mL of formulation.

In certain embodiments, otic compositions or devices described hereincontain lower endotoxin levels (e.g. <0.5 EU/mL of formulation) whencompared to conventionally acceptable endotoxin levels (e.g., 0.5 EU/mLof formulation). In some embodiments, the auris-acceptable otictherapeutic agent formulation or device has less than about 0.5 EU/mL offormulation. In other embodiments, the auris-acceptable otic therapeuticagent formulation has less than about 0.4 EU/mL of formulation. Inadditional embodiments, the auris-acceptable otic therapeutic agentformulation has less than about 0.2 EU/mL of formulation.

Pyrogen detection, by way of example only, is performed by severalmethods. Suitable tests for sterility include tests described in UnitedStates Pharmacopoeia (USP) <71> Sterility Tests (23rd edition, 1995).The rabbit pyrogen test and the Limulus amebocyte lysate test are bothspecified in the United States Pharmacopeia Chapters <85> and <151>(USP23/NF 18, Biological Tests, The United States PharmacopeialConvention, Rockville, Md., 1995). Alternative pyrogen assays have beendeveloped based upon the monocyte activation-cytokine assay. Uniformcell lines suitable for quality control applications have been developedand have demonstrated the ability to detect pyrogenicity in samples thathave passed the rabbit pyrogen test and the Limulus amebocyte lysatetest (Taktak et al, J. Pharm. Pharmacol. (1990), 43:578-82). In anadditional embodiment, the auris-acceptable otic therapeutic agentformulation is subject to depyrogenation. In a further embodiment, theprocess for the manufacture of the auris-acceptable otic therapeuticagent formulation comprises testing the formulation for pyrogenicity. Incertain embodiments, the formulations described herein are substantiallyfree of pyrogens.

pH and Practical Osmolarity

As used herein, “practical osmolarity” means the osmolarity of aformulation that is measured by including the active agent and allexcipients except the gelling and/or the thickening agent (e.g.,polyoxyethylene-polyooxypropylene copolymers, carboxymethylcellulose orthe like). The practical osmolarity of a formulation described herein ismeasured by any suitable method, e.g., a freezing point depressionmethod as described in Viegas et. al., Int. J. Pharm., 1998, 160,157-162. In some instances, the practical osmolarity of a compositiondescribed herein is measured by vapor pressure osmometry (e.g., vaporpressure depresssion method) that allows for determination of theosmolarity of a composition at higher temperatures. In some instances,vapor pressure depression method allows for determination of theosmolarity of a formulation comprising a gelling agent (e.g., athermoreversible polymer) at a higher temperature wherein the gellingagent is in the form of a gel. The practical osmolality of an oticformulation described herein is from about 100 mOsm/kg to about 1000mOsm/kg, from about 200 mOsm/kg to about 800 mOsm/kg, from about 250mOsm/kg to about 500 mOsm/kg, or from about 250 mOsm/kg to about 320mOsm/kg, or from about 250 mOsm/kg to about 350 mOsm/kg or from about280 mOsm/kg to about 320 mOsm/kg. In some embodiments, the formulationsdescribed herein have a practical osmolarity of about 100 mOsm/L toabout 1000 mOsm/L, about 200 mOsm/L to about 800 mOsm/L, about 250mOsm/L to about 500 mOsm/L, about 250 mOsm/L to about 350 mOsm/L, about250 mOsm/L to about 320 mOsm/L, or about 280 mOsm/L to about 320 mOsm/L.

In some embodiments, the osmolarity at a target site of action (e.g.,the perilymph) is about the same as the delivered osmolarity (i.e.,osmolarity of materials that cross or penetrate the round windowmembrane) of any formulation described herein. In some embodiments, theformulations described herein have a deliverable osmolarity of about 150mOsm/L to about 500 mOsm/L, about 250 mOsm/L to about 500 mOsm/L, about250 mOsm/L to about 350 mOsm/L, about 280 mOsm/L to about 370 mOsm/L orabout 250 mOsm/L to about 320 mOsm/L.

The main cation present in the endolymph is potassium. In addition theendolymph has a high concentration of positively charged amino acids.The main cation present in the perilymph is sodium. In certaininstances, the ionic composition of the endolymph and perilymph regulatethe electrochemical impulses of hair cells. In certain instances, anychange in the ionic balance of the endolymph or perilymph results in aloss of hearing due to changes in the conduction of electrochemicalimpulses along otic hair cells. In some embodiments, a compositiondisclosed herein does not disrupt the ionic balance of the perilymph. Insome embodiments, a composition disclosed herein has an ionic balancethat is the same as or substantially the same as the perilymph. In someembodiments, a composition disclosed herein does not disrupt the ionicbalance of the endolymph. In some embodiments, a composition disclosedherein has an ionic balance that is the same as or substantially thesame as the endolymph. In some embodiments, an otic formulationdescribed herein is formulated to provide an ionic balance that iscompatible with inner ear fluids (e.g., endolymph and/or perilymph).

The endolymph and the perilymph have a pH that is close to thephysiological pH of blood. The endolymph has a pH range of about7.2-7.9; the perilymph has a pH range of about 7.2-7.4. The in situ pHof the proximal endolymph is about 7.4 while the pH of distal endolymphis about 7.9.

In some embodiments, the pH of a composition described herein isadjusted (e.g., by use of a buffer) to an endolymph-compatible pH rangeof about 5.5 to 9.0. In specific embodiments, the pH of a compositiondescribed herein is adjusted to a perilymph-suitable pH range of about5.5 to about 9.0. In some embodiments, the pH of a composition describedherein is adjusted to a perilymph-suitable range of about 5.5 to about8.0, about 6 to about 8.0 or about 6.6 to about 8.0. In someembodiments, the pH of a composition described herein is adjusted to aperilymph-suitable pH range of about 7.0-7.6.

In some embodiments, useful formulations also include one or more pHadjusting agents or buffering agents. Suitable pH adjusting agents orbuffers include, but are not limited to acetate, bicarbonate, ammoniumchloride, citrate, phosphate, pharmaceutically acceptable salts thereofand combinations or mixtures thereof.

In one embodiment, when one or more buffers are utilized in theformulations of the present disclosure, they are combined, e.g., with apharmaceutically acceptable vehicle and are present in the finalformulation, e.g., in an amount ranging from about 0.1% to about 20%,from about 0.5% to about 10%. In certain embodiments of the presentdisclosure, the amount of buffer included in the gel formulations are anamount such that the pH of the gel formulation does not interfere withthe body's natural buffering system.

In one embodiment, diluents are also used to stabilize compounds becausethey can provide a more stable environment. Salts dissolved in bufferedsolutions (which also can provide pH control or maintenance) areutilized as diluents in the art, including, but not limited to aphosphate buffered saline solution.

In some embodiments, any gel formulation described herein has a pH thatallows for sterilization (e.g, by filtration or aseptic mixing or heattreatment and/or autoclaving (e.g., terminal sterilization)) of a gelformulation without degradation of the pharmaceutical agent (e.g.,steroid) or the polymers comprising the gel. In order to reducehydrolysis and/or degradation of the otic agent and/or the gel polymerduring sterilization, the buffer pH is designed to maintain pH of theformulation in the 7-8 range during the process of sterilization (e.g.,high temperature autoclaving).

In specific embodiments, any gel formulation described herein has a pHthat allows for terminal sterilization (e.g, by heat treatment and/orautoclaving) of a gel formulation without degradation of thepharmaceutical agent (e.g., corticosteroid) or the polymers comprisingthe gel. For example, in order to reduce hydrolysis and/or degradationof the otic agent and/or the gel polymer during autoclaving, the bufferpH is designed to maintain pH of the formulation in the 7-8 range atelevated temperatures. Any appropriate buffer is used depending on theotic agent used in the formulation. In some instances, since pK_(a) ofTRIS decreases as temperature increases at approximately −0.03/° C. andpK_(a) of PBS increases as temperature increases at approximately0.003/° C., autoclaving at 250° F. (121° C.) results in a significantdownward pH shift (i.e. more acidic) in the TRIS buffer whereas arelatively much less upward pH shift in the PBS buffer and thereforemuch increased hydrolysis and/or degradation of an otic agent in TRISthan in PBS. Degradation of an otic agent is reduced by the use of anappropriate combination of a buffer and polymeric additives (e.g. P407,CMC) as described herein.

In some embodiments, a formulation pH of between about 5.0 and about9.0, between about 5.5 and about 8.5, between about 6.0 and about 7.6,between about 7 and about 7.8, between about 7.0 and about 7.6, betweenabout 7.2 and 7.6, or between about 7.2 and about 7.4 is suitable forsterilization (e.g, by filtration or aseptic mixing or heat treatmentand/or autoclaving (e.g., terminal sterilization)) of auris formulationsdescribed herein. In specific embodiments a formulation pH of about 6.0,about 6.5, about 7.0, about 7.1, about 7.2, about 7.3, about 7.4, about7.5, or about 7.6 is suitable for sterilization (e.g, by filtration oraseptic mixing or heat treatment and/or autoclaving (e.g., terminalsterilization)) of any composition described herein.

In some embodiments, the formulations have a pH as described herein, andinclude a thickening agent (e.g, a viscosity enhancing agent) such as,by way of non-limiting example, a cellulose based thickening agentdescribed herein. In some instances, the addition of a secondary polymer(e.g., a thickening agent) and a pH of formulation as described herein,allows for sterilization of a formulation described herein without anysubstantial degradation of the otic agent and/or the polymer componentsin the otic formulation. In some embodiments, the ratio of athermoreversible poloxamer to a thickening agent in a formulation thathas a pH as described herein, is about 40:1, about 35:1, about 30:1,about 25:1, about 20:1, about 15:1 about 10:1, or about 5:1. Forexample, in certain embodiments, a sustained and/or extended releaseformulation described herein comprises a combination of poloxamer 407(pluronic F127) and carboxymethylcellulose (CMC) in a ratio of about40:1, about 35:1, about 30:1, about 25:1, about 20:1, about 15:1, about10:1 or about 5:1. In some embodiments, the amount of thermoreversiblepolymer in any formulation described herein is about 10%, about 15%,about 20%, about 25%, about 30%, about 35% or about 40% of the totalweight of the formulation. In some embodiments, the amount ofthermoreversible polymer in any formulation described herein is about14%, about 15%, about 16%, about 17%, about 18%, about 19%, about 20%,about 21%, about 22%, about 23%, about 24% or about 25% of the totalweight of the formulation. In some embodiments, the amount of thickeningagent (e.g., a gelling agent) in any formulation described herein isabout 1%, about 5%, about 10%, or about 15% of the total weight of theformulation. In some embodiments, the amount of thickening agent (e.g.,a gelling agent) in any formulation described herein is about 0.5%,about 1%, about 1.5%, about 2%, about 2.5%, about 3%, about 3.5%, about4%, about 4.5%, or about 5% of the total weight of the formulation.

In some embodiments, the pharmaceutical formulations described hereinare stable with respect to pH over a period of any of at least about 1day, at least about 2 days, at least about 3 days, at least about 4days, at least about 5 days, at least about 6 days, at least about 1week, at least about 2 weeks, at least about 3 weeks, at least about 4weeks, at least about 5 weeks, at least about 6 weeks, at least about 7weeks, at least about 8 weeks, at least about 1 month, at least about 2months, at least about 3 months, at least about 4 months, at least about5 months, or at least about 6 months. In other embodiments, theformulations described herein are stable with respect to pH over aperiod of at least about 1 week. Also described herein are formulationsthat are stable with respect to pH over a period of at least about 1month.

Tonicity Agents

In general, the endolymph has a higher osmolality than the perilymph.For example, the endolymph has an osmolality of about 304 mOsm/kg H₂Owhile the perilymph has an osmolality of about 294 mOsm/kg H₂O. Incertain embodiments, tonicity agents are added to the formulationsdescribed herein in an amount as to provide a practical osmolality of anotic formulation of about 100 mOsm/kg to about 1000 mOsm/kg, from about200 mOsm/kg to about 800 mOsm/kg, from about 250 mOsm/kg to about 500mOsm/kg, or from about 250 mOsm/kg to about 350 mOsm/kg or from about280 mOsm/kg to about 320 mOsm/kg. In some embodiments, the formulationsdescribed herein have a practical osmolarity of about 100 mOsm/L toabout 1000 mOsm/L, about 200 mOsm/L to about 800 mOsm/L, about 250mOsm/L to about 500 mOsm/L, about 250 mOsm/L to about 350 mOsm/L, about280 mOsm/L to about 320 mOsm/L or about 250 mOsm/L to about 320 mOsm/L.

In some embodiments, the deliverable osmolarity of any formulationdescribed herein is designed to be isotonic with the targeted oticstructure (e.g., endolymph, perilymph or the like). In specificembodiments, auris compositions described herein are formulated toprovide a delivered perilymph-suitable osmolarity at the target site ofaction of about 250 to about 320 mOsm/L (osmolality of about 250 toabout 320 mOsm/kg H₂O); and preferably about 270 to about 320 mOsm/L(osmolality of about 270 to about 320 mOsm/kg H₂O). In specificembodiments, the deliverable osmolarity/osmolality of the formulations(i.e., the osmolarity/osmolality of the formulation in the absence ofgelling or thickening agents (e.g., thermoreversible gel polymers)) isadjusted, for example, by the use of appropriate salt concentrations(e.g., concentration of potassium or sodium salts) or the use oftonicity agents which renders the formulations endolymph-compatibleand/or perilymph-compatible (i.e. isotonic with the endolymph and/orperilymph) upon delivery at the target site. The osmolarity of aformulation comprising a thermoreversible gel polymer is an unreliablemeasure due to the association of varying amounts of water with themonomeric units of the polymer. The practical osmolarity of aformulation (i.e., osmolarity in the absence of a gelling or thickeningagent (e.g. a thermoreversible gel polymer)) is a reliable measure andis measured by any suitable method (e.g., freezing point depressionmethod, vapor depression method). In some instances, the formulationsdescribed herein provide a deliverable osmolarity (e.g., at a targetsite (e.g., perilymph)) that causes minimal disturbance to theenvironment of the inner ear and causes minimum discomfort (e.g.,vertigo and/or nausea) to a mammal upon administration.

In some embodiments, any formulation described herein is isotonic withthe perilymph and/or endolymph. Isotonic formulations are provided bythe addition of a tonicity agent. Suitable tonicity agents include, butare not limited to any pharmaceutically acceptable sugar, salt or anycombinations or mixtures thereof, such as, but not limited to dextrose,glycerin, mannitol, sorbitol, sodium chloride, and other electrolytes.

Useful auris compositions include one or more salts in an amountrequired to bring osmolality of the composition into an acceptablerange. Such salts include those having sodium, potassium or ammoniumcations and chloride, citrate, ascorbate, borate, phosphate,bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable saltsinclude sodium chloride, potassium chloride, sodium thiosulfate, sodiumbisulfite and ammonium sulfate.

In some embodiments, the formulations described herein have a pH and/orpractical osmolarity as described herein, and have a concentration ofactive pharmaceutical ingredient between about 1 μM and about 10 μM,between about 1 mM and about 100 mM, between about 0.1 mM and about 100mM, between about 0.1 mM and about 100 nM. In some embodiments, theformulations described herein have a pH and/or practical osmolarity asdescribed herein, and have a concentration of active pharmaceuticalingredient between about 0.1-about 20%, between about 0.1-about 10%,between about 0.1-about 7.5%, between about 0.1-6%, between about0.1-5%, between about 0.2-about 3%, between about 0.1-about 2% of theactive ingredient by weight of the formulation. In some embodiments, theformulations described herein have a pH and/or practical osmolarity asdescribed herein, and have a concentration of active pharmaceuticalingredient between about 0.1-about 70 mg/mL, between about 1 mg-about 70mg/mL, between about 1 mg-about 50 mg/mL, between about 1 mg/mL andabout 20 mg/mL, between about 1 mg/mL to about 10 mg/mL, between about 1mg/mL to about 5 mg/mL, or between about 0.5 mg/mL to about 5 mg/mL ofthe active agent by volume of the formulation.

Particle Size

Size reduction is used to increase surface area and/or modulateformulation dissolution properties. It is also used to maintain aconsistent average particle size distribution (PSD) (e.g.,micrometer-sized particles, nanometer-sized particles or the like) forany formulation described herein. In some embodiments, any formulationdescribed herein comprises mulitparticulates, i.e., a plurality ofparticle sizes (e.g., micronized particles, nano-sized particles,non-sized particles, colloidal particles); i.e, the formulation is amultiparticulate formulation. In some embodiments, any formulationdescribed herein comprises one or more multiparticulate (e.g.,micronized) therapeutic agents. Micronization is a process of reducingthe average diameter of particles of a solid material. Micronizedparticles are from about micrometer-sized in diameter to aboutnanometer-sized in diameter. In some embodiments, the average diameterof particles in a micronized solid is from about 0.5 μm to about 500 μm.In some embodiments, the average diameter of particles in a micronizedsolid is from about 1 μm to about 200 μm. In some embodiments, theaverage diameter of particles in a micronized solid is from about 2 μmto about 100 μm. In some embodiments, the average diameter of particlesin a micronized solid is from about 3 μm to about 50 μm. In someembodiments, a particulate micronized solid comprises particle sizes ofless than about 5 microns, less than about 20 microns and/or less thanabout 100 microns. In some embodiments, the use of particulates (e.g.,micronized particles) of corticosteroid allows for extended and/orsustained release of the corticosteroid from any formulation describedherein compared to a formulation comprising non-multiparticulate (e.g,non-micronized) corticosteroid. In some instances, formulationscontaining multiparticulate (e.g. micronized) corticosteroid are ejectedfrom a 1 mL syringe adapted with a 27G needle without any plugging orclogging.

In some instances, any particle in any formulation described herein is acoated particle (e.g., a coated micronized particle, nano-particle)and/or a microsphere and/or a liposomal particle. Particle sizereduction techniques include, by way of example, grinding, milling(e.g., air-attrition milling (jet milling), ball milling), coacervation,complex coacervation, high pressure homogenization, spray drying and/orsupercritical fluid crystallization. In some instances, particles aresized by mechanical impact (e.g., by hammer mills, ball mill and/or pinmills). In some instances, particles are sized via fluid energy (e.g.,by spiral jet mills, loop jet mills, and/or fluidized bed jet mills). Insome embodiments formulations described herein comprise crystallineparticles and/or isotropic particles. In some embodiments, formulationsdescribed herein comprise amorphous particles and/or anisotropicparticles. In some embodiments, formulations described herein comprisetherapeutic agent particles wherein the therapeutic agent is a freebase, or a salt, or a prodrug of a therapeutic agent, or any combinationthereof.

In some embodiments, a formulation described herein comprises one ormore corticosteroids wherein the corticosteroid comprisesnanoparticulates. In some embodiments, a formulation described hereincomprises corticosteroid beads (e.g., dexamethasone beads) that areoptionally coated with controlled release excipients. In someembodiments, a formulation described herein comprises a corticosteroidthat is granulated and/or reduced in size and coated with controlledrelease excipients; the granulated coated corticosteroid particulatesare then optionally micronized and/or formulated in any of thecompositions described herein.

In some instances, a combination of a corticosteroid as a free acid orfree base and a salt of the corticosteroid is used to prepare pulsedrelease otic agent formulations using the procedures described herein.In some formulations, a combination of a micronized corticosteroid(and/or salt or prodrug thereof) and coated particles (e.g.,nanoparticles, liposomes, microspheres) is used to prepare pulsedrelease otic agent formulations using any procedure described herein.Alternatively, a pulsed release profile is achieved by solubilizing upto 20% of the delivered dose of the corticosteroid (e.g., micronizedcorticosteroid, free alcohol, free acid or salt or prodrug thereof;multiparticulate corticosteroid, free alcohol, free acid or salt orprodrug thereof) with the aid of cyclodextrins, surfactants (e.g.,poloxamers (407, 338, 188), tween (80, 60, 20, 81), PEG-hydrogenatedcastor oil, cosolvents like N-methyl-2-Pyrrolidone or the like andpreparing pulsed release formulations using any procedure describedherein.

In specific embodiments, any auris-compatible formulation describedherein comprises one or more micronized pharmaceutical agents (e.g.,steroids). In some of such embodiments, a micronized pharmaceuticalagent comprises micronized particles, coated (e.g., with an extendedrelease coat) micronized particles, or a combination thereof. In some ofsuch embodiments, a micronized pharmaceutical agent comprisingmicronized particles, coated micronized particles, or a combinationthereof, comprises a corticosteroid as a free acid, a free base, a salt,a prodrug or any combination thereof. In certain embodiments, apharmaceutical composition described herein comprises dexamethasone,methylprednisolone or prednisolone as a micronized powder. In certainembodiments, a pharmaceutical composition described herein comprisesdexamethasone in the form of a micro-dexamethasone powder.

The multiparticulates and/or micronized corticosteroids described hereinare delivered to an auris structure (e.g., inner ear) by means of anytype of matrix including solid, liquid or gel matrices. In someembodiments, the multiparticulates and/or micronized corticosteroidsdescribed herein are delivered to an auris structure (e.g., inner ear)by means of any type of matrix including solid, liquid or gel matricesvia intratympanic injection.

Pharmaceutical Formulations

Provided herein are pharmaceutical compositions or devices that includeat least one corticosteroid and a pharmaceutically acceptablediluent(s), excipient(s), or carrier(s). In some embodiments, thepharmaceutical compositions include other medicinal or pharmaceuticalagents, carriers, adjuvants, such as preserving, stabilizing, wetting oremulsifying agents, solution promoters, salts for regulating the osmoticpressure, and/or buffers. In other embodiments, the pharmaceuticalcompositions also contain other therapeutic substances.

In some embodiments, the compositions or devices described hereininclude a dye to help enhance the visualization of the gel when applied.In some embodiments, dyes that are compatible with the auris-acceptablecompositions or devices described herein include Evans blue (e.g., 0.5%of the total weight of an otic formulation), Methylene blue (e.g., 1% ofthe total weight of an otic formulation), Isosulfan blue (e.g., 1% ofthe total weight of an otic formulation), Trypan blue (e.g., 0.15% ofthe total weight of an otic formulation), and/or indocyanine green(e.g., 25 mg/vial). Other common dyes, e.g, FD&C red 40, FD&C red 3,FD&C yellow 5, FD&C yellow 6, FD&C blue 1, FD&C blue2, FD&C green 3,fluorescence dyes (e.g., Fluorescein isothiocyanate, rhodamine, AlexaFluors, DyLight Fluors) and/or dyes that are visualizable in conjunctionwith non-invasive imaging techniques such as MRI, CAT scans, PET scansor the like. Gadolinium-based MRI dyes, iodine-base dyes, barium-baseddyes or the like are also contemplated for use with any otic formulationdescribed herein. Other dyes that are compatible with any formulation orcomposition described herein are listed in the Sigma-Aldrich catalogunder dyes (which is included herein by reference for such disclosure).

Any pharmaceutical composition or device described herein isadministered by locating the composition or device in contact with thecrista fenestrae cochlea, the round window, the tympanic cavity, thetympanic membrane, the auris media or the auris externa.

In one specific embodiment of the auris-acceptable controlled releasecorticosteroid pharmaceutical formulations described herein, thecorticosteroid is provided in a gel matrix, also referred to herein as“auris acceptable gel formulations,” “auris interna-acceptable gelformulations,” “auris media-acceptable gel formulations,” “aurisexterna-acceptable gel formulations”, “auris gel formulations” orvariations thereof. All of the components of the gel formulation must becompatible with the targeted auris structure. Further, the gelformulations provide controlled release of the corticosteroid to thedesired site within the targeted auris structure; in some embodiments,the gel formulation also has an immediate or rapid release component fordelivery of the corticosteroid to the desired target site. In otherembodiments, the gel formulation has a sustained release component fordelivery of the corticosteroid. In some embodiments, the gel formulationcomprises a multiparticulate (e.g., micronized) corticosteroid. In someembodiments, the auris gel formulations are biodegradable. In otherembodiments, the auris gel formulations include a mucoadhesive excipientto allow adhesion to the external mucous layer of the round windowmembrane. In yet other embodiments, the auris gel formulations include apenetration enhancer excipient; in further embodiments, the auris gelformulation contains a viscosity enhancing agent sufficient to provide aviscosity of between about 500 and 1,000,000 centipoise, between about750 and 1,000,000 centipoise; between about 1000 and 1,000,000centipoise; between about 1000 and 400,000 centipoise; between about2000 and 100,000 centipoise; between about 3000 and 50,000 centipoise;between about 4000 and 25,000 centipoise; between about 5000 and 20,000centipoise; or between about 6000 and 15,000 centipoise. In someembodiments, the auris gel formulation contains a viscosity enhancingagent sufficient to provide a viscosity of between about 50,0000 and1,000,000 centipoise.

In further or alternative embodiments, the auris gel formulations arecapable of being administered on or near the round window membrane viaintratympanic injection. In other embodiments, the auris gelformulations are administered on or near the round window or the cristafenestrae cochleae through entry via a post-auricular incision andsurgical manipulation into or near the round window or the cristafenestrae cochleae area. Alternatively, the auris gel formulation isapplied via syringe and needle, wherein the needle is inserted throughthe tympanic membrane and guided to the area of the round window orcrista fenestrae cochleae. The auris gel formulations are then depositedon or near the round window or crista fenestrae cochleae for localizedtreatment of autoimmune otic disorders. In other embodiments, the aurisgel formulations are applied via microcathethers implanted into thepatient, and in yet further embodiments the formulations areadministered via a pump device onto or near the round window membrane.In still further embodiments, the auris gel formulations are applied ator near the round window membrane via a microinjection device. In yetother embodiments, the auris gel formulations are applied in thetympanic cavity. In some embodiments, the auris gel formulations areapplied on the tympanic membrane. In still other embodiments, the aurisgel formulations are applied onto or in the auditory canal.

In further specific embodiments, any pharmaceutical composition ordevice described herein comprises a multiparticulate corticosteroid in aliquid matrix (e.g., a liquid composition for intratympanic injection,or otic drops). In certain embodiments, any pharmaceutical compositiondescribed herein comprises a multiparticulate corticosteroid in a solidmatrix.

Controlled Release Formulations

In general, controlled release drug formulations impart control over therelease of drug with respect to site of release and time of releasewithin the body. As discussed herein, controlled release refers toimmediate release, delayed release, sustained release, extended release,variable release, pulsatile release and bi-modal release. Manyadvantages are offered by controlled release. First, controlled releaseof a pharmaceutical agent allows less frequent dosing and thus minimizesrepeated treatment. Second, controlled release treatment results in moreefficient drug utilization and less of the compound remains as aresidue. Third, controlled release offers the possibility of localizeddrug delivery by placement of a delivery device or formulation at thesite of disease. Still further, controlled release offers theopportunity to administer and release two or more different drugs, eachhaving a unique release profile, or to release the same drug atdifferent rates or for different durations, by means of a single dosageunit.

Accordingly, one aspect of the embodiments disclosed herein is toprovide a controlled release corticosteroid auris-acceptable compositionor device for the treatment of autoimmune disorders and/or inflammatorydisorders. The controlled release aspect of the compositions and/orformulations and/or devices disclosed herein is imparted through avariety of agents, including but not limited to excipients, agents ormaterials that are acceptable for use in the auris interna or other oticstructure.

Auris-Acceptable Gels

Gels, sometimes referred to as jellies, have been defined in variousways. For example, the United States Pharmacopoeia defines gels assemisolid systems consisting of either suspensions made up of smallinorganic particles or large organic molecules interpenetrated by aliquid. Gels include a single-phase or a two-phase system. Asingle-phase gel consists of organic macromolecules distributeduniformly throughout a liquid in such a manner that no apparentboundaries exist between the dispersed macromolecules and the liquid.Some single-phase gels are prepared from synthetic macromolecules (e.g.,carbomer) or from natural gums, (e.g., tragacanth). In some embodiments,single-phase gels are generally aqueous, but will also be made usingalcohols and oils. Two-phase gels consist of a network of small discreteparticles.

Gels can also be classified as being hydrophobic or hydrophilic. Incertain embodiments, the base of a hydrophobic gel consists of a liquidparaffin with polyethylene or fatty oils gelled with colloidal silica,or aluminum or zinc soaps. In contrast, the base of hydrophobic gelsusually consists of water, glycerol, or propylene glycol gelled with asuitable gelling agent (e.g., tragacanth, starch, cellulose derivatives,carboxyvinylpolymers, and magnesium-aluminum silicates). In certainembodiments, the rheology of the compositions or devices disclosedherein is pseudo plastic, plastic, thixotropic, or dilatant.

In one embodiment the enhanced viscosity auris-acceptable formulationdescribed herein is not a liquid at room temperature. In certainembodiments, the enhanced viscosity formulation is characterized by aphase transition between room temperature and body temperature(including an individual with a serious fever, e.g., up to about 42°C.). In some embodiments, the phase transition occurs at 1° C. belowbody temperature, at 2° C. below body temperature, at 3° C. below bodytemperature, at 4° C. below body temperature, at 6° C. below bodytemperature, at 8° C. below body temperature, or at 10° C. below bodytemperature. In some embodiments, the phase transition occurs at about15° C. below body temperature, at about 20° C. below body temperature orat about 25° C. below body temperature. In specific embodiments, thegelation temperature (Tgel) of a formulation described herein is about20° C., about 25° C., or about 30° C. In certain embodiments, thegelation temperature (Tgel) of a formulation described herein is about35° C., or about 40° C. In one embodiment, administration of anyformulation described herein at about body temperature reduces orinhibits vertigo associated with intratympanic administration of oticformulations. Included within the definition of body temperature is thebody temperature of a healthy individual, or an unhealthy individual,including an individual with a fever (up to ˜42° C.)). In someembodiments, the pharmaceutical compositions or devices described hereinare liquids at about room temperature and are administered at or aboutroom temperature, reducing or ameliorating side effects such as, forexample, vertigo.

Polymers composed of polyoxypropylene and polyoxyethylene formthermoreversible gels when incorporated into aqueous solutions. Thesepolymers have the ability to change from the liquid state to the gelstate at temperatures close to body temperature, therefore allowinguseful formulations that are applied to the targeted auris structure(s).The liquid state-to-gel state phase transition is dependent on thepolymer concentration and the ingredients in the solution.

Poloxamer 407 (PF-127) is a nonionic surfactant composed ofpolyoxyethylene-polyoxypropylene copolymers. Other poloxamers include188 (F-68 grade), 237 (F-87 grade), 338 (F-108 grade). Aqueous solutionsof poloxamers are stable in the presence of acids, alkalis, and metalions. PF-127 is a commercially availablepolyoxyethylene-polyoxypropylene triblock copolymer of general formulaE106 P70 E106, with an average molar mass of 13,000. The polymer can befurther purified by suitable methods that will enhance gelationproperties of the polymer. It contains approximately 70% ethylene oxide,which accounts for its hydrophilicity. It is one of the series ofpoloxamer ABA block copolymers, whose members share the chemical formulashown below.

PF-127 is of particular interest since concentrated solutions (>20% w/w)of the copolymer are transformed from low viscosity transparentsolutions to solid gels on heating to body temperature. This phenomenon,therefore, suggests that when placed in contact with the body, the gelpreparation will form a semisolid structure and a sustained releasedepot. Furthermore, PF-127 has good solubilizing capacity, low toxicityand is, therefore, considered a good medium for drug delivery systems.

In an alternative embodiment, the thermogel is a PEG-PLGA-PEG triblockcopolymer (Jeong et al, Nature (1997), 388:860-2; Jeong et al, J.Control. Release (2000), 63:155-63; Jeong et al, Adv. Drug Delivery Rev.(2002), 54:37-51). The polymer exhibits sol-gel behavior over aconcentration of about 5% w/w to about 40% w/w. Depending on theproperties desired, the lactide/glycolide molar ratio in the PLGAcopolymer ranges from about 1:1 to about 20:1. The resulting copolymersare soluble in water and form a free-flowing liquid at room temperature,but form a hydrogel at body temperature. A commercially availablePEG-PLGA-PEG triblock copolymer is RESOMER RGP t50106 manufactured byBoehringer Ingelheim. This material is composed of a PGLA copolymer of50:50 poly(DL-lactide-co-glycolide) and is 10% w/w of PEG and has amolecular weight of about 6000.

ReGel® is a tradename of MacroMed Incorporated for a class of lowmolecular weight, biodegradable block copolymers having reverse thermalgelation properties as described in U.S. Pat. Nos. 6,004,573, 6,117,949,6,201,072, and 6,287,588. It also includes biodegradable polymeric drugcarriers disclosed in pending U.S. patent application Ser. Nos.09/906,041, 09/559,799 and Ser. No. 10/919,603. The biodegradable drugcarrier comprises ABA-type or BAB-type triblock copolymers or mixturesthereof, wherein the A-blocks are relatively hydrophobic and comprisebiodegradable polyesters or poly(orthoester)s, and the B-blocks arerelatively hydrophilic and comprise polyethylene glycol (PEG), saidcopolymers having a hydrophobic content of between 50.1 to 83% by weightand a hydrophilic content of between 17 to 49.9% by weight, and anoverall block copolymer molecular weight of between 2000 and 8000Daltons. The drug carriers exhibit water solubility at temperaturesbelow normal mammalian body temperatures and undergo reversible thermalgelation to then exist as a gel at temperatures equal to physiologicalmammalian body temperatures. The biodegradable, hydrophobic A polymerblock comprises a polyester or poly(ortho ester), in which the polyesteris synthesized from monomers selected from the group consisting ofD,L-lactide, D-lactide, L-lactide, D,L-lactic acid, D-lactic acid,L-lactic acid, glycolide, glycolic acid, ε-caprolactone,ε-hydroxyhexanoic acid, γ-butyrolactone, γ-hydroxybutyric acid,δ-valerolactone, δ-hydroxyvaleric acid, hydroxybutyric acids, malicacid, and copolymers thereof and having an average molecular weight ofbetween about 600 and 3000 Daltons. The hydrophilic B-block segment ispreferably polyethylene glycol (PEG) having an average molecular weightof between about 500 and 2200 Daltons.

Additional biodegradable thermoplastic polyesters include AtriGel®(provided by Atrix Laboratories, Inc.) and/or those disclosed, e.g., inU.S. Pat. Nos. 5,324,519; 4,938,763; 5,702,716; 5,744,153; and5,990,194; wherein the suitable biodegradable thermoplastic polyester isdisclosed as a thermoplastic polymer. Examples of suitable biodegradablethermoplastic polyesters include polylactides, polyglycolides,polycaprolactones, copolymers thereof, terpolymers thereof, and anycombinations thereof. In some such embodiments, the suitablebiodegradable thermoplastic polyester is a polylactide, a polyglycolide,a copolymer thereof, a terpolymer thereof, or a combination thereof. Inone embodiment, the biodegradable thermoplastic polyester is 50/50poly(DL-lactide-co-glycolide) having a carboxy terminal group; ispresent in about 30 wt. % to about 40 wt. % of the composition; and hasan average molecular weight of about 23,000 to about 45,000.Alternatively, in another embodiment, the biodegradable thermoplasticpolyester is 75/25 poly (DL-lactide-co-glycolide) without a carboxyterminal group; is present in about 40 wt. % to about 50 wt. % of thecomposition; and has an average molecular weight of about 15,000 toabout 24,000. In further or alternative embodiments, the terminal groupsof the poly(DL-lactide-co-glycolide) are either hydroxyl, carboxyl, orester depending upon the method of polymerization. Polycondensation oflactic or glycolic acid provides a polymer with terminal hydroxyl andcarboxyl groups. Ring-opening polymerization of the cyclic lactide orglycolide monomers with water, lactic acid, or glycolic acid providespolymers with the same terminal groups. However, ring-opening of thecyclic monomers with a monofunctional alcohol such as methanol, ethanol,or 1-dodecanol provides a polymer with one hydroxyl group and one esterterminal groups. Ring-opening polymerization of the cyclic monomers witha diol such as 1,6-hexanediol or polyethylene glycol provides a polymerwith only hydroxyl terminal groups.

Since the polymer systems of thermoreversible gels dissolve morecompletely at reduced temperatures, methods of solubilization includeadding the required amount of polymer to the amount of water to be usedat reduced temperatures. Generally after wetting the polymer by shaking,the mixture is capped and placed in a cold chamber or in a thermostaticcontainer at about 0-10° C. in order to dissolve the polymer. Themixture is stirred or shaken to bring about a more rapid dissolution ofthe thermoreversible gel polymer. The corticosteroid and variousadditives such as buffers, salts, and preservatives are subsequentlyadded and dissolved. In some instances the corticosteroid and/or otherpharmaceutically active agent is suspended if it is insoluble in water.The pH is modulated by the addition of appropriate buffering agents.round window membrane mucoadhesive characteristics are optionallyimparted to a thermoreversible gel by incorporation of round windowmembrane mucoadhesive carbomers, such as Carbopol® 934P, to thecomposition (Majithiya et al, AAPS PharmSciTech (2006), 7(3), p. E1;EP0551626, both of which is incorporated herein by reference for suchdisclosure).

In one embodiment are auris-acceptable pharmaceutical gel formulationswhich do not require the use of an added viscosity enhancing agent. Suchgel formulations incorporate at least one pharmaceutically acceptablebuffer. In one aspect is a gel formulation comprising an corticosteroidand a pharmaceutically acceptable buffer. In another embodiment, thepharmaceutically acceptable excipient or carrier is a gelling agent.

In other embodiments, useful corticosteroid auris-acceptablepharmaceutical formulations also include one or more pH adjusting agentsor buffering agents to provide an endolymph or perilymph suitable pH.Suitable pH adjusting agents or buffers include, but are not limited toacetate, bicarbonate, ammonium chloride, citrate, phosphate,pharmaceutically acceptable salts thereof and combinations or mixturesthereof. Such pH adjusting agents and buffers are included in an amountrequired to maintain pH of the composition between a pH of about 5 andabout 9, in one embodiment a pH between about 6.5 to about 7.5, and inyet another embodiment at a pH of about 6.5, 6.6, 6.7, 6.8, 6.9, 7.0,7.1, 7.2, 7.3, 7.4, 7.5. In one embodiment, when one or more buffers areutilized in the formulations of the present disclosure, they arecombined, e.g., with a pharmaceutically acceptable vehicle and arepresent in the final formulation, e.g., in an amount ranging from about0.1% to about 20%, from about 0.5% to about 10%. In certain embodimentsof the present disclosure, the amount of buffer included in the gelformulations are an amount such that the pH of the gel formulation doesnot interfere with the auris media or auris interna's natural bufferingsystem, or does not interfere with the natural pH of the endolymph orperilymph: depending on where in the cochlea the corticosteroidformulation is targeted. In some embodiments, from about 10 μM to about200 mM concentration of a buffer is present in the gel formulation. Incertain embodiments, from about a 20 mM to about a 100 mM concentrationof a buffer is present. In one embodiment is a buffer such as acetate orcitrate at slightly acidic pH. In one embodiment the buffer is a sodiumacetate buffer having a pH of about 4.5 to about 6.5. In one embodimentthe buffer is a sodium citrate buffer having a pH of about 5.0 to about8.0, or about 5.5 to about 7.0.

In an alternative embodiment, the buffer used istris(hydroxymethyl)aminomethane, bicarbonate, carbonate or phosphate atslightly basic pH. In one embodiment, the buffer is a sodium bicarbonatebuffer having a pH of about 6.5 to about 8.5, or about 7.0 to about 8.0.In another embodiment the buffer is a sodium phosphate dibasic bufferhaving a pH of about 6.0 to about 9.0.

Also described herein are controlled release formulations or devicescomprising a corticosteroid and a viscosity enhancing agent. Suitableviscosity-enhancing agents include by way of example only, gellingagents and suspending agents. In one embodiment, the enhanced viscosityformulation does not include a buffer. In other embodiments, theenhanced viscosity formulation includes a pharmaceutically acceptablebuffer. Sodium chloride or other tonicity agents are optionally used toadjust tonicity, if necessary.

By way of example only, the auris-acceptable viscosity agent includehydroxypropyl methylcellulose, hydroxyethyl cellulose,polyvinylpyrrolidone, carboxymethyl cellulose, polyvinyl alcohol, sodiumchondroitin sulfate, sodium hyaluronate. Other viscosity enhancingagents compatible with the targeted auris structure include, but are notlimited to, acacia (gum arabic), agar, aluminum magnesium silicate,sodium alginate, sodium stearate, bladderwrack, bentonite, carbomer,carrageenan, Carbopol, xanthan, cellulose, microcrystalline cellulose(MCC), ceratonia, chitin, carboxymethylated chitosan, chondrus,dextrose, furcellaran, gelatin, Ghatti gum, guar gum, hectorite,lactose, sucrose, maltodextrin, mannitol, sorbitol, honey, maize starch,wheat starch, rice starch, potato starch, gelatin, sterculia gum,xanthum gum, gum tragacanth, ethyl cellulose, ethylhydroxyethylcellulose, ethylmethyl cellulose, methyl cellulose, hydroxyethylcellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose,poly(hydroxyethyl methacrylate), oxypolygelatin, pectin, polygeline,povidone, propylene carbonate, methyl vinyl ether/maleic anhydridecopolymer (PVM/MA), poly(methoxyethyl methacrylate),poly(methoxyethoxyethyl methacrylate), hydroxypropyl cellulose,hydroxypropylmethyl-cellulose (HPMC), sodium carboxymethyl-cellulose(CMC), silicon dioxide, polyvinylpyrrolidone (PVP: povidone), Splenda®(dextrose, maltodextrin and sucralose) or combinations thereof. Inspecific embodiments, the viscosity-enhancing excipient is a combinationof MCC and CMC. In another embodiment, the viscosity-enhancing agent isa combination of carboxymethylated chitosan, or chitin, and alginate.The combination of chitin and alginate with the corticosteroidsdisclosed herein acts as a controlled release formulation, restrictingthe diffusion of the corticosteroids from the formulation. Moreover, thecombination of carboxymethylated chitosan and alginate is optionallyused to assist in increasing the permeability of the corticosteroidsthrough the round window membrane.

In some embodiments is an enhanced viscosity formulation, comprisingfrom about 0.1 mM and about 100 mM of a corticosteroid, apharmaceutically acceptable viscosity agent, and water for injection,the concentration of the viscosity agent in the water being sufficientto provide a enhanced viscosity formulation with a final viscosity fromabout 100 to about 100,000 cP. In certain embodiments, the viscosity ofthe gel is in the range from about 100 to about 50,000 cP, about 100 cPto about 1,000 cP, about 500 cP to about 1500 cP, about 1000 cP to about3000 cP, about 2000 cP to about 8,000 cP, about 4,000 cP to about 50,000cP, about 10,000 cP to about 500,000 cP, about 15,000 cP to about1,000,000 cP. In other embodiments, when an even more viscous medium isdesired, the biocompatible gel comprises at least about 35%, at leastabout 45%, at least about 55%, at least about 65%, at least about 70%,at least about 75%, or even at least about 80% or so by weight of thecorticosteroid. In highly concentrated samples, the biocompatibleenhanced viscosity formulation comprises at least about 25%, at leastabout 35%, at least about 45%, at least about 55%, at least about 65%,at least about 75%, at least about 85%, at least about 90% or at leastabout 95% or more by weight of the corticosteroid.

In some embodiments, the viscosity of the gel formulations presentedherein are measured by any means described. For example, in someembodiments, an LVDV-II+CP Cone Plate Viscometer and a Cone SpindleCPE-40 is used to calculate the viscosity of the gel formulationdescribed herein. In other embodiments, a Brookfield (spindle and cup)viscometer is used to calculate the viscosity of the gel formulationdescribed herein. In some embodiments, the viscosity ranges referred toherein are measured at room temperature. In other embodiments, theviscosity ranges referred to herein are measured at body temperature(e.g., at the average body temperature of a healthy human).

In one embodiment, the pharmaceutically acceptable enhanced viscosityauris-acceptable formulation comprises at least one corticosteroid andat least one gelling agent. Suitable gelling agents for use inpreparation of the gel formulation include, but are not limited to,celluloses, cellulose derivatives, cellulose ethers (e.g.,carboxymethylcellulose, ethylcellulose, hydroxyethylcellulose,hydroxymethylcellulose, hydroxypropylmethylcellulose,hydroxypropylcellulose, methylcellulose), guar gum, xanthan gum, locustbean gum, alginates (e.g., alginic acid), silicates, starch, tragacanth,carboxyvinyl polymers, carrageenan, paraffin, petrolatum and anycombinations or mixtures thereof. In some other embodiments,hydroxypropylmethylcellulose (Methocel®) is utilized as the gellingagent. In certain embodiments, the viscosity enhancing agents describedherein are also utilized as the gelling agent for the gel formulationspresented herein.

In some embodiments, other gel formulations are useful depending uponthe particular corticosteroid, other pharmaceutical agent orexcipients/additives used, and as such are considered to fall within thescope of the present disclosure. For example, othercommercially-available glycerin-based gels, glycerin-derived compounds,conjugated, or crosslinked gels, matrices, hydrogels, and polymers, aswell as gelatins and their derivatives, alginates, and alginate-basedgels, and even various native and synthetic hydrogel andhydrogel-derived compounds are all expected to be useful in thecorticosteroid formulations described herein. In some embodiments,auris-acceptable gels include, but are not limited to, alginatehydrogels SAF®-Gel (ConvaTec, Princeton, N.J.), Duoderm® Hydroactive Gel(ConvaTec), Nu-gel®(Johnson & Johnson Medical, Arlington, Tex.);Carrasyn®(V) Acemannan Hydrogel (Carrington Laboratories, Inc., Irving,Tex.); glycerin gels Elta® Hydrogel (Swiss-American Products, Inc.,Dallas, Tex.) and K-Y® Sterile (Johnson & Johnson). In furtherembodiments, biodegradable biocompatible gels also represent compoundspresent in auris-acceptable formulations disclosed and described herein.

In some formulations developed for administration to a mammal, and forcompositions formulated for human administration, the auris-acceptablegel comprises substantially all of the weight of the composition. Inother embodiments, the auris-acceptable gel comprises as much as about98% or about 99% of the composition by weight. This is desirous when asubstantially non-fluid, or substantially viscous formulation is needed.In a further embodiment, when slightly less viscous, or slightly morefluid auris-acceptable pharmaceutical gel formulations are desired, thebiocompatible gel portion of the formulation comprises at least about50% by weight, at least about 60% by weight, at least about 70% byweight, or even at least about 80% or 90% by weight of the compound. Allintermediate integers within these ranges are contemplated to fallwithin the scope of this disclosure, and in some alternativeembodiments, even more fluid (and consequently less viscous)auris-acceptable gel compositions are formulated, such as for example,those in which the gel or matrix component of the mixture comprises notmore than about 50% by weight, not more than about 40% by weight, notmore than about 30% by weight, or even those than comprise not more thanabout 15% or about 20% by weight of the composition.

Round Window Membrane Mucoadhesives

Also contemplated within the scope of the embodiments is the addition ofa round window membrane mucoadhesive with the corticosteroidformulations and compositions and devices disclosed herein. The term‘mucoadhesion’ is used for materials that bind to the mucin layer of abiological membrane, such as the external membrane of the 3-layeredround window membrane. To serve as round window membrane mucoadhesivepolymers, the polymers possess some general physiochemical features suchas predominantly anionic hydrophilicity with numerous hydrogen bondforming groups, suitable surface property for wetting mucus/mucosaltissue surfaces or sufficient flexibility to penetrate the mucusnetwork.

Round window membrane mucoadhesive agents that are used with theauris-acceptable formulations include, but are not limited to, at leastone soluble polyvinylpyrrolidone polymer (PVP); a water-swellable, butwater-insoluble, fibrous, cross-linked carboxy-functional polymer; acrosslinked poly(acrylic acid) (e.g. Carbopol® 947P); a carbomerhomopolymer; a carbomer copolymer; a hydrophilic polysaccharide gum,maltodextrin, a cross-linked alginate gum gel, a water-dispersiblepolycarboxylated vinyl polymer, at least two particulate componentsselected from the group consisting of titanium dioxide, silicon dioxide,and clay, or a mixture thereof. The round window membrane mucoadhesiveagent is optionally used in combination with an auris-acceptableviscosity increasing excipient, or used alone to increase theinteraction of the composition with the mucosal layer target oticcomponent. In one non-limiting example, the mucoadhesive agent ismaltodextrin and/or an alginate gum. When used, the round windowmembrane mucoadhesive character imparted to the composition is at alevel that is sufficient to deliver an effective amount of thecorticosteroid composition to, for example, the mucosal layer of roundwindow membrane or the crista fenestrae cochleae in an amount that coatsthe mucosal membrane, and thereafter deliver the composition to theaffected areas, including by way of example only, the vestibular and/orcochlear structures of the auris interna. One method for determiningsufficient mucoadhesiveness includes monitoring changes in theinteraction of the composition with a mucosal layer, including but notlimited to measuring changes in residence or retention time of thecomposition in the absence and presence of the mucoadhesive excipient.

In one non-limiting example, the round window membrane mucoadhesiveagent is maltodextrin. Maltodextrin is a carbohydrate produced by thehydrolysis of starch that is optionally derived from corn, potato, wheator other plant products. Maltodextrin is optionally used either alone orin combination with other round window membrane mucoadhesive agents toimpart mucoadhesive characteristics on the compositions disclosedherein. In one embodiment, a combination of maltodextrin and a carbopolpolymer are used to increase the round window membrane mucoadhesivecharacteristics of the compositions or devices disclosed herein.

In another embodiment, the round window membrane mucoadhesive agent isan alkyl-glycoside and/or a saccharide alkyl ester. As used herein, an“alkyl-glycoside” means a compound comprising any hydrophilic saccharide(e.g. sucrose, maltose, or glucose) linked to a hydrophobic alkyl. Insome embodiments, the round window membrane mucoadhesive agent is analkyl-glycoside wherein the alkyl-glycoside comprises a sugar linked toa hydrophobic alkyl (e.g., an alkyl comprising about 6 to about 25carbon atoms) by an amide linkage, an amine linkage, a carbamatelinkage, an ether linkage, a thioether linkage, an ester linkage, athioester linkage, a glycosidic linkage, a thioglycosidic linkage,and/or a ureide linkage. In some embodiments, the round window membranemucoadhesive agent is a hexyl-, heptyl-, octyl-, nonyl-, decyl-,undecyl-, dodecyl-, tridecyl-, tetradecyl, pentadecyl-, hexadecyl-,heptadecyl-, and octadecyl α- or β-D-maltoside; hexyl-, heptyl-, octyl-,nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-, tetradecyl, pentadecyl-,hexadecyl-, heptadecyl-, and octadecyl α- or β-D-glucoside; hexyl-,heptyl-, octyl-, nonyl-, decyl-, undecyl-, dodecyl-, tridecyl-,tetradecyl, pentadecyl-, hexadecyl-, heptadecyl-, and octadecyl α- orβ-D-sucroside; hexyl-, heptyl-, octyl-, dodecyl-, tridecyl-, andtetradecyl-β-D-thiomaltoside; heptyl- or octyl-1-thio-α- orβ-D-glucopyranoside; alkyl thiosucroses; alkyl maltotriosides; longchain aliphatic carbonic acid amides of sucrose β-amino-alkyl ethers;derivatives of palatinose or isomaltamine linked by an amide linkage toan alkyl chain and derivatives of isomaltamine linked by urea to analkyl chain; long chain aliphatic carbonic acid ureides of sucroseβ-amino-alkyl ethers and long chain aliphatic carbonic acid amides ofsucrose β-amino-alkyl ethers. In some embodiments, the round windowmembrane mucoadhesive agent is an alkyl-glycoside wherein the alkylglycoside is maltose, sucrose, glucose, or a combination thereof linkedby a glycosidic linkage to an alkyl chain of 9-16 carbon atoms (e.g.,nonyl-, decyl-, dodecyl- and tetradecyl sucroside; nonyl-, decyl-,dodecyl- and tetradecyl glucoside; and nonyl-, decyl-, dodecyl- andtetradecyl maltoside). In some embodiments, the round window membranemucoadhesive agent is an alkyl-glycoside wherein the alkyl glycoside isdodecylmaltoside, tridecylmaltoside, and tetradecylmaltoside. In someembodiments, the auris acceptable penetration enhancer is a surfactantcomprising an alkyl-glycoside wherein the alkyl glycoside istetradecyl-β-D-maltodise. In some embodiments, the round window membranemucoadhesive agent is an alkyl-glycoside wherein the alkyl-glycoside isa disaccharide with at least one glucose. In some embodiments, the aurisacceptable penetration enhancer is a surfactant comprisingα-D-glucopyranosyl-β-glycopyranoside,n-Dodecyl-4-O-α-D-glucopyranosyl-β-glycopyranoside, and/orn-tetradecyl-4-O-α-D-glucopyranosyl-β-glycopyranoside. In someembodiments, the round window membrane mucoadhesive agent is analkyl-glycoside wherein the alkyl-glycoside has a critical miscelleconcentration (CMC) of less than about 1 mM in pure water or in aqueoussolutions. In some embodiments, the round window membrane mucoadhesiveagent is an alkyl-glycoside wherein an oxygen atom within thealkyl-glycoside is substituted with a sulfur atom. In some embodiments,the round window membrane mucoadhesive agent is an alkyl-glycosidewherein the alkylglycoside is the β anomer. In some embodiments, theround window membrane mucoadhesive agent is an alkyl-glycoside whereinthe alkylglycoside comprises 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,98%, 99%, 99.1%, 99.5%, or 99.9% of the β anomer.

Auris-Acceptable Cyclodextrin and Other Stabilizing Formulations

In a specific embodiment, the auris-acceptable formulationsalternatively comprises a cyclodextrin. Cyclodextrins are cyclicoligosaccharides containing 6, 7, or 8 glucopyranose units, referred toas α-cyclodextrin, β-cyclodextrin, or γ-cyclodextrin respectively.Cyclodextrins have a hydrophilic exterior, which enhances water-soluble,and a hydrophobic interior which forms a cavity. In an aqueousenvironment, hydrophobic portions of other molecules often enter thehydrophobic cavity of cyclodextrin to form inclusion compounds.Additionally, cyclodextrins are also capable of other types ofnonbonding interactions with molecules that are not inside thehydrophobic cavity. Cyclodextrins have three free hydroxyl groups foreach glucopyranose unit, or 18 hydroxyl groups on α-cyclodextrin, 21hydroxyl groups on β-cyclodextrin, and 24 hydroxyl groups onγ-cyclodextrin. One or more of these hydroxyl groups can be reacted withany of a number of reagents to form a large variety of cyclodextrinderivatives, including hydroxypropyl ethers, sulfonates, andsulfoalkylethers. Shown below is the structure of β-cyclodextrin and thehydroxypropyl-β-cyclodextrin (HPβCD).

In some embodiments, the use of cyclodextrins in the pharmaceuticalcompositions described herein improves the solubility of the drug.Inclusion compounds are involved in many cases of enhanced solubility;however other interactions between cyclodextrins and insoluble compoundsalso improves solubility. Hydroxypropyl-β-cyclodextrin (HβCD) iscommercially available as a pyrogen free product. It is a nonhygroscopicwhite powder that readily dissolves in water. HPβCD is thermally stableand does not degrade at neutral pH. Thus, cyclodextrins improve thesolubility of a therapeutic agent in a composition or formulation.Accordingly, in some embodiments, cyclodextrins are included to increasethe solubility of the auris-acceptable corticosteroids within theformulations described herein. In other embodiments, cyclodextrins inaddition serve as controlled release excipients within the formulationsdescribed herein.

By way of example only, cyclodextrin derivatives for use includeα-cyclodextrin, β-cyclodextrin, γ-cyclodextrin, hydroxyethylβ-cyclodextrin, hydroxypropyl γ-cyclodextrin, sulfated β-cyclodextrin,sulfated α-cyclodextrin, sulfobutyl ether β-cyclodextrin.

The concentration of the cyclodextrin used in the compositions andmethods disclosed herein varies according to the physiochemicalproperties, pharmacokinetic properties, side effect or adverse events,formulation considerations, or other factors associated with thetherapeutically active agent, or a salt or prodrug thereof, or with theproperties of other excipients in the composition. Thus, in certaincircumstances, the concentration or amount of cyclodextrin used inaccordance with the compositions and methods disclosed herein will vary,depending on the need. When used, the amount of cyclodextrins needed toincrease solubility of the corticosteroid and/or function as acontrolled release excipient in any of the formulations described hereinis selected using the principles, examples, and teachings describedherein.

Other stabilizers that are useful in the auris-acceptable formulationsdisclosed herein include, for example, fatty acids, fatty alcohols,alcohols, long chain fatty acid esters, long chain ethers, hydrophilicderivatives of fatty acids, polyvinyl pyrrolidones, polyvinyl ethers,polyvinyl alcohols, hydrocarbons, hydrophobic polymers,moisture-absorbing polymers, and combinations thereof. In someembodiments, amide analogues of stabilizers are also used. In furtherembodiments, the chosen stabilizer changes the hydrophobicity of theformulation (e.g., oleic acid, waxes), or improves the mixing of variouscomponents in the formulation (e.g., ethanol), controls the moisturelevel in the formula (e.g., PVP or polyvinyl pyrrolidone), controls themobility of the phase (substances with melting points higher than roomtemperature such as long chain fatty acids, alcohols, esters, ethers,amides etc. or mixtures thereof; waxes), and/or improves thecompatibility of the formula with encapsulating materials (e.g., oleicacid or wax). In another embodiment some of these stabilizers are usedas solvents/co-solvents (e.g., ethanol). In other embodiments,stabilizers are present in sufficient amounts to inhibit the degradationof the corticosteroid. Examples of such stabilizing agents, include, butare not limited to: (a) about 0.5% to about 2% w/v glycerol, (b) about0.1% to about 1% w/v methionine, (c) about 0.1% to about 2% w/vmonothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% toabout 2% w/v ascorbic acid, (f) 0.003% to about 0.02% w/v polysorbate80, (g) 0.001% to about 0.05% w/v. polysorbate 20, (h) arginine, (i)heparin, (j) dextran sulfate, (k) cyclodextrins, (l) pentosanpolysulfate and other heparinoids, (m) divalent cations such asmagnesium and zinc; or (n) combinations thereof.

Additional useful corticosteroid auris-acceptable formulations includeone or more anti-aggregation additives to enhance stability ofcorticosteroid formulations by reducing the rate of protein aggregation.The anti-aggregation additive selected depends upon the nature of theconditions to which the corticosteroids, for example corticosteroidantibodies are exposed. For example, certain formulations undergoingagitation and thermal stress require a different anti-aggregationadditive than a formulation undergoing lyophilization andreconstitution. Useful anti-aggregation additives include, by way ofexample only, urea, guanidinium chloride, simple amino acids such asglycine or arginine, sugars, polyalcohols, polysorbates, polymers suchas polyethylene glycol and dextrans, alkyl saccharides, such as alkylglycoside, and surfactants.

Other useful formulations optionally include one or moreauris-acceptable antioxidants to enhance chemical stability whererequired. Suitable antioxidants include, by way of example only,ascorbic acid, methionine, sodium thiosulfate and sodium metabisulfite.In one embodiment, antioxidants are selected from metal chelatingagents, thiol containing compounds and other general stabilizing agents.

Still other useful compositions include one or more auris-acceptablesurfactants to enhance physical stability or for other purposes.Suitable nonionic surfactants include, but are not limited to,polyoxyethylene fatty acid glycerides and vegetable oils, e.g.,polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylenealkylethers and alkylphenyl ethers, e.g., octoxynol 10, octoxynol 40.

In some embodiments, the auris-acceptable pharmaceutical formulationsdescribed herein are stable with respect to compound degradation over aperiod of any of at least about 1 day, at least about 2 days, at leastabout 3 days, at least about 4 days, at least about 5 days, at leastabout 6 days, at least about 1 week, at least about 2 weeks, at leastabout 3 weeks, at least about 4 weeks, at least about 5 weeks, at leastabout 6 weeks, at least about 7 weeks, at least about 8 weeks, at leastabout 3 months, at least about 4 months, at least about 5 months, or atleast about 6 months. In other embodiments, the formulations describedherein are stable with respect to compound degradation over a period ofat least about 1 week. Also described herein are formulations that arestable with respect to compound degradation over a period of at leastabout 1 month.

In other embodiments, an additional surfactant (co-surfactant) and/orbuffering agent is combined with one or more of the pharmaceuticallyacceptable vehicles previously described herein so that the surfactantand/or buffering agent maintains the product at an optimal pH forstability. Suitable co-surfactants include, but are not limited to: a)natural and synthetic lipophilic agents, e.g., phospholipids,cholesterol, and cholesterol fatty acid esters and derivatives thereof;b) nonionic surfactants, which include for example, polyoxyethylenefatty alcohol esters, sorbitan fatty acid esters (Spans),polyoxyethylene sorbitan fatty acid esters (e.g., polyoxyethylene (20)sorbitan monooleate (Tween 80), polyoxyethylene (20) sorbitanmonostearate (Tween 60), polyoxyethylene (20) sorbitan monolaurate(Tween 20) and other Tweens, sorbitan esters, glycerol esters, e.g.,Myrj and glycerol triacetate (triacetin), polyethylene glycols, cetylalcohol, cetostearyl alcohol, stearyl alcohol, polysorbate 80,poloxamers, poloxamines, polyoxyethylene castor oil derivatives (e.g.,Cremophor® RH40, Cremphor A25, Cremphor A20, Cremophor® EL) and otherCremophors, sulfosuccinates, alkyl sulphates (SLS); PEG glyceryl fattyacid esters such as PEG-8 glyceryl caprylate/caprate (Labrasol), PEG-4glyceryl caprylate/caprate (Labrafac Hydro WL 1219), PEG-32 glyceryllaurate (Gelucire 444/14), PEG-6 glyceryl mono oleate (Labrafil M 1944CS), PEG-6 glyceryl linoleate (Labrafil M 2125 CS); propylene glycolmono- and di-fatty acid esters, such as propylene glycol laurate,propylene glycol caprylate/caprate; Brij® 700, ascorbyl-6-palmitate,stearylamine, sodium lauryl sulfate, polyoxethyleneglyceroltriiricinoleate, and any combinations or mixtures thereof; c) anionicsurfactants include, but are not limited to, calciumcarboxymethylcellulose, sodium carboxymethylcellulose, sodiumsulfosuccinate, dioctyl, sodium alginate, alkyl polyoxyethylenesulfates, sodium lauryl sulfate, triethanolamine stearate, potassiumlaurate, bile salts, and any combinations or mixtures thereof; and d)cationic surfactants such as cetyltrimethylammonium bromide, andlauryldimethylbenzyl-ammonium chloride.

In a further embodiment, when one or more co-surfactants are utilized inthe auris-acceptable formulations of the present disclosure, they arecombined, e.g., with a pharmaceutically acceptable vehicle and ispresent in the final formulation, e.g., in an amount ranging from about0.1% to about 20%, from about 0.5% to about 10%.

In one embodiment, diluents are also used to stabilize thecorticosteroid or other pharmaceutical compounds because they provide amore stable environment. Salts dissolved in buffered solutions (whichalso can provide pH control or maintenance) are utilized as diluents,including, but not limited to a phosphate buffered saline solution. Inother embodiments, the gel formulation is isotonic with the endolymph orthe perilymph: depending on the portion of the cochlea that thecorticosteroid formulation is targeted. Isotonic formulations areprovided by the addition of a tonicity agent. Suitable tonicity agentsinclude, but are not limited to any pharmaceutically acceptable sugar,salt or any combinations or mixtures thereof, such as, but not limitedto dextrose and sodium chloride. The amount of tonicity agents willdepend on the target structure of the pharmaceutical formulation, asdescribed herein.

Useful tonicity compositions also include one or more salts in an amountrequired to bring osmolality of the composition into an acceptable rangefor the perilymph or the endolymph. Such salts include those havingsodium, potassium or ammonium cations and chloride, citrate, ascorbate,borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfiteanions; suitable salts include sodium chloride, potassium chloride,sodium thiosulfate, sodium bisulfite and ammonium sulfate.

In some embodiments, the auris-acceptable gel formulations disclosedherein alternatively or additionally contains preservatives to preventmicrobial growth. Suitable auris-acceptable preservatives for use in theenhanced viscosity formulations described herein include, but are notlimited to benzoic acid, boric acid, p-hydroxybenzoates, alcohols,quarternary compounds, stabilized chlorine dioxide, mercurials, such asmerfen and thiomersal, mixtures of the foregoing and the like.

In a further embodiment, the preservative is, by way of example only, anantimicrobial agent, within the auris-acceptable formulations presentedherein. In one embodiment, the formulation includes a preservative suchas by way of example only, methyl paraben, sodium bisulfite, sodiumthiosulfate, ascorbate, chorobutanol, thimerosal, parabens, benzylalcohol, phenylethanol and others. In another embodiment, the methylparaben is at a concentration of about 0.05% to about 1.0%, about 0.1%to about 0.2%. In a further embodiment, the gel is prepared by mixingwater, methylparaben, hydroxyethylcellulose and sodium citrate. In afurther embodiment, the gel is prepared by mixing water, methylparaben,hydroxyethylcellulose and sodium acetate. In a further embodiment, themixture is sterilized by autoclaving at 120° C. for about 20 minutes,and tested for pH, methylparaben concentration and viscosity beforemixing with the appropriate amount of the corticosteroid disclosedherein.

Suitable auris-acceptable water soluble preservatives which are employedin the drug delivery vehicle include sodium bisulfite, sodiumthiosulfate, ascorbate, chorobutanol, thimerosal, parabens, benzylalcohol, Butylated hydroxytoluene (BHT), phenylethanol and others. Theseagents are present, generally, in amounts of about 0.001% to about 5% byweight and, preferably, in the amount of about 0.01 to about 2% byweight. In some embodiments, auris-compatible formulations describedherein are free of preservatives.

Round Window Membrane Penetration Enhancers

In another embodiment, the formulation further comprises one or moreround window membrane penetration enhancers. Penetration across theround window membrane is enhanced by the presence of round windowmembrane penetration enhancers. Round window membrane penetrationenhancers are chemical entities that facilitate transport ofcoadministered substances across the round window membrane. Round windowmembrane penetration enhancers are grouped according to chemicalstructure. Surfactants, both ionic and nonionic, such as sodium laurylsulfate, sodium laurate, polyoxyethylene-20-cetyl ether, laureth-9,sodium dodecylsulfate, dioctyl sodium sulfosuccinate,polyoxyethylene-9-lauryl ether (PLE), Tween® 80,nonylphenoxypolyethylene (NP-POE), polysorbates and the like, functionas round window membrane penetration enhancers. Bile salts (such assodium glycocholate, sodium deoxycholate, sodium taurocholate, sodiumtaurodihydrofusidate, sodium glycodihydrofusidate and the like), fattyacids and derivatives (such as oleic acid, caprylic acid, mono- anddi-glycerides, lauric acids, acylcholines, caprylic acids,acylcarnitines, sodium caprates and the like), chelating agents (such asEDTA, citric acid, salicylates and the like), sulfoxides (such asdimethyl sulfoxide (DMSO), decylmethyl sulfoxide and the like), andalcohols (such as ethanol, isopropanol, glycerol, propanediol and thelike) also function as round window membrane penetration enhancers.

Round Window Membrane Permeable Liposomes

Liposomes or lipid particles may also be employed to encapsulate thecorticosteroid formulations or compositions. Phospholipids that aregently dispersed in an aqueous medium form multilayer vesicles withareas of entrapped aqueous media separating the lipid layers.Sonication, or turbulent agitation, of these multilayer vesicles resultsin the formation of single layer vesicles, commonly referred to asliposomes, with sizes of about 10-1000 nm. These liposomes have manyadvantages as corticosteroids or other pharmaceutical agent carriers.They are biologically inert, biodegradable, non-toxic and non-antigenic.Liposomes are formed in various sizes and with varying compositions andsurface properties. Additionally, they are able to entrap a wide varietyof agents and release the agent at the site of liposome collapse.

Suitable phospholipids for use in auris-acceptable liposomes here are,for example, phosphatidyl cholines, ethanolamines and serines,sphingomyelins, cardiolipins, plasmalogens, phosphatidic acids andcerebrosides, in particular those which are soluble together with thecorticosteroids herein in non-toxic, pharmaceutically acceptable organicsolvents. Preferred phospholipids are, for example, phosphatidylcholine, phosphatidyl ethanolamine, phosphatidyl serine, phosphatidylinositol, lysophosphatidyl choline, phosphatidyl glycerol and the like,and mixtures thereof especially lecithin, e.g. soya lecithin. The amountof phospholipid used in the present formulation range from about 10 toabout 30%, preferably from about 15 to about 25% and in particular isabout 20%.

Lipophilic additives may be employed advantageously to modifyselectively the characteristics of the liposomes. Examples of suchadditives include by way of example only, stearylamine, phosphatidicacid, tocopherol, cholesterol, cholesterol hemisuccinate and lanolinextracts. The amount of lipophilic additive used range from 0.5 to 8%,preferably from 1.5 to 4% and in particular is about 2%. Generally, theratio of the amount of lipophilic additive to the amount of phospholipidranges from about 1:8 to about 1:12 and in particular is about 1:10.Said phospholipid, lipophilic additive and the corticosteroid and otherpharmaceutical compounds are employed in conjunction with a non-toxic,pharmaceutically acceptable organic solvent system which dissolve saidingredients. Said solvent system not only must dissolve thecorticosteroid completely, but it also has to allow the formulation ofstable single bilayered liposomes. The solvent system comprisesdimethylisosorbide and tetraglycol (glycofurol, tetrahydrofurfurylalcohol polyethylene glycol ether) in an amount of about 8 to about 30%.In said solvent system, the ratio of the amount of dimethylisosorbide tothe amount of tetraglycol range from about 2:1 to about 1:3, inparticular from about 1:1 to about 1:2.5 and preferably is about 1:2.The amount of tetraglycol in the final composition thus vary from 5 to20%, in particular from 5 to 15% and preferably is approximately 10%.The amount of dimethylisosorbide in the final composition thus rangefrom 3 to 10%, in particular from 3 to 7% and preferably isapproximately 5%.

The term “organic component” as used hereinafter refers to mixturescomprising said phospholipid, lipophilic additives and organic solvents.The corticosteroid may be dissolved in the organic component, or othermeans to maintain full activity of the agent. The amount ofcorticosteroid in the final formulation may range from 0.1 to 5.0%. Inaddition, other ingredients such as anti-oxidants may be added to theorganic component. Examples include tocopherol, butylatedhydroxyanisole, butylated hydroxytoluene, ascorbyl palmitate, ascorbyloleate and the like.

In other embodiments, the auris-acceptable formulations, including gelformulations and viscosity-enhanced formulations, further includeexcipients, other medicinal or pharmaceutical agents, carriers,adjuvants, such as preserving, stabilizing, wetting or emulsifyingagents, solution promoters, salts, solubilizers, an antifoaming agent,an antioxidant, a dispersing agent, a wetting agent, a surfactant, andcombinations thereof.

Suitable carriers for use in an auris-acceptable formulation describedherein include, but are not limited to, any pharmaceutically acceptablesolvent compatible with the targeted auris structure's physiologicalenvironment. In other embodiments, the base is a combination of apharmaceutically acceptable surfactant and solvent.

In some embodiments, other excipients include, sodium stearyl fumarate,diethanolamine cetyl sulfate, isostearate, polyethoxylated castor oil,nonoxyl 10, octoxynol 9, sodium lauryl sulfate, sorbitan esters(sorbitan monolaurate, sorbitan monooleate, sorbitan monopalmitate,sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate,sorbitan tristearate, sorbitan laurate, sorbitan oleate, sorbitanpalmitate, sorbitan stearate, sorbitan dioleate, sorbitansesqui-isostearate, sorbitan sesquistearate, sorbitan tri-isostearate),lecithin pharmaceutical acceptable salts thereof and combinations ormixtures thereof.

In other embodiments, the carrier is a polysorbate. Polysorbates arenonionic surfactants of sorbitan esters. Polysorbates useful in thepresent disclosure include, but are not limited to polysorbate 20,polysorbate 40, polysorbate 60, polysorbate 80 (Tween 80) and anycombinations or mixtures thereof. In further embodiments, polysorbate 80is utilized as the pharmaceutically acceptable carrier.

In one embodiment, water-soluble glycerin-based auris-acceptableenhanced viscosity formulations utilized in the preparation ofpharmaceutical delivery vehicles comprise at least one corticosteroidcontaining at least about 0.1% of the water-soluble glycerin compound ormore. In some embodiments, the percentage of corticosteroid is variedbetween about 1% and about 95%, between about 5% and about 80%, betweenabout 10% and about 60% or more of the weight or volume of the totalpharmaceutical formulation. In some embodiments, the amount of thecompound(s) in each therapeutically useful corticosteroid formulation isprepared in such a way that a suitable dosage will be obtained in anygiven unit dose of the compound. Factors such as solubility,bioavailability, biological half-life, route of administration, productshelf life, as well as other pharmacological considerations arecontemplated herein.

If desired, the auris-acceptable pharmaceutical gels also containco-solvents, and buffering agents. Suitable auris-acceptable watersoluble buffering agents are alkali or alkaline earth metal carbonates,phosphates, bicarbonates, citrates, borates, acetates, succinates andthe like, such as sodium phosphate, citrate, borate, acetate,bicarbonate, carbonate and tromethamine (TRIS). These agents are presentin amounts sufficient to maintain the pH of the system at 7.4±0.2 andpreferably, 7.4. As such, the buffering agent is as much as 5% on aweight basis of the total composition.

Cosolvents are used to enhance corticosteroid solubility, however, somecorticosteroids or other pharmaceutical compounds are insoluble. Theseare often suspended in the polymer vehicle with the aid of suitablesuspending or viscosity enhancing agents.

Moreover, some pharmaceutical excipients, diluents or carriers arepotentially ototoxic. For example, benzalkonium chloride, a commonpreservative, is ototoxic and therefore potentially harmful ifintroduced into the vestibular or cochlear structures. In formulating acontrolled release corticosteroid formulation, it is advised to avoid orcombine the appropriate excipients, diluents or carriers to lessen oreliminate potential ototoxic components from the formulation, or todecrease the amount of such excipients, diluents or carriers.Optionally, a controlled release corticosteroid formulation includesotoprotective agents, such as antioxidants, alpha lipoic acid, calcium,fosfomycin or iron chelators, to counteract potential ototoxic effectsthat may arise from the use of specific therapeutic agents orexcipients, diluents or carriers.

Modes of Treatment

Dosing Methods and Schedules

Drugs delivered to the inner ear have been administered systemically viaoral, intravenous or intramuscular routes. However, systemicadministration for pathologies local to the inner ear increases thelikelihood of systemic toxicities and adverse side effects and creates anon-productive distribution of drug in which high levels of drug arefound in the serum and correspondingly lower levels are found at theinner ear.

Intratympanic injection of therapeutic agents is the technique ofinjecting a therapeutic agent behind the tympanic membrane into themiddle and/or inner ear. In one embodiment, the formulations describedherein are administered directly onto the round window membrane viatranstympanic injection. In another embodiment, the corticosteroidauris-acceptable formulations described herein are administered onto theround window membrane via a non-transtympanic approach to the inner ear.In additional embodiments, the formulation described herein isadministered onto the round window membrane via a surgical approach tothe round window membrane comprising modification of the cristafenestrae cochleae.

In one embodiment the delivery system is a syringe and needle apparatusthat is capable of piercing the tympanic membrane and directly accessingthe round window membrane or crista fenestrae cochleae of the aurisinterna. In some embodiments, the needle on the syringe is wider than a18 gauge needle. In another embodiment, the needle gauge is from 18gauge to 31 gauge. In a further embodiment, the needle gauge is from 25gauge to 30 gauge. Depending upon the thickness or viscosity of thecorticosteroid compositions or formulations, the gauge level of thesyringe or hypodermic needle may be varied accordingly.

In another embodiment, the needle is a hypodermic needle used forinstant delivery of the gel formulation. The hypodermic needle may be asingle use needle or a disposable needle. In some embodiments, a syringemay be used for delivery of the pharmaceutically acceptable gel-basedcorticosteroid-containing compositions as disclosed herein wherein thesyringe has a press-fit (Luer) or twist-on (Luer-lock) fitting. In oneembodiment, the syringe is a hypodermic syringe. In another embodiment,the syringe is made of plastic or glass. In yet another embodiment, thehypodermic syringe is a single use syringe. In a further embodiment, theglass syringe is capable of being sterilized. In yet a furtherembodiment, the sterilization occurs through an autoclave. In anotherembodiment, the syringe comprises a cylindrical syringe body wherein thegel formulation is stored before use. In other embodiments, the syringecomprises a cylindrical syringe body wherein the corticosteroidpharmaceutically acceptable gel-based compositions as disclosed hereinis stored before use which conveniently allows for mixing with asuitable pharmaceutically acceptable buffer. In other embodiments, thesyringe may contain other excipients, stabilizers, suspending agents,diluents or a combination thereof to stabilize or otherwise stably storethe corticosteroid or other pharmaceutical compounds contained therein.

In some embodiments, the syringe comprises a cylindrical syringe bodywherein the body is compartmentalized in that each compartment is ableto store at least one component of the auris-acceptable corticosteroidgel formulation. In a further embodiment, the syringe having acompartmentalized body allows for mixing of the components prior toinjection into the auris media or auris interna. In other embodiments,the delivery system comprises multiple syringes, each syringe of themultiple syringes contains at least one component of the gel formulationsuch that each component is pre-mixed prior to injection or is mixedsubsequent to injection. In a further embodiment, the syringes disclosedherein comprise at least one reservoir wherein the at least onereservoir comprises an corticosteroid, or a pharmaceutically acceptablebuffer, or a viscosity enhancing agent, such as a gelling agent or acombination thereof. Commercially available injection devices areoptionally employed in their simplest form as ready-to-use plasticsyringes with a syringe barrel, needle assembly with a needle, plungerwith a plunger rod, and holding flange, to perform an intratympanicinjection.

In some embodiments, the delivery device is an apparatus designed foradministration of therapeutic agents to the middle and/or inner ear. Byway of example only: GYRUS Medical Gmbh offers micro-otoscopes forvisualization of and drug delivery to the round window niche; Arenberghas described a medical treatment device to deliver fluids to inner earstructures in U.S. Pat. Nos. 5,421,818; 5,474,529; and 5,476,446, eachof which is incorporated by reference herein for such disclosure. U.S.patent application Ser. No. 08/874,208, which is incorporated herein byreference for such disclosure, describes a surgical method forimplanting a fluid transfer conduit to deliver therapeutic agents to theinner ear. U.S. Patent Application Publication 2007/0167918, which isincorporated herein by reference for such disclosure, further describesa combined otic aspirator and medication dispenser for intratympanicfluid sampling and medicament application.

The formulations described herein, and modes of administration thereof,are also applicable to methods of direct instillation or perfusion ofthe inner ear compartments. Thus, the formulations described herein areuseful in surgical procedures including, by way of non-limitingexamples, cochleostomy, labyrinthotomy, mastoidectomy, stapedectomy,endolymphatic sacculotomy or the like.

The auris-acceptable compositions or formulations containing thecorticosteroid compound(s) described herein are administered forprophylactic and/or therapeutic treatments. In therapeutic applications,the corticosteroid compositions are administered to a patient alreadysuffering from an autoimmune disease, condition or disorder, in anamount sufficient to cure or at least partially arrest the symptoms ofthe disease, disorder or condition. Amounts effective for this use willdepend on the severity and course of the disease, disorder or condition,previous therapy, the patient's health status and response to the drugs,and the judgment of the treating physician.

In the case wherein the patient's condition does not improve, upon thedoctor's discretion the administration of the corticosteroid compoundsmay be administered chronically, that is, for an extended period oftime, including throughout the duration of the patient's life in orderto ameliorate or otherwise control or limit the symptoms of thepatient's disease or condition.

In the case wherein the patient's status does improve, upon the doctor'sdiscretion the administration of the corticosteroid compounds may begiven continuously; alternatively, the dose of drug being administeredmay be temporarily reduced or temporarily suspended for a certain lengthof time (i.e., a “drug holiday”). The length of the drug holiday variesbetween 2 days and 1 year, including by way of example only, 2 days, 3days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days,180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days,and 365 days. The dose reduction during a drug holiday may be from10%-100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%,40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.

Once improvement of the patient's autoimmune conditions has occurred, amaintenance corticosteroid dose is administered if necessary.Subsequently, the dosage or the frequency of administration, or both, isoptionally reduced, as a function of the symptoms, to a level at whichthe improved disease, disorder or condition is retained. In certainembodiments, patients require intermittent treatment on a long-termbasis upon any recurrence of symptoms.

The amount of corticosteroid that will correspond to such an amount willvary depending upon factors such as the particular compound, diseasecondition and its severity, according to the particular circumstancessurrounding the case, including, e.g., the specific corticosteroid beingadministered, the route of administration, the autoimmune conditionbeing treated, the target area being treated, and the subject or hostbeing treated. In general, however, doses employed for adult humantreatment will typically be in the range of 0.02-50 mg peradministration, preferably 1-15 mg per administration. The desired doseis presented in a single dose or as divided doses administeredsimultaneously (or over a short period of time) or at appropriateintervals.

In some embodiments, the initial administration is a particularcorticosteroid and the subsequent administration a different formulationor corticosteroid.

Pharmacokinetics of Controlled Release Formulations

In one embodiment, the formulations disclosed herein additionallyprovides an immediate release of an corticosteroid from the formulation,or within 1 minute, or within 5 minutes, or within 10 minutes, or within15 minutes, or within 30 minutes, or within 60 minutes or within 90minutes. In other embodiments, a therapeutically effective amount of atleast one corticosteroid is released from the formulation immediately,or within 1 minute, or within 5 minutes, or within 10 minutes, or within15 minutes, or within 30 minutes, or within 60 minutes or within 90minutes. In certain embodiments the formulation comprises anauris-pharmaceutically acceptable gel formulation providing immediaterelease of at least one corticosteroid. Additional embodiments of theformulation may also include an agent that enhances the viscosity of theformulations included herein.

In other or further embodiments, the formulation provides an extendedrelease formulation of at least one corticosteroid. In certainembodiments, diffusion of at least one corticosteroid from theformulation occurs for a time period exceeding 5 minutes, or 15 minutes,or 30 minutes, or 1 hour, or 4 hours, or 6 hours, or 12 hours, or 18hours, or 1 day, or 2 days, or 3 days, or 4 days, or 5 days, or 6 days,or 7 days, or 10 days, or 12 days, or 14 days, or 18 days, or 21 days,or 25 days, or 30 days, or 45 days, or 2 months or 3 months or 4 monthsor 5 months or 6 months or 9 months or 1 year. In other embodiments, atherapeutically effective amount of at least one corticosteroid isreleased from the formulation for a time period exceeding 5 minutes, or15 minutes, or 30 minutes, or 1 hour, or 4 hours, or 6 hours, or 12hours, or 18 hours, or 1 day, or 2 days, or 3 days, or 4 days, or 5days, or 6 days, or 7 days, or 10 days, or 12 days, or 14 days, or 18days, or 21 days, or 25 days, or 30 days, or 45 days, or 2 months or 3months or 4 months or 5 months or 6 months or 9 months or 1 year.

In other embodiments, the formulation provides both an immediate releaseand an extended release formulation of an corticosteroid. In yet otherembodiments, the formulation contains a 0.25:1 ratio, or a 0.5:1 ratio,or a 1:1 ratio, or a 1:2 ratio, or a 1:3, or a 1:4 ratio, or a 1:5ratio, or a 1:7 ratio, or a 1:10 ratio, or a 1:15 ratio, or a 1:20 ratioof immediate release and extended release formulations. In a furtherembodiment the formulation provides an immediate release of a firstcorticosteroid and an extended release of a second corticosteroid orother therapeutic agent. In yet other embodiments, the formulationprovides an immediate release and extended release formulation of atleast one corticosteroid, and at least one therapeutic agent. In someembodiments, the formulation provides a 0.25:1 ratio, or a 0.5:1 ratio,or a 1:1 ratio, or a 1:2 ratio, or a 1:3, or a 1:4 ratio, or a 1:5ratio, or a 1:7 ratio, or a 1:10 ratio, or a 1:15 ratio, or a 1:20 ratioof immediate release and extended release formulations of a firstcorticosteroid and second therapeutic agent, respectively.

In a specific embodiment the formulation provides a therapeuticallyeffective amount of at least one corticosteroid at the site of diseasewith essentially no systemic exposure. In an additional embodiment theformulation provides a therapeutically effective amount of at least onecorticosteroid at the site of disease with essentially no detectablesystemic exposure. In other embodiments, the formulation provides atherapeutically effective amount of at least one corticosteroid at thesite of disease with little or no detectable detectable systemicexposure.

The combination of immediate release, delayed release and/or extendedrelease corticosteroid compositions or formulations may be combined withother pharmaceutical agents, as well as the excipients, diluents,stabilizers, tonicity agents and other components disclosed herein. Assuch, depending upon the corticosteroid used, the thickness or viscositydesired, or the mode of delivery chosen, alternative aspects of theembodiments disclosed herein are combined with the immediate release,delayed release and/or extended release embodiments accordingly.

In certain embodiments, the pharmacokinetics of the corticosteroidformulations described herein are determined by injecting theformulation on or near the round window membrane of a test animal(including by way of example, a guinea pig or a chinchilla). At adetermined period of time (e.g., 6 hours, 12 hours, 1 day, 2 days, 3days, 4 days, 5 days, 6 days, and 7 days for testing thepharmacokinetics of a formulation over a 1 week period), the test animalis euthanized and a 5 mL sample of the perilymph fluid is tested. Theinner ear removed and tested for the presence of the corticosteroid. Asneeded, the level of corticosteroid is measured in other organs. Inaddition, the systemic level of the corticosteroid is measured bywithdrawing a blood sample from the test animal. In order to determinewhether the formulation impedes hearing, the hearing of the test animalis optionally tested.

Alternatively, an inner ear is provided (as removed from a test animal)and the migration of the corticosteroid is measured. As yet anotheralternative, an in vitro model of a round window membrane is providedand the migration of the corticosteroid is measured.

Kits/Articles of Manufacture

The disclosure also provides kits for preventing, treating orameliorating the symptoms of a disease or disorder in a mammal. Suchkits generally will comprise one or more of the corticosteroidcontrolled-release compositions or devices disclosed herein, andinstructions for using the kit. The disclosure also contemplates the useof one or more of the corticosteroid controlled-release compositions, inthe manufacture of medicaments for treating, abating, reducing, orameliorating the symptoms of a disease, dysfunction, or disorder in amammal, such as a human that has, is suspected of having, or at risk fordeveloping an inner ear disorder.

In some embodiments, kits include a carrier, package, or container thatis compartmentalized to receive one or more containers such as vials,tubes, and the like, each of the container(s) including one of theseparate elements to be used in a method described herein. Suitablecontainers include, for example, bottles, vials, syringes, and testtubes. In other embodiments, the containers are formed from a variety ofmaterials such as glass or plastic.

The articles of manufacture provided herein contain packaging materials.Packaging materials for use in packaging pharmaceutical products arealso presented herein. See, e.g., U.S. Pat. Nos. 5,323,907, 5,052,558and 5,033,252. Examples of pharmaceutical packaging materials include,but are not limited to, blister packs, bottles, tubes, inhalers, pumps,bags, vials, containers, syringes, bottles, and any packaging materialsuitable for a selected formulation and intended mode of administrationand treatment. A wide array of corticosteroid formulations compositionsprovided herein are contemplated as are a variety of treatments for anydisease, disorder, or condition that would benefit by controlled releaseadministration of a corticosteroid to the inner ear.

In some embodiments, a kit includes one or more additional containers,each with one or more of various materials (such as reagents, optionallyin concentrated form, and/or devices) desirable from a commercial anduser standpoint for use of a formulation described herein. Non-limitingexamples of such materials include, but not limited to, buffers,diluents, filters, needles, syringes; carrier, package, container, vialand/or tube labels listing contents and/or

EXAMPLES Example 1 Preparation of a Thermoreversible Gel DexamethasoneFormulation or Device

Quantity Ingredient (mg/g of formulation) Dexamethasone 20.0methylparaben 1.0 HPMC 10.0 Poloxamer 407 180.0 TRIS HCl buffer (0.1M)789.0

A 10-g batch of gel formulation containing 2.0% of Dexamethasone isprepared by suspending 1.80 g of Poloxamer 407 (BASF Corp.) in 5.00 g ofTRIS HCl buffer (0.1 M) and the components are mixed under agitationovernight at 4° C. to ensure complete dissolution. Dexamethasone (200.0mg), hydroxypropylmethylcellulose (100.0 mg), methylparaben (10 mg) andadditional TRIS HCl buffer (0.1 M) (2.89 g) is added and furtherstirring allowed until complete dissolution is observed. The mixture ismaintained below room temperature until use.

Example 2 Preparation of a Mucoadhesive, Thermoreversible GelPrednisolone Formulation or Device

Quantity Ingredient (mg/g of formulation) Prednisolone 30 methylparaben1.0 HPMC 10.0 Carbopol 934P 2.0 Poloxamer 407 180.0 TRIS HCl buffer(0.1M) 787.0

A 10-g batch of mucoadhesive, gel formulation containing 2.0% ofPrednisolone is prepared by suspending 2.0 mg of Carbopol 934P and 1.80g of Poloxamer 407 (BASF Corp.) in 5.00 g of TRIS HCl buffer (0.1 M) andthe components are mixed under agitation overnight at 4° C. to ensurecomplete dissolution. The Prednisolone, hydroxypropylmethylcellulose(100.0 mg), methylparaben (10 mg) and additional TRIS HCl buffer (0.1 M)(2.87 g) are added and further stirring allowed until completedissolution is observed. The mixture is maintained below roomtemperature until use.

Example 3 Preparation of a Cyclodextrin-Containing Thermoreversible Gel2.5% Dexamethasone Formulation or Device

Quantity Ingredient (mg/g of formulation) 5% CD solution 500.0methylparaben 1.0 Poloxamer 407 180.0 TRIS HCl buffer (0.1M) 317.0

The Poloxamer 407 (BASF Corp.) is suspended in the TRIS HCl buffer (0.1M) and the components are mixed under agitation overnight at 4° C. toensure complete dissolution. The cyclodextrin solution and methylparabenis added and further stirring allowed until complete dissolution isobserved. The mixture is maintained below room temperature until use.

Example 4 Preparation of a Cyclodextrin-Containing Mucoadhesive,Thermoreversible Gel Dexamethasone Formulation or Device

Quantity Ingredient (mg/g of formulation) 5% CD solution 500.0methylparaben 1.0 Poloxamer 407 180.0 Carbopol 934P 2.0 TRIS HCl buffer(0.1M) 317.0

The Carbopol 934P and Poloxamer 407 (BASF Corp.) is suspended in theTRIS HCl buffer (0.1 M) and the components are mixed under agitationovernight at 4° C. to ensure complete dissolution. The cyclodextrinsolution and methylparaben is added and further stirring allowed untilcomplete dissolution is observed. The mixture is maintained below roomtemperature until use.

Example 5 Preparation of a Thermoreversible Gel DexamethasoneFormulation or Device Comprising Micronized Dexamethasone Powder

Quantity Ingredient (mg/g of formulation) Dexamethasone 20.0 BHT 0.002Poloxamer 407 160.0 PBS buffer (0.1M) 9.0

A 10-g batch of gel formulation containing 2.0% of micronizedDexamethasone, 13.8 mg of sodium phosphate dibasic dihydrate USP (FisherScientific.)+3.1 mg of sodium phosphate monobasic monohydrate USP(Fisher Scientific.)+74 mg of sodium chloride USP (Fisher Scientific.)was dissolved with 8.2 g of sterile filtered DI water and the pH wasadjusted to 7.4 with 1 M NaOH. The buffer solution was chilled down and1.6 g of poloxamer 407 (BASF Corp., containing approximately 100 ppm ofBHT) was sprinkled into the chilled PBS solution while mixing, solutionwas mixed until all the poloxamer was dissolved. The poloxamer wassterile filtered using a 33 mm PVDF 0.22 μm sterile syringe filter(Millipore Corp.) and delivered to 2 mL sterile glass vials (Wheaton) inan aseptic environment, the vials were closed with sterile butyl rubberstoppers (Kimble) and crimped sealed with 13 mm Al seals (Kimble). 20 mgof micronized dexamethasone (Spectrum chemicals) was placed in separateclean depyrogenated vials, the vials were closed with sterile butylrubber stoppers (Kimble) and crimped sealed with 13 mm Al seals(Kimble), vials were dry heat sterilized (Fisher SCientific Isotempoven) for 7 hours at 140° C. Before administration for the experimentsdescribed herein, 1 mL of the cold poloxamer solution was delivered to avial containing 20 mg of sterile micronized dexamethasone using a 21Gneedle (Becton Dickinson) attached to a 1 mL sterile syringe (BectonDickinson), suspension mixed well by shaking to ensure homogeneity ofthe suspension. The suspension was then withdrawn with the 21G syringeand the needle was switched to a 27 G needle for administration.

Example 6 Preparation of a Thermoreversible Gel Micronized PrednisoneFormulation or Device Comprising a Penetration Enhancer

Quantity Ingredient (mg/g of formulation) Prednisone 20.0 methylparaben1.0 Dodecyl maltoside (A3) 1.0 HPMC 10.0 Poloxamer 407 180.0 TRIS HClbuffer (0.1M) 789.0

A 10-g batch of gel formulation containing 2.0% of micronized prednisoneis prepared by suspending 1.80 g of Poloxamer 407 (BASF Corp.) in 5.00 gof TRIS HCl buffer (0.1 M) and the components are mixed under agitationovernight at 4° C. to ensure complete dissolution. Prednisone (200.0mg), hydroxypropylmethylcellulose (100.0 mg), methylparaben (10 mg) anddodecyl maltoside (10 mg) and additional TRIS HCl buffer (0.1 M) (2.89g) is added and further stirring allowed until complete dissolution isobserved. The mixture is maintained below room temperature until use.

Example 7 Effect of pH on Degradation Products for Autoclaved 17%Poloxamer 407NF/2% Dexamethasone Phosphate (DSP) in PBS Buffer

A stock solution of a 17% poloxamer 407/2% dexamethasone phosphate (DSP)is prepared by dissolving 351.4 mg of sodium chloride (FisherScientific), 302.1 mg of sodium phosphate dibasic anhydrous (FisherScientific), 122.1 mg of sodium phosphate monobasic anhydrous (FisherScientific) and 2.062 g dexamethasone phosphate (DSP) with 79.3 g ofsterile filtered DI water. The solution is cooled down in a ice chilledwater bath and then 17.05 g of poloxamer 407NF (SPECTRUM CHEMICALS) issprinkled into the cold solution while mixing. The mixture is furthermixed until the poloxamer is completely dissolved. The pH for thissolution is measured.

17% Poloxamer 407/2% Dexamethasone Phosphate (DSP) in PBS pH of 5.3.

Take an aliquot (approximately 30 mL) of the above solution and adjustthe pH to 5.3 by the addition of 1 M HCl.

17% Poloxamer 407/2% Dexamethasone Phosphate (DSP) in PBS pH of 8.0.

Take an aliquot (approximately 30 mL) of the above stock solution andadjust the pH to 8.0 by the addition of 1 M NaOH.

A PBS buffer (pH 7.3) is prepared by dissolving 805.5 mg of sodiumchloride (Fisher Scientific), 606 mg of sodium phosphate dibasicanhydrous (Fisher Scientific), 247 mg of sodium phosphate monobasicanhydrous (Fisher Scientific), then QS to 200 g with sterile filtered DIwater.

A 2% solution of dexamethasone phosphate (DSP) in PBS pH 7.3 is preparedby dissolving 206 mg of dexamethasone phosphate (DSP) in the PBS bufferand QS to 10 g with PBS buffer.

One mL samples are individually placed in 3 mL screw cap glass vials(with rubber lining) and closed tightly. The vials are placed in aMarket Forge-sterilmatic autoclave (settings, slow liquids) andsterilized at 250° F. for 15 minutes. After the autoclave the samplesare left to cool down to room temperature and then placed inrefrigerator. The samples are homogenized by mixing the vials whilecold.

Appearance (e.g., discoloration and/or precipitation) is observed andrecorded. The 2% DSP in PBS alone showed discoloration (slight yellow)and some precipitation, while the samples containing poloxamer did notshow signs of discoloration. Of the poloxamer containing samples,precipitation was only observed with the sample at a pH of 5.3.

HPLC analysis is performed using an Agilent 1200 equipped with a LunaC18(2) 3 μm, 100 Å, 250×4.6 mm column) using a 30-80 acetonitrilegradient (1-10 min) of (water-acetonitrile mixture containing 0.05%TFA), for a total run of 15 minutes. The main peaks were recorded in thetable below. Samples are diluted by taking 30 μL of sample and dissolvedwith 1.5 mL of a 1:1 acetonitrile water mixture. Purity of the samplesbefore autoclaving was always greater than 99%.

TABLE 1 Observed properties after autoclaving samples containingdexamethasone sodium phosphate (DSP) % Dex (RRT = % RRT of % RRT ofAppearance % DSP 1.27) 1.54 1.68 2% DSP Yellowish 89 6.5 1.41 — pH = 7.317% 407/ Precipitate 53 45.9 0.48 0.56 2% DSP PBS, pH = 5.3 17% 407/Clear 88 10 0.79 — 2% DSP PBS, Solution/Gel pH = 7.3 17% 407/ Clear 924.9 1.18 — 2% DSP PBS, Solution/Gel pH = 8.0 Purity before autoclavingwas 99+% for all samples.

Example 8 Effect of Autoclaving on the Release Profile and Viscosity ofa 17% Poloxamer 407NF/2% Dexamethasone Phosphate (DSP) in PBS

An aliquot of the sample from example 6 (autoclaved and not autoclaved)is evaluated for release profile and viscosity measurement to evaluatethe impact of heat sterilization on the properties of the gel.

Dissolution is performed at 37° C. in snapwells (6.5 mm diameterpolycarbonate membrane with a pore size of 0.4 μm). 0.2 mL of gel isplaced into snapwell and left to harden, then 0.5 mL is placed intoreservoir and shaken using a Labline orbit shaker at 70 rpm. Samples aretaken every hour (0.1 mL withdrawn and replace with warm buffer).Samples are analyzed for poloxamer concentration by UV at 624 nm usingthe cobalt thiocyanate method, against an external calibration standardcurve. In brief, 20 μL of the sample is mixed with 19804, of a 15 mMcobalt thiocyanate solution and absorbance measured at 625 nm, using aEvolution 160 UV/Vis spectrophotometer (Thermo Scientific).

The released dexamethasone phosphate (DSP) is fitted to theKorsmeyer-Peppas equation

$\frac{Q}{Q_{\alpha}} = {{kt}^{n} + b}$where Q is the amount of otic agent released at time t, Q_(α) is theoverall released amount of otic agent, k is a release constant of thenth order, n is a dimensionless number related to the dissolutionmechanism and b is the axis intercept, characterizing the initial burstrelease mechanism wherein n=1 characterizes an erosion controlledmechanism. The mean dissolution time (MDT) is the sum of differentperiods of time the drug molecules stay in the matrix before release,divided by the total number of molecules and is calculated by:

${MDT} = \frac{{nk}^{\frac{- 1}{n}}}{n + 1}$

Viscosity measurements are performed using a Brookfield viscometerRVDV-II+P with a CPE-51 spindle rotated at 0.08 rpm (shear rate of 0.31s⁻¹), equipped with a water jacketed temperature control unit(temperature ramped from 15-34° C. at 1.6° C./min). Tgel is defined asthe inflection point of the curve where the increase in viscosity occursdue to the sol-gel transition.

TABLE 2 Effect of autoclaving on the release profile and viscosity of a17% poloxamer 407NF/2% dexamethasone sodium phosphate (DSP) in PBS. MDT(hr) Tgel (° C.) Max Viscosity* (Pas) Non-autoclaved 3.2 25 403Autoclaved 3.2 26 341 *Maximum apparent viscosity in the gel state (upto 37° C.) at a shear rate of 0.31 s⁻¹ The results show little effect onviscosity and release profile after autoclaving a 17% poloxamer 407NF/2%dexamethasone sodium phosphate (DSP) in PBS.

Example 9 Effect of Addition of a Secondary Polymer on the DegradationProducts and Viscosity of a Formulation Containing 2% DexamethasonePhosphate (DSP) and 17% Poloxamer 407NF after Heat Sterilization(Autoclaving)

Solution A.

A solution of pH 7.0 comprising sodium carboxymethylcellulose (CMC) inPBS buffer is prepared by dissolving 178.35 mg of sodium chloride(Fisher Scientific), 300.5 mg of sodium phosphate dibasic anhydrous(Fisher Scientific), 126.6 mg of sodium phosphate monobasic anhydrous(Fisher Scientific) dissolved with 78.4 of sterile filtered DI water,then 1 g of Blanose 7M65 CMC (Hercules, viscosity of 5450 cP @ 2%) issprinkled into the buffer solution and heated to aid dissolution, andthe solution is then cooled down.

A solution of pH 7.0 comprising 17% poloxamer 407NF/1% CMC/2%dexamethasone sodium phosphate (DSP) in PBS buffer is made by coolingdown 8.1 g of solution A in a ice chilled water bath and then adding 205mg of dexamethasone sodium phosphate (DSP) followed by mixing. 1.74 g ofpoloxamer 407NF (Spectrum Chemicals) is sprinkled into the cold solutionwhile mixing. The mixture is further mixed until all the poloxamer iscompletely dissolved.

Two mL of the above sample is placed in a 3 mL screw cap glass vial(with rubber lining) and closed tightly. The vial is placed in a MarketForge-sterilmatic autoclave (settings, slow liquids) and sterilized at250° F. for 25 minutes. After autoclaving the sample is left to cooldown to room temperature and then placed in refrigerator. The sample ishomogenized by mixing while the vials are cold.

No Precipitation or discoloration was observed after autoclaving. HPLCanalysis is performed as described in Example 6. Less than 1% ofdegradation products due to hydrolysis of dexamethasone products weredetected, i.e., the formulation was stable to autoclaving.

Viscosity measurements were performed as described in Example 7. Theresults showed that autoclaving had little effect on the viscosity ofthe gel, or the Tgel temperature. Less overall impurities were observedin poloxamer containing formulations compared to the control sample (2%DSP in PBS).

Dissolution testing was performed as described in example 7. The resultsshowed a MDT of 11.9 hr compared to a MDT of 3.2 hr for a formulationcontaining no CMC. The addition of CMC or a secondary polymer introducesa diffusional barrier that reduces the rate of release of thedexamethasone (i.e., increases MDT).

Example 10 Effect of Buffer Type on the Degradation Products forFormulations Containing Poloxamer 407NF after Heat Sterilization(Autoclaving)

A TRIS buffer is made by dissolving 377.8 mg of sodium chloride (FisherScientific), and 602.9 mg of Tromethamine (Sigma Chemical Co.) then QSto 100 g with sterile filtered DI water, pH is adjusted to 7.4 with 1MHCl.

Stock Solution Containing 25% Poloxamer 407 Solution in TRIS Buffer:

Weigh 45 g of TRIS buffer, chill in an ice chilled bath then sprinkleinto the buffer, while mixing, 15 g of poloxamer 407 NF (SpectrumChemicals). The mixture is further mixed until all the poloxamer iscompletely dissolved.

Stock Solution (pH 7.3) Containing 25% Poloxamer 407 Solution in PBSBuffer:

Dissolve 704 mg of sodium chloride (Fisher Scientific), 601.2 mg ofsodium phosphate dibasic anhydrous (Fisher Scientific), 242.7 mg ofsodium phosphate monobasic anhydrous (Fisher Scientific) with 140.4 g ofsterile filtered DI water. The solution is cooled down in an ice chilledwater bath and then 50 g of poloxamer 407NF (SPECTRUM CHEMICALS) issprinkled into the cold solution while mixing. The mixture is furthermixed until the poloxamer is completely dissolved and a clear translucidsolution was obtained. The pH obtained for this solution was measured at7.3.

A series of formulations are prepared with the above stock solutions.Dexamethasone phosphate (DSP) and micronized Dexamethasone USP fromspectrum chemicals were used for all experiments.

One mL samples are individually placed in 3 mL screw cap glass vials(with rubber lining) and closed tightly. The vials are placed in aMarket Forge-sterilmatic autoclave (setting, slow liquids) andsterilized at 250° F. for 25 minutes. After the autoclaving the samplesare left to cool down to room temperature. The vials are placed in therefrigerator and mixed while cold to homogenize the samples.

HPLC analysis is performed as described in example 6. The stability offormulations in TRIS and PBS buffers is compared.

TABLE 3 Effect of buffer type on the degradation of dexamethasone anddexamethasone phosphate containing formulations. % Dex % RRT of % RRT ofSample ID Appearance % DSP (RRT = 1.27) 1.54 1.68  1% DSP/TRIS Yellowish& 41 54 2.68 0.97 Precipitate  2% DSP/TRIS Yellowish & 41 55 2.4 0.57Precipitate  4% DSP/TRIS Yellowish & 58 36 2.4 0.23 Precipitate 16%P407/2DSP/TRIS Precipitate 54 41 0.79 0.62 18% P407/2DSP/TRISPrecipitate 52 45 1.21 0.51 20% P407/2DSP/TRIS Precipitate 55 43 0.860.49 18% P407/2DEX/TRIS Suspension — 99 0.22 0.55  2% DEX/TRISSuspension — 99 — 0.28  2% DSP/PBS Yellowish & 85.6 9.8 2.09 —Precipitate 16% P407/2DSP/PBS Clear solution 78 17.5 1.86 — 18%P407/2DSP/PBS Clear solution 81.2 16.2 1.14 — 20% P407/2DSP/PBS Clearsolution 81.5 16.1 1.04 — 18% P407/2DEX/PBS Suspension — 97 1.06 0.45 2% DEX/PBS Suspension — 94.7 1.34 —

Viscosity measurements were performed as described in example 7.

The results show that in order to reduce hydrolysis during autoclaving,the buffer needs to maintain a pH in the 7-8 range at elevatedtemperatures. Increased drug hydrolysis was observed in TRIS buffer thanin PBS (Table 3). Occurrence of other degradation products are reducedby the use of the polymeric additives (e.g. P407) described in thisapplication. A decrease in degradation products is observed from theformulation containing 20% poloxamer 407 compared to the one with nopoloxamer 407 (Table 7).

The formulations containing suspended micronized dexamethasone hadgreater stability upon autoclaving, than their solution counterparts.

Example 11 Pulsed Release Otic Formulations

A combination of dexamethasone and dexamethasone sodium phosphate (DSP)(ratio of 1:1) is used to prepare a pulsed release formulation using theprocedures described herein. 20% of the deliverable dose ofdexamethasone is solubilized in a 17% poloxamer solution of example 7with the aid of beta-cyclodextrins. The remaining 80% of the deliverabledexamethasone is then added to the mixture and the final formulation isprepared using any procedure described herein.

Pulsed release formulations comprising dexamethasone are preparedaccording to the procedures and examples described herein, and aretested using procedures described herein to determine pulse releaseprofiles.

Example 12 Preparation of a 17% Poloxamer 407/2% DSP/78 Ppm Evans Bluein PBS

A Stock solution of Evans Blue (5.9 mg/mL) in PBS buffer is prepared bydissolving 5.9 mg of Evans Blue (Sigma Chemical Co) with 1 mL of PBSbuffer (from example 61).

A Stock solution containing 25% Poloxamer 407 solution in PBS bufferfrom example 8 is used in this study. An appropriate amount of DSP isadded to the stock solution from example 8 to prepare formulationscomprising 2% DSP (Table 4).

TABLE 4 Stock solution containing 25% Poloxamer 407 solution in PBSbuffer from example 9 was used for this study. PBS Evans Blue 25% P407inDSP Buffer Solution Sample ID PBS (g) (mg) (g) (μL) 17% P407/2DSP/EB13.6 405.6 6 265 20% P407/2DSP/EB 16.019 407 3.62 265 25% P407/2DSP/EB19.63 407 — 265

The above formulations are dosed to guinea pigs in the middle ear byprocedures described herein and the ability of formulations to gel uponcontact and the location of the gel is identified after dosing and at 24hours after dosing.

Example 13 Terminal Sterilization of Poloxamer 407 Formulations with andwithout a Visualization Dye

17% Poloxamer407/2% DSP/in Phosphate Buffer, pH 7.3:

Dissolve 709 mg of sodium chloride (Fisher Scientific), 742 mg of sodiumphosphate dibasic dehydrate USP (Fisher Scientific), 251.1 mg of sodiumphosphate monobasic monohydrate USP (Fisher Scientific) and anappropriate amount of DSP with 158.1 g of sterile filtered DI water. Thesolution is cooled down in an ice chilled water bath and then 34.13 g ofpoloxamer 407NF (Spectrum chemicals) is sprinkled into the cold solutionwhile mixing. The mixture is further mixed until the poloxamer iscompletely dissolved and a clear translucid solution was obtained. ThepH of this solution was 7.3.

17% Poloxamer407/2% DSP/59 Ppm Evans Blue in Phosphate Buffer:

Take two mL of the 17% poloxamer407/2% DSP/in phosphate buffer solutionand add 2 mL of a 5.9 mg/mL Evans blue (Sigma-Aldrich chemical Co)solution in PBS buffer.

25% Poloxamer407/2% DSP/in Phosphate Buffer:

Dissolve 330.5 mg of sodium chloride (Fisher Scientific), 334.5 mg ofsodium phosphate dibasic dihydrate USP (Fisher Scientific), 125.9 mg ofsodium phosphate monobasic monohydrate USP (Fisher Scientific) and 2.01g of dexamethasone sodium phosphate USP (Spectrum Chemicals) with 70.5 gof sterile filtered DI water.

The solution is cooled down in an ice chilled water bath and then 25.1 gof poloxamer 407NF (Spectrum chemicals) is sprinkled into the coldsolution while mixing. The mixture is further mixed until the poloxameris completely dissolved and a clear translucid solution is obtained. ThepH of this solution was 7.3.

25% Poloxamer407/2% DSP/59 Ppm Evans Blue in Phosphate Buffer:

Take two mL of the 25% poloxamer407/2% DSP/in phosphate buffer solutionand add 2 mL of a 5.9 mg/mL Evans blue (Sigma-Aldrich chemical Co)solution in PBS buffer.

Place 2 mL of formulation into a 2 mL glass vial (Wheaton serum glassvial) and seal with 13 mm butyl str (kimble stoppers) and crimp with a13 mm aluminum seal. The vials are placed in a Market Forge-sterilmaticautoclave (settings, slow liquids) and sterilized at 250° F. for 25minutes. After the autoclaving the samples are left to cool down to roomtemperature and then placed in refrigeration. The vials are placed inthe refrigerator and mixed while cold to homogenize the samples. Samplediscoloration or precipitation after autoclaving is recorded.

HPLC analysis is performed as described in Example 6.

TABLE 5 Effect of autoclaving on the purity of formulations containingdexamethasone sodium phosphate with and without visualization dye. % Dex% RRT of (RRT = % RRT of % RRT of Sample ID 0.68 % DSP 1.28) 1.41 1.7617% P407 1.1 84.5 12.0 0.7 0.09 17% P407/ 1.1 84.4 11.7 0.8 0.09 EvansBlue 25% P407 0.8 80.9 16.0 0.7 0.10 25% P407/ 0.9 80.9 15.3 0.7 0.12Evans Blue

Viscosity measurements are performed as described in example 7. Theresults showed that autoclaving formulations comprising a visual dye hadno effect on degradation products and viscosity of the formulations.

Mean dissolution time (determined as described in example 7, measuringthe amount of dexamethasone phosphate released by UV @ 245 nm) for the25% poloxamer 407 formulations was measured to be 5.6 hr and for the 17%poloxamer 407 formulation showed to be 3.2 hr.

Example 14 In Vitro Comparison of Release Profile

Dissolution is performed at 37° C. in snapwells (6.5 mm diameterpolycarbonate membrane with a pore size of 0.4 μm), 0.2 mL of a gelformulation described herein is placed into snapwell and left to harden,then 0.5 mL buffer is placed into reservoir and shaken using a Lablineorbit shaker at 70 rpm. Samples are taken every hour (0.1 mL withdrawnand replace with warm buffer). Samples are analyzed for dexamethasoneconcentration by UV at 245 nm against an external calibration standardcurve. Pluronic concentration is analyzed at 624 nm using the cobaltthiocyanate method. Relative rank-order of mean dissolution time (MDT)as a function of % P407 is determined. A linear relationship between theformulations mean dissolution time (MDT) and the P407 concentrationindicates that dexamethasone is released due to the erosion of thepolymer gel (poloxamer) and not via diffusion. A non-linear relationshipindicates release of dexamethasone via a combination of diffusion and/orpolymer gel degradation.

Alternatively, samples are analyzed using the method described by LiXin-Yu paper [Acta Pharmaceutica Sinica 2008, 43(2):208-203] andRank-order of mean dissolution time (MDT) as a function of % P407 isdetermined.

FIG. 1. illustrates in vitro release profile of Dexamethasoneformulations with varying concentrations of. Poloxamer 407. FIG. 2illustrates the nearly linear relationship (1:1 correlation) between theformulations' mean dissolution time (MDT) and the P407 concentration.The results indicate that dexamethasone is released due to the erosionof the polymer gel (poloxamer) and not via diffusion.

Example 15 In Vitro Comparison of Gelation Temperature

The effect of Poloxamer 188 and dexamethasone on the gelationtemperature and viscosity of Poloxamer 407 formulations is evaluatedwith the purpose of manipulating the the gelation temperature.

A 25% Poloxamer 407 stock solution in PBS buffer (from example 9) andthe PBS solutions from example 6 are used. Poloxamer 188NF from BASF isused.

TABLE 6 Preparation of samples containing poloxamer 407/poloxamer 18825% P407 Stock Poloxamer 188 PBS Buffer Sample Solution (g) (mg) (g) 16%P407/10% P188 3.207 501 1.3036 17% P407/10% P188 3.4089 500 1.1056 18%P407/10% P188 3.6156 502 0.9072 19% P407/10% P188 3.8183 500 0.7050 20%P407/10% P188 4.008 501 0.5032 20% P407/5% P188 4.01 256 0.770

Mean dissolution time (method describe in example 7) for the 20%poloxamer 407/10% poloxamer 188 was measured to be 2.2 hr and for the20% poloxamer 407/5% poloxamer 188 showed to be 2.6 hr. Viscosity isdetermined using procedure described in example 7. Autoclaving had noeffect on the viscosity or Tgel of formulations containing poloxamer188.

An equation is fitted to the data obtained and can be utilized toestimate the gelation temperature of F127/F68 mixtures (for 17-20% F127and 0-10% F68).T _(gel)=−1.8(% F127)+1.3(% F68)+53

An equation is fitted to the data obtained and can be utilized toestimate the Mean Dissolution Time (hr) based on the gelationtemperature of F127/F68 mixtures (for 17-25% F127 and 0-10% F68), usingresults obtained in example 12 and 14.MDT=−0.2(T _(gel))+8

Example 16 Determination of Temperature Range for Sterile Filtration

The viscosity at low temperatures is measured to help guide thetemperature range at which the sterile filtration needs to occur toreduce the possibility of clogging.

Viscosity measurements are performed using a Brookfield viscometerRVDV-II+P with a CPE-40 spindle rotated at 1, 5 and 10 rpm (shear rateof 7.5, 37.5 and 75 s⁻¹), equipped with a water jacketed temperaturecontrol unit (temperature ramped from 10-25° C. at 1.6° C./min).

The Tgel of a 17% Pluronic P407 is determined as a function ofincreasing concentration of otic agent. The increase in Tgel for a 17%pluronic formulation is estimated by:ΔT _(gel)=0.93[% otic agent]

TABLE 7 Viscosity of potential formulations at manufacturing/filtrationconditions. Apparent Viscosity^(a) (cP) Temperature @ Sample 5° C. belowTgel 20° C. 100 cP Placebo 52 cP @ 17° C. 120 cP   19° C. 17% P407/2%DSP 90 cP @ 18° C. 147 cP 18.5° C. 17% P407/6% DSP 142 cP @ 22° C.  105cP 19.7° C. ^(a)Viscosity measured at a shear rate of 37.5 s⁻¹

The results show that sterile filtration of formulations describedherein can be carried out at about 19° C.

Example 17 Determination of Manufacturing Conditions

An 8 liter batch of a 17% P407 placebo is manufactured to evaluate themanufacturing/filtration conditions. The placebo is manufactured byplacing 6.4 liters of DI water in a 3 gallon SS pressure vessel, andleft to cool down in the refrigerator overnight. The following morningthe tank was taken out (water temperature 5° C., RT 18° C.) and 48 g ofsodium chloride, 29.6 g of sodium phosphate dibasic dehydrate and 10 gof sodium phosphate monobasic monohydrate is added and dissolved with anoverhead mixer (IKA RW20 @ 1720 rpm). Half hour later, once the bufferis dissolved (solution temperature 8° C., RT 18° C.), 1.36 kg ofpoloxamer 407 NF (spectrum chemicals) is slowly sprinkled into thebuffer solution in a 15 minute interval (solution temperature 12° C., RT18° C.), then speed is increased to 2430 rpm. After an additional onehour mixing, mixing speed is reduced to 1062 rpm (complete dissolution).

The temperature of the room is maintained below 25° C. to retain thetemperature of the solution at below 19° C. The temperature of thesolution is maintained at below 19° C. up to 3 hours of the initiationof the manufacturing, without the need to chill/cool the container.

Three different Sartoscale (Sartorius Stedim) filters with a surfacearea of 17.3 cm² are evaluated at 20 psi and 14° C. of solution

-   -   1) Sartopore 2, 0.2 μm 5445307HS-FF (PES), flow rate of 16        mL/min    -   2) Sartobran P, 0.2 μm 5235307HS-FF (cellulose ester), flow rate        of 12 mL/min    -   3) Sartopore 2 XLI, 0.2 μm 5445307IS-FF (PES), flow rate of 15        mL/min

Sartopore 2 filter 5441307H4-SS is used, filtration is carried out atthe solution temperature using a 0.45, 0.2 μm Sartopore 2 150 sterilecapsule (Sartorius Stedim) with a surface area of 0.015 m² at a pressureof 16 psi. Flow rate is measured at approximately 100 mL/min at 16 psi,with no change in flow rate while the temperature is maintained in the6.5-14° C. range. Decreasing pressure and increasing temperature of thesolution causes a decrease in flow rate due to an increase in theviscosity of the solution. Discoloration of the solution is monitoredduring the process.

TABLE 8 Predicted filtration time for a 17% poloxamer 407 placebo at asolution temperature range of 6.5-14° C. using Sartopore 2, 0.2 μmfilters at a pressure of 16 psi of pressure. Estimated flow rate Time tofilter 8 L Filter Size (m²) (mL/min) (estimated) Sartopore 2, size 40.015 100 mL/min 80 min Sartopore 2, size 7 0.05 330 mL/min 24 minSartopore 2, size 8 0.1 670 mL/min 12 min

Viscosity, Tgel and UV/Vis absorption are checked before filtrationevaluation. Pluronic UV/Vis spectra are obtained by a Evolution 160UV/Vis (Thermo Scientific). A peak in the range of 250-300 nm isattributed to BHT stabilizer present in the raw material (poloxamer).

The above process is applicable for manufacture of 17% P407formulations, and includes temperature analysis of the room conditions.A temperature of about 19° C. reduces cost of cooling the containerduring manufacturing. In some instances, a jacketed container is used tofurther control the temperature of the solution to ease manufacturingconcerns.

Example 18 In Vitro Release of Dexamethasone from an AutoclavedMicronized Sample

17% poloxamer 407/1.5% dexamethasone in TRIS buffer: 250.8 mg of sodiumchloride (Fisher Scientific), and 302.4 mg of Tromethamine (SigmaChemical Co.) is dissolved in 39.3 g of sterile filtered DI water, pH isadjusted to 7.4 with 1M HCl. 4.9 g of the above solution is used and75.5 mg of micronized dexamethasone USP (Spectrum Scientific) issuspended and dispersed well. 2 mL of the formulation is transferredinto a 2 mL glass vial (Wheaton serum glass vial) and sealed with 13 mmbutyl styrene (kimble stoppers) and crimped with a 13 mm aluminum seal.The vial is placed in a Market Forge-sterilmatic autoclave (settings,slow liquids) and sterilized at 250° F. for 25 minutes. After theautoclaving the sample is left to cool down to room temperature. Thevial is placed in the refrigerator and mixed while cold to homogenizethe sample. Sample discoloration or precipitation after autoclaving isrecorded.

Dissolution is performed at 37° C. in snapwells (6.5 mm diameterpolycarbonate membrane with a pore size of 0.4 μm), 0.2 mL of gel isplaced into snapwell and left to harden, then 0.5 mL PBS buffer isplaced into reservoir and shaken using a Labline orbit shaker at 70 rpm.Samples are taken every hour [0.1 mL withdrawn and replaced with warmPBS buffer containing 2% PEG-40 hydrogenated castor oil (BASF) toenhance dexamethasone solubility]. Samples are analyzed fordexamethasone concentration by UV at 245 nm against an externalcalibration standard curve. The release rate is compared to otherformulations disclosed herein. MDT time is calculated for each sample.

Solubilization of dexamethasone in the 17% poloxamer system is evaluatedby measuring the concentration of dexamethasone in the supernatant aftercentrifuging samples at 15,000 rpm for 10 minutes using an eppendorfcentrifuge 5424. Dexamethasone concentration in the supernatant ismeasured by UV at 245 nm against an external calibration standard curve.FIG. 3. illustrates release profiles of various steroidal formulationscontaining 17% P407. Table 17 describes dexamethasone solubility in TRISbuffer and 17% P407 solution.

TABLE 9 Dexamethasone solubility in TRIS buffer and 17% P407 solutionDexamethasone concentration Sample in supernatant (μg/mL) 17% P407/1.5%DEX/TRIS 580  2% DEX in TRIS buffer (from example 4) 86  2% DEX in TRISbuffer autoclaved 153 (from example 4)

Example 19 Release Rate or MDT and Viscosity of Formulation ContainingSodium Carboxymethyl Cellulose

17% Poloxamer 407/2% DSP/1% CMC (Hercules Blanose 7M):

A sodium carboxymethylcellulose (CMC) solution (pH 7.0) in PBS buffer isprepared by dissolving 205.6 mg of sodium chloride (Fisher Scientific),372.1 mg of sodium phosphate dibasic dihydrate (Fisher Scientific),106.2 mg of sodium phosphate monobasic monohydrate (Fisher Scientific)in 78.1 g of sterile filtered DI water. 1 g of Blanose 7M CMC (Hercules,viscosity of 533 cP @ 2%) is sprinkled into the buffer solution andheated to ease solution, solution is then cooled down and 17.08 gpoloxamer 407NF (Spectrum Chemicals) is sprinkled into the cold solutionwhile mixing. A formulation comprising 17% poloxamer 407NF/1% CMC/2% DSPin PBS buffer is made adding/dissolving 205 mg of dexamethasone to 9.8 gof the above solution, and mixing until all the dexamethasone iscompletely dissolved. The pH of this solution is 7.0.

17% Poloxamer 407/2% DSP/0.5% CMC (Blanose 7M65):

A sodium carboxymethylcellulose (CMC) solution (pH 7.2) in PBS buffer isprepared by dissolving 257 mg of sodium chloride (Fisher Scientific),375 mg of sodium phosphate dibasic dihydrate (Fisher Scientific), 108 mgof sodium phosphate monobasic monohydrate (Fisher Scientific) in 78.7 gof sterile filtered DI water. 0.502 g of Blanose 7M65 CMC (Hercules,viscosity of 5450 cP @ 2%) is sprinkled into the buffer solution andheated to ease solution, solution is then cooled down and 17.06 gpoloxamer 407NF (Spectrum Chemicals) is sprinkled into the cold solutionwhile mixing. A 17% poloxamer 407NF/1% CMC/2% DSP solution in PBS bufferis made adding/dissolving 201 mg of DSP to 9.8 g of the above solution,and mixing until the DSP is completely dissolved. The pH of thissolution is 7.2.

17% Poloxamer 407/2% DSP/0.5% CMC (Blanose 7H9):

A sodium carboxymethylcellulose (CMC) solution (pH 7.3) in PBS buffer isprepared by dissolving 256.5 mg of sodium chloride (Fisher Scientific),374 mg of sodium phosphate dibasic dihydrate (Fisher Scientific), 107 mgof sodium phosphate monobasic monohydrate (Fisher Scientific) in 78.6 gof sterile filtered DI water, then 0.502 g of Blanose 7H9 CMC (Hercules,viscosity of 5600 cP @ 1%) is sprinkled to the buffer solution andheated to ease solution, solution is then cooled down and 17.03 gpoloxamer 407NF (Spectrum Chemicals) is sprinkled into the cold solutionwhile mixing. A 17% poloxamer 407NF/1% CMC/2% DSP solution in PBS bufferis made adding/dissolving 203 mg of DSP to 9.8 of the above solution,and mixing until the DSP is completely dissolved. The pH of thissolution is 7.3.

Viscosity measurements are performed as described in example 7.Dissolution is performed as described in example 7.

FIG. 4. illustrates the correlation between mean dissolution time (MDT)and apparent viscosity of formulation. The release rate is modulated bythe incorporation of a secondary polymer. The selection of the grade andconcentration of a secondary polymer is facilitated by the use of graphslike the ones shown below in FIG. 5 and FIG. 6 for commonly availablewater soluble polymers.

Example 20 Dry Sterilization of Micro-Dexamethasone Powder

Ten milligrams of micronized dexamethsone powder (Spectrum lot XD0385)were filled into 2 mL glass vials and sealed with a 13 mm butyl strrubber stopper (Kimble) and placed in the oven at different temperaturesfor 7-11 hours.

HPLC analysis was performed using an Agilent 1200 equipped with a LunaC18(2) 3 μm, 100 Å, 250×4.6 mm column) using a 30-95 of solvent B(solvent A 35% methanol:35% water:30% acetate buffer, solvent B 70%methanol: 30% acetate buffer pH 4) gradient (1-6 min), then isocratic(95% solvent B) for 11 minutes, for a total run of 22 minutes. Sampleswere dissolved in ethanol and analyzed. Dry-heat sterilization ofmicronized dexamethasone at a temperature of up to 138° C. did notaffect particle size distribution of the micronized dexamethasone. HPLCanalysis indicated 99% purity of the dry-heat sterilized micronizeddexamethasone.

Example 21 Application of a Enhanced Viscosity CorticosteroidFormulation onto the Round Window Membrane

A formulation according to Example 1 is prepared and loaded into 5 mlsiliconized glass syringes attached to a 15-gauge luer lock disposableneedle. Lidocaine is topically applied to the tympanic membrane, and asmall incision made to allow visualization into the middle ear cavity.The needle tip is guided into place over the round window membrane, andthe anti-inflammatory corticosteroid formulation applied directly ontothe round window membrane.

Example 22 In Vivo Testing of Intratympanic Injection of CorticosteroidFormulation in a Guinea Pig

A cohort of 21 guinea pigs (Charles River, females weighing 200-300 g)was intratympanically injected with 20-120 μL of a 2% DSP formulation.FIG. 7 shows the gel fate in the guinea pig ear up to 5 days afterintratympanic injection. Increasing injection volume increased gelretention for injection volumes up to 90 μL. However, an injectionvolume of 120 μL showed a lower gel retention.

A cohort of 21 guinea pigs (Charles River, females weighing 200-300 g)was intratympanically injected with 50 μL of different P407-DSPformulations described herein, containing 0 to 6% DSP. FIGS. 8A and 8Bshow the gel elimination time course for each formulation. The gelelimination time course of a 6% DSP formulation was faster (lower meandissolution time (MDT)) than those of the other formulations containinglower concentrations of DSP (0, 0.6, and 2% respectively). Furthermore,when the P407 concentration was increased from 17% to 19% for the 6% DSPformulation (6% Dex-P(*)), a faster gel elimination was observed, asshown in FIG. 8A. Thus the injection volume and the concentration of acorticosteroid in a formulation described herein are tested to determineoptimal parameters for preclinical and clinical studies. It was observedthat intratympanic formulations with high concentrations of DSP have arelease profile that is different form intratympanic formulations with alower concentration of DSP.

Example 23 In Vivo Extended Release Kinetics

A cohort of 21 guinea pigs (Charles River, females weighing 200-300 g)was intratympanically injected with 50 μL 17% Pluronic F-127 formulationbuffered at 280mOsm/kg and containing 1.5% to 4.5% dexamethasone byweight of the formulation. Animals were dosed on day 1. FIG. 9 shows therelease profile for the formulations that were tested base on analysisof the perilymph. In the 1.5% Dexamethasone regimen, the exposure levelsat day 7-10 are about 10% of the Cmax with a mean residence time ofabout 3.5 days. In the 4.5% Dexamethasone regimen, the exposure levelswere maintained for at least 10 days at levels similar to or higher thanthe levels seen at day 1 with a projected mean residence time of over 18days.

Example 24 Evaluation of Corticosteroid Formulations in an MED AnimalModel

Methods and Materials

Induction of Immune Response

Female albino National Institutes of Health-Swiss mice (HarlanSprague-Dawley, Inc., Indianapolis, Inc.) weighing 20 to 24 g are used.Keyhole limpet hemocyanin (KLH; Pacific Biomarine Supply Co., Venice,Calif.) is suspended in phosphate-buffered saline (PBS) (pH 6.4),dialyzed aseptically against PBS and centrifuged twice. The precipitate(associated KLH) is dissolved in PBS and injected subcutaneously in theback of the animal (0.2 mg emulsified in Freund's complete adjuvant).The animals are given a booster (0.2 mg KLH in Freund's incompleteadjuvant, and then injected ten weeks later with 0.1 mg KLH in 5 μl PBS(pH 6.4) through a microhole drilled through the cochlear capsule. Thecochlea is approached using an operating microscope and steriletechnique. A postauricular incision is made, and a hole is drilled intothe bullae to allow good visualization of the promontory of the cochlearbasal turn, stapedial artery, and round window niche. The stapedialartery is cauterized and removed, and a 25 μm hole is drilled throughthe cochlear capsule into the scala tympani of the lateral basal turn.KLH or PBS control is slowly injected using a Hamilton syringe coupledwith a plastic tube to a glass micropipette filled with the antigen orcontrol. The hole is sealed with bone wax after injection, and excessfluid is removed. Only one cochlea per animal is treated with KLH.

Treatment

KLH and control mice are sorted into two groups (n=10 in each group).Corticosteroid formulation of Example 1 containing dexamethasone isapplied to the round window membrane of one group of animals. Controlformulation containing no dexamethasone is applied to the second group.The dexamethasone and control formulations are reapplied three daysafter the initial application. The animals are sacrificed after theseventh day of treatment.

Analysis of Results

Electrophysiologic Testing

The hearing threshold for the auditory brainstem response threshold(ABR) to click stimuli for each ear of each animal is initially measuredand 1 week after the experimental procedure. The animals are placed in asingle-walled acoustic booth (Industrial Acoustics Co, Bronx, N.Y., USA)on a heating pad. Subdermal electrodes (Astro-Med, Inc. Grass InstrumentDivision, West Warwick, R.I., USA) were inserted at the vertex (activeelectrode), the mastoid (reference), and the hind leg (ground). Clickstimuli (0.1 millisecond) are computer generated and delivered to aBeyer DT 48, 200 Ohm speaker fitted with an ear speculum for placementin the external auditory meatus. The recorded ABR is amplified anddigitized by a battery-operated preamplifier and input to a Tucker-DavisTechnologies ABR recording system that provides computer control of thestimulus, recording, and averaging functions (Tucker Davis Technology,Gainesville, Fla., USA). Successively decreasing amplitude stimuli arepresented in 5-dB steps to the animal, and the recorded stimulus-lockedactivity is averaged (n=512) and displayed. Threshold is defined as thestimulus level between the record with no visibly detectable responseand a clearly identifiable response.

Histochemical Analysis

Animals are anesthsized and sacrificed via intracardiac perfusion ofheparinized warm saline followed by approximately 40 mlperiodate-lysine-paraformaldehyde (4% paraformaldehyde finalconcentration) fixative. Right-side temporal bones are immediatelyremoved and decalcified with buffered 5% ethylenediamine tetra-acetate(pH 7.2) for 14 days (4° C.). After decalcification, temporal bones areimmersed sequentially in increasing concentrations (50%, 75%, 100%) ofoptimal cutting temperature (OCT) compound (Tissue-Tek, Miles Inc.,Elkhart, Ind.), snap-frozen (−70° C.), and cryostat-sectioned (4 μm)parallel to the modiolus. Sections are collected for hematoxylin andeosin (H&E) staining and immunohistochemical analysis.

The severity of inflammation is assessed according to the amount ofcellular infiltration of the scala tympani, and an unbiased score isgiven to each cochlea. A score of 0 indicates no inflammation, and ascore of 5 indicates that all cochlear turns had severe infiltration ofinflammatory cells.

Example 25 Evaluation of Corticosteroid Formulations in an Otitis MediaAnimal Model Induction of Otitis Media

Healthy adult chinchillas weight 400 to 600 g with normal middle ears,ascertained by otoscopy and tympanometry are used for these studies.Eustachian tube obstruction is performed 24 hours before inoculation toprevent the inoculum from flowing out of the eustachian tube. Onemilliliter of type 3 S. pneumoniae strain at 4-h-log phase (containingapproximately 40 colony forming units (CFU)) is placed directly intoboth middle ear hypotympanic bullae of the chinchillas. Control mice areinoculated with one milliliter sterile PBS.

Treatment

S. pneumoniae inoculated and control mice are sorted into two groups(n=10 in each group). The prednisolone formulation of Example 2 isapplied to the walls of the tympanic cavity of one group of animals.Control formulation containing no prednisolone is applied to the secondgroup. The prednisolone and control formulations are reapplied threedays after the initial application. The animals are sacrificed after theseventh day of treatment.

Analysis of Results

Auris media ear fluid (MEF) is sampled at 1, 2, 6, 12, 24, 48 and 72hours after pneumoccal inoculation. Quantitative MEF cultures areperformed on sheep blood agar, with the quantitation threshold set at 50CFU/ml. Inflammatory cells are quantitated with a hemocytometer, anddifferential cell enumeration performed with Wright's staining.

Example 26 AIED Clinical Trials Using a Dexamethasone Formulation

Ten adult patients who have previously responded to systemicdexamethasone therapy, but currently have discontinued therapy due toadverse events are selected. The dexamethasone thermoreversible gelformulation of Example 1 is administered to each patient's round windowmembrane through piercing of the tympanic membrane. Reapplication of thedexamethasone gel formulation is performed 7 days after the initialapplication, and again at 2 and 3 weeks of treatment.

Hearing evaluations consisting of pure tone audiometry (250-8000 Hz) andspeech testing using dissyllabic word lists in French are administeredto each patient. Testing is carried out both before the application ofthe dexamethasone formulation and at 1, 2, 3 and 4 weeks post-initialtreatment.

Example 27 Evaluation of Prednisolone in an Acoustic Trauma Mouse Model

Methods and Materials

Induction of Ototoxicity

Twelve Harlan Sprague-Dawley mice weighing 20 to 24 g are used. Baselineauditory brainstem response (ABR) at 4-20 mHz is measured. The mice areanesthetized and exposed for 30 minutes to a continuous pure tone of 6kHz at a loudness of 120 dB.

Treatment

The control group (n=10) are administered saline following acoustictrauma. The experimental group (n=10) are administered prednisolone asformulated in Example 2 (2.0 mg/kg of body weight) following acoustictrauma.

Electrophysiologic Testing

The hearing threshold for the auditory brainstem response threshold(ABR) to click stimuli for each ear of each animal is initially measuredand 1 week after the experimental procedure. The animals are placed in asingle-walled acoustic booth (Industrial Acoustics Co, Bronx, N.Y., USA)on a heating pad. Subdermal electrodes (Astro-Med, Inc. Grass InstrumentDivision, West Warwick, R.I., USA) were inserted at the vertex (activeelectrode), the mastoid (reference), and the hind leg (ground). Clickstimuli (0.1 millisecond) are computer generated and delivered to aBeyer DT 48, 200 Ohm speaker fitted with an ear speculum for placementin the external auditory meatus. The recorded ABR is amplified anddigitized by a battery-operated preamplifier and input to a Tucker-DavisTechnologies ABR recording system that provides computer control of thestimulus, recording, and averaging functions (Tucker Davis Technology,Gainesville, Fla., USA). Successively decreasing amplitude stimuli arepresented in 5-dB steps to the animal, and the recorded stimulus-lockedactivity is averaged (n=512) and displayed. Threshold is defined as thestimulus level between the record with no visibly detectable responseand a clearly identifiable response.

Example 28 Clinical Trials of Dexamethasone in Meniere's DiseasePatients

Study Objective

The primary objective of this study will be to assess the safety andefficacy of dexamethasone compared with that of placebo in amelioratingtinnitus symptoms in Meniere's Disease afflicted patients.

Study Design

This will be a phase 3, multicentre, double-blind, randomised,placebo-controlled, three-arm study comparing JB004/A to placebo in thetreatment of tinnitus. Approximately 250 subjects will be enrolled inthis study, and randomised (1:1) to 1 of 3 treatment groups based on arandomisation sequence prepared by sponsor. Each group will receive 300mg dexamethasone delivered in a thermoreversible gel, or controlledrelease placebo formulation. Release of dexamethasone is controlledrelease and occurs over 30 days. Route of Administration will beintratympanic injection.

Primary Outcome Measure

Visual Analog Scales (VAS) to measure the change in tinnitus loudness asperceived at the moment of the measurement at 2 hrs after dosing (or atany other time point vs. pre-dose baseline). Alternatively, audiometryis used in the healthy ear to match the tone of the tinnitus in theaffected ear.

Secondary Outcome Measures

VAS to measure tinnitus pitch, distress and anxiety. Pure ToneAudiometry & Psychoacoustic assessment. Sleep & Tinnitus questionnaires.Safety, tolerability and pharmacokinetics of drug. [Time Frame:perceived at the moment of the measurement at 2 hrs after dosing (or atany other time point vs. pre-dose baseline).

Inclusion Criteria

Patients may be included if they meet any of the following criteria:

-   -   Male or female subjects diagnosed with a tinnitus.    -   Subjects willing to restrict alcohol intake.    -   Women of childbearing potential who abstain from intercourse OR        agree to birth control.    -   Women of non-childbearing potential.        Exclusion Criteria

Patients may be excluded if they meet any of the following criteria:

-   -   Intermittent or pulsatile tinnitus    -   Subject with pathologic level of anxiety or depression.    -   Subject with no audiogram deficit and with normal hearing.    -   Subjects that do not respond to the lidocaine infusion test or        show a large variability in pre-infusion values.    -   Existence of any surgical or medical condition which might        interfere with the PK of the drug.    -   Subjects with hepatic impairment or a history of liver        dysfunction.    -   Subjects with renal impairment.    -   Subjects positive for HIV, hepatitis C or hepatitis B.    -   Subjects with abnormal laboratory, ECG or physical examination        findings.    -   Subjects who are not euthyroid.    -   Subjects with a history of hepatic, cardiac, renal, neurologic,        cerebrovascular, metabolic or pulmonary disease.    -   Subjects who have had a myocardial infarction.    -   Subjects with a history of seizure disorders.    -   Subjects with history of cancer.    -   Subjects with a history of drug or other allergy.    -   Subjects positive for drug use and/or a history of substance        abuse or dependence.    -   Subjects who have taken psychotropic drugs or antidepressants        within specified time frames.    -   Medication or foodstuff (e.g. grapefruit or grapefruit juice)        which is known to interfere with liver enzymes.    -   Subjects who have recently used an investigational drug or        recently participated in a trial.    -   Women who have a positive pregnancy test.    -   Female subjects who intend to get pregnant or male subjects who        intend to father a child within the next 4 weeks following the        last study drug administration in the study.    -   Subjects, who have donated a unit of blood or more within the        previous month or who intend to donate blood within one month of        completing the study.

Example 29 Evaluation of a Dexamethasone Formation in an EndolymphaticHydrops Animal Model

The procedure is used to determine the efficacy of the dexamethasoneformulation prepared in Example 1.

Materials and Methods

Thirty-five Hartley guinea pigs with a positive Preyer's reflex andweighing about 300 g are used. Five animals, which serve as controls(normal ear group), are fed for 5 weeks with neither operation nortreatment, and the remaining 30 serve as experimental animals. Allexperimental animals received electro-cauterization of the endolymphaticsac (Lee et al., Acta Otolaryngol. (1992) 112:658-666; Takeda et al.,Equilib. Res. (1993) 9:139-143). Four weeks after surgery, these animalsare divided into three groups of non-infusion hydropic ears,vehicle-treated hydropic ears and dexamethasone-treated hydropic ears,consisting of 10 animals each. The group of non-infusion hydropic earsreceive no treatment except for electro-cauterization of theendolymphatic sac. In the groups of vehicle-treated hydropic ears anddexamethasone-treated hydropic ears, the liposomal formulation isapplied to the round window membrane. One week after administration ofthe composition, all animals are sacrificed for assessment of thechanges of the endolymphatic space. All animals are left undisturbed andfreely moving in individual cages in a quiet room throughout the period,except during experimental procedures.

To assess the changes to the endolymphatic space, all animals aretranscardially perfused with physiological saline solution under deepanesthesia by a peritoneal injection of pentobarbital, and fixation isperformed with 10% formalin. The left temporal bones are removed andpostfixed in 10% formalin solution for 10 days or more. Thereafter, theyare decalcified with 5% trichloroacetic acid for 12 days and dehydratedin a graded ethanol series. They are embedded in paraffin and celloidin.The prepared blocks are cut horizontally into 6 μm sections. Thesections are stained with hematoxylin and eosin and observed under alight microscope. Quantitative assessment of changes of theendolymphatic space is performed according to the method of Takeda(Takeda et al., Hearing Res. (2003) 182:9-18).

Example 30 Evaluation of Intratympanic Dexamethasone on IdiopathicSudden Sensorineural Hearing Loss (ISSHL)

Study Objective

The primary objective of this study will be to assess the safety andefficacy of oral steroid treatment, or intratympanic (IT) steroidtreatment.

Primary Outcome Measurements

Pure Tone Average (PTA) and Word Recognition as equally weightedendpoints; For Speech Discrimination Scoring, a 50-word monosyllablesystem will be employed; Greater than 20 dB improvement in PTA or overALL or SOME of the frequencies where the deficiencies are greater than30 dB, and/or a 20% or greater improvement in the WDS; In addition toabsolute changes, recovery with respect to the contralateral ear willalso be determined.

Complete Recovery—recovery to within 5% points of the contralateralspeech discrimination score, or within 5 dB of the contralateral PTA.

Study Design

This will be a multicentre, double-blind, randomized,placebo-controlled, parallel group study comparing intratympanicDexamethasone to placebo in the treatment of ISSHL. Approximately 140subjects will be enrolled in this study, and randomized (1:1) to 1 of 3treatment groups based on a randomization sequence.

-   -   a. Subjects in Group I will receive oral prednisone (1 mg/kg/day        prednisone for 14 days followed by a daily 10 mg diminution in        dose until no further steroid is given)    -   b. Subjects in Group II will receive IT dexamethasone sodium        phosphate (1 injection of 0.3-0.5 mL of dexamethasone/mL of        vehicle administered monthly up to a maximum of 3 injections)        and oral prednisone (1 mg/kg/day prednisone for 14 days followed        by a daily 10 mg diminution in dose until no further steroid is        given)    -   c. Subjects in Group III will receive a placebo IT injections (1        injection of 0.3-0.5 mL of vehicle administered monthly up to a        maximum of 3 injections) and oral prednisone Hearing Assessments        Hearing Assessments Comprise:    -   a. Pure Tone Average (500 Hz, 1& 2 kHz; 4, 6 & 8 kHz).        -   i. Two PTA values would then be determined: a low frequency            value (500 Hz-2 kHz) and a high frequency value (4-8 kHz).    -   b. Stapedial Reflex    -   c. Tympanometry & tone decay    -   d. Speech Recognition Threshold

Before treatment begins hearing loss for each subject will be measured(twice prior to allocation to the study, and once prior torandomization). Hearing assessment at 1, 2, 4 & 8 weeks, 4& 6 monthspost start of treatment

Main Criteria for Inclusion

-   -   Male or female patients aged between 18 and 75 years    -   Unilateral SHL (sensorineural hearing loss) developing within 72        hours    -   Subjects will have a hearing loss that at any one frequency,        does not exceed 70 dB.        Exclusion Criteria    -   Greater than 10 days of prior oral steroid treatment for any        reason within the preceding 30 days    -   5 or more days of prior oral steroid treatment for ISSHL within        the preceding 14 days    -   History of fluctuating hearing in either ear

Example 31 Evaluation of Intratympanic Dexamethasone on Meniere'sDisease

Study Objective

The primary objective of this study will be to assess the safety andefficacy of intratympanic (IT) dexamethasone treatment.

Primary Outcome Measurements

Vertigo

-   -   a. Self-Reporting System with the following regimen—        -   i. Vertigo-free days—0 score;        -   ii. Days with a mild attack—1;        -   iii. Moderately severe attacks lasting more than 20            minutes-2;        -   iv. Severe attacks lasting an hour or more or accompanied by            nausea or vomiting—3;        -   v. Worst attack to date—4;        -   vi. Treatment failure to be defined as a monthly vertigo            score of 50 or greater for 2 consecutive months            Inclusion Criteria    -   Clinical diagnosis of MD according to the 1995 AAO-HNS Criteria:        -   a. At least two definitive attacks of vertigo.        -   b. A definitive spell is spontaneous (rotational) vertigo            lasting at least 20 minutes.            Exclusion Criteria    -   Treatment with aminoglycoside or macrolide antibiotics;    -   Treatment with antineoplastic drugs        -   a. Platinum compounds,        -   b. Difluoromethylornithine            Study Design

This will be a multicentre, double-blind, randomized,placebo-controlled, parallel group study comparing intratympanicdexamethasone to placebo in the treatment of ISSHL. Approximately 140subjects will be enrolled in this study, and randomized (1:1) to 1 of 3treatment groups based on a randomization sequence.

-   -   a. Subjects in Group I will receive standard of care (sodium        diet of nmt 1500 mg/day, abstinence from xanthine intake, and/or        diuretics)    -   b. Subjects in Group II will receive IT dexamethasone sodium        phosphate (1 injection of 0.3-0.5 mL of dexamethasone/mL of        vehicle administered monthly up to a maximum of 3 injections)        and standard of care    -   c. Subjects in Group IV will receive a placebo IT injections (1        injection of 0.3-0.5 mL of vehicle administered monthly up to a        maximum of 3 injections) and standard of care        Assessments

Before treatment begins severity of Meniere's for each subject will bemeasured (twice prior to allocation to the study, and once prior torandomization)

Meniere's assessment at 1, 2, 4 & 8 weeks, 4& 6 months post start oftreatment

Assessments

-   -   a. Date of onset, frequency, duration and severity of attacks of        vertigo and tinnitus;    -   b. Reduced aural pressure sensation, measured using standard VAS        questionnaires, and validated rating protocols    -   c. Measurement of serum vasopressin

While preferred embodiments of the present invention have been shown anddescribed herein, such embodiments are provided by way of example only.Various alternatives to the embodiments described herein are optionallyemployed in practicing the inventions. It is intended that the followingclaims define the scope of the invention and that methods and structureswithin the scope of these claims and their equivalents be coveredthereby.

We claim:
 1. A method of ameliorating an inner ear disease or disorderin a patient in need thereof comprising injecting through the tympanicmembrane into the middle ear cavity of the patient a controlled releasecomposition comprising dexamethasone and a thermosetting polymer;wherein the dexamethasone is uncoated and is suspended in thecomposition, and the thermosetting polymer is poloxamer 407 at aconcentration of at least 10% w/w and up to 20% w/w, and wherein asingle dose of the controlled release composition in the syringe is from300 μL to 500 μL.
 2. The method of claim 1, wherein the controlledrelease composition provides controlled release of the pharmaceuticalagent for an extended period of time of one or more days.
 3. The methodof claim 1, wherein the controlled release composition is a suspensionin which the pharmaceutically active agent is dispersed within thethermosetting polymer.
 4. The method of claim 1, wherein the controlledrelease composition further comprises a phosphate which buffers the pHof the controlled release composition to about 7.4.
 5. The method ofclaim 1, wherein the controlled release composition is contained in asyringe optionally connected to a needle.
 6. The method of claim 1,wherein the inner ear disease or disorder is selected from the groupconsisting of tinnitus, hearing loss, vertigo, Meniere's disease,autoimmune disorders, and inner ear infections and inflammations.
 7. Themethod of claim 1, wherein the inner ear disease or disorder isMeniere's disease.
 8. The method of claim 1, wherein the thermosettingpolymer has a gelation temperature of between about 12° C. to about 20°C.